<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence - Wagner, C - 2022 | Cochrane Library</title> <meta content="Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence - Wagner, C - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014963.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence - Wagner, C - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014963.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014963.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence" name="citation_title"/> <meta content="Carina Wagner&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Mirko Griesel&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Agata Mikolajewska" name="citation_author"/> <meta content="Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin" name="citation_author_institution"/> <meta content="Maria-Inti Metzendorf" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf" name="citation_author_institution"/> <meta content="Anna-Lena Fischer" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Miriam Stegemann" name="citation_author"/> <meta content="Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin" name="citation_author_institution"/> <meta content="Manuel Spagl" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Avinash Anil Nair" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Jefferson Daniel" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Falk Fichtner&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Nicole Skoetz&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="nicole.skoetz@uk-koeln.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD014963.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/11/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014963.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014963.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014963.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [adverse effects]; *COVID-19 Drug Treatment; Dexamethasone [adverse effects]; *Invasive Fungal Infections; Methylprednisolone; Post-Acute COVID-19 Syndrome; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014963.pub2&amp;doi=10.1002/14651858.CD014963.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014963\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014963\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014963.pub2",title:"Systemic corticosteroids for the treatment of COVID\\u201019: Equity\\u2010related analyses and update on evidence",firstPublishedDate:"Nov 17, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014963.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014963.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014963.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014963.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014963.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014963.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014963.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014963.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014963.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014963.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9086 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014963.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-sec-0146"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-sec-0119"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/appendices#CD014963-sec-0151"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/supinfo/CD014963StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/supinfo/CD014963StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="contributed equally (first author)"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0004">Carina Wagner</a><sup>a</sup></li> <li class="author custom-tooltip" title="contributed equally (first author)"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0005">Mirko Griesel</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0006">Agata Mikolajewska</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0007">Maria-Inti Metzendorf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0008">Anna-Lena Fischer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0009">Miriam Stegemann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0010">Manuel Spagl</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0011">Avinash Anil Nair</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0012">Jefferson Daniel</a></li> <li class="author custom-tooltip" title="contributed equally (last author)"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0013">Falk Fichtner</a><sup>a</sup></li> <li class="author custom-tooltip" title="contributed equally (last author)"><a href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information#CD014963-cr-0014"><i class="icon corresponding-author fa fa-envelope"></i>Nicole Skoetz</a><sup>a</sup></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information/en#CD014963-sec-0157">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 November 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014963.pub2">https://doi.org/10.1002/14651858.CD014963.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014963-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014963-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014963-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014963-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014963-abs-0009">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014963-abs-0001" lang="en"> <section id="CD014963-sec-0001"> <h3 class="title" id="CD014963-sec-0001">Background</h3> <p>Systemic corticosteroids are used to treat people with COVID‐19 because they counter hyper‐inflammation. Existing evidence syntheses suggest a slight benefit on mortality. Nonetheless, size of effect, optimal therapy regimen, and selection of patients who are likely to benefit most are factors that remain to be evaluated. </p> </section> <section id="CD014963-sec-0002"> <h3 class="title" id="CD014963-sec-0002">Objectives</h3> <p>To assess whether and at which doses systemic corticosteroids are effective and safe in the treatment of people with COVID‐19, to explore equity‐related aspects in subgroup analyses, and to keep up to date with the evolving evidence base using a living systematic review approach. </p> </section> <section id="CD014963-sec-0003"> <h3 class="title" id="CD014963-sec-0003">Search methods</h3> <p>We searched the Cochrane COVID‐19 Study Register (which includes PubMed, Embase, CENTRAL, ClinicalTrials.gov, WHO ICTRP, and medRxiv), Web of Science (Science Citation Index, Emerging Citation Index), and the WHO COVID‐19 Global literature on coronavirus disease to identify completed and ongoing studies to 6 January 2022. </p> </section> <section id="CD014963-sec-0004"> <h3 class="title" id="CD014963-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that evaluated systemic corticosteroids for people with COVID‐19. </p> <p>We included any type or dose of systemic corticosteroids and the following comparisons: systemic corticosteroids plus standard care versus standard care, different types, doses and timings (early versus late) of corticosteroids. </p> <p>We excluded corticosteroids in combination with other active substances versus standard care, topical or inhaled corticosteroids, and corticosteroids for long‐COVID treatment. </p> </section> <section id="CD014963-sec-0005"> <h3 class="title" id="CD014963-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methodology. To assess the risk of bias in included studies, we used the Cochrane 'Risk of bias' 2 tool for RCTs. We rated the certainty of the evidence using the GRADE approach for the following outcomes: all‐cause mortality up to 30 and 120 days, discharged alive (clinical improvement), new need for invasive mechanical ventilation or death (clinical worsening), serious adverse events, adverse events, hospital‐acquired infections, and invasive fungal infections. </p> </section> <section id="CD014963-sec-0006"> <h3 class="title" id="CD014963-sec-0006">Main results</h3> <p>We included 16 RCTs in 9549 participants, of whom 8271 (87%) originated from high‐income countries. A total of 4532 participants were randomised to corticosteroid arms and the majority received dexamethasone (n = 3766). These studies included participants mostly older than 50 years and male. We also identified 42 ongoing and 23 completed studies lacking published results or relevant information on the study design. </p> <p><b>Hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</b> </p> <p><b><i>Systemic corticosteroids plus standard care versus standard care plus/minus placebo</i> </b> </p> <p>We included 11 RCTs (8019 participants), one of which did not report any of our pre‐specified outcomes and thus our analyses included outcome data from 10 studies. </p> <p>Systemic corticosteroids plus standard care compared to standard care probably reduce <i>all‐cause mortality (up to 30 days)</i> slightly (risk ratio (RR) 0.90, 95% confidence interval (CI) 0.84 to 0.97; 7898 participants; estimated absolute effect: 274 deaths per 1000 people not receiving systemic corticosteroids compared to 246 deaths per 1000 people receiving the intervention (95% CI 230 to 265 per 1000 people); moderate‐certainty evidence). </p> <p>The evidence is very uncertain about the effect on <i>all‐cause mortality (up to 120 days)</i> (RR 0.74, 95% CI 0.23 to 2.34; 485 participants). The chance of c<i>linical improvement (discharged alive at day 28)</i> may slightly increase (RR 1.07, 95% CI 1.03 to 1.11; 6786 participants; low‐certainty evidence) while the risk of <i>clinical worsening (new need for invasive mechanical ventilation or death)</i> may slightly decrease (RR 0.92, 95% CI 0.84 to 1.01; 5586 participants; low‐certainty evidence). </p> <p>For serious adverse events (two RCTs, 678 participants), adverse events (three RCTs, 447 participants), hospital‐acquired infections (four RCTs, 598 participants), and invasive fungal infections (one study, 64 participants), we did not perform any analyses beyond the presentation of descriptive statistics due to very low‐certainty evidence (high risk of bias, heterogeneous definitions, and underreporting). </p> <p><b><i>Different types, dosages or timing of systemic corticosteroids</i> </b> </p> <p>We identified one RCT (86 participants) comparing methylprednisolone to dexamethasone, thus the evidence is very uncertain about the effect of methylprednisolone on all‐cause mortality (up to 30 days) (RR 0.51, 95% CI 0.24 to 1.07; 86 participants). None of the other outcomes of interest were reported in this study. </p> <p>We included four RCTs (1383 participants) comparing high‐dose dexamethasone (12 mg or higher) to low‐dose dexamethasone (6 mg to 8 mg). </p> <p>High‐dose dexamethasone compared to low‐dose dexamethasone may reduce all‐cause mortality (up to 30 days) (RR 0.87, 95% CI 0.73 to 1.04; 1269 participants; low‐certainty evidence), but the evidence is very uncertain about the effect of high‐dose dexamethasone on all‐cause mortality (up to 120 days) (RR 0.93, 95% CI 0.79 to 1.08; 1383 participants) and it may have little or no impact on clinical improvement (discharged alive at 28 days) (RR 0.98, 95% CI 0.89 to 1.09; 200 participants; low‐certainty evidence). Studies did not report data on clinical worsening (new need for invasive mechanical ventilation or death). </p> <p>For serious adverse events, adverse events, hospital‐acquired infections, and invasive fungal infections, we did not perform analyses beyond the presentation of descriptive statistics due to very low‐certainty evidence. </p> <p>We could not identify studies for comparisons of different timing and systemic corticosteroids versus other active substances. </p> <p><b><i>Equity‐related subgroup analyses</i> </b> </p> <p>We conducted the following subgroup analyses to explore equity‐related factors: sex, age (&lt; 70 years; ≥ 70 years), ethnicity (Black, Asian or other versus White versus unknown) and place of residence (high‐income versus low‐ and middle‐income countries). Except for age and ethnicity, no evidence for differences could be identified. For all‐cause mortality up to 30 days, participants younger than 70 years seemed to benefit from systemic corticosteroids in comparison to those aged 70 years and older. The few participants from a Black, Asian, or other minority ethnic group showed a larger estimated effect than the many White participants. </p> <p><b>Outpatients with asymptomatic or mild disease</b> </p> <p>There are no studies published in populations with asymptomatic infection or mild disease. </p> </section> <section id="CD014963-sec-0007"> <h3 class="title" id="CD014963-sec-0007">Authors' conclusions</h3> <p>Systemic corticosteroids probably slightly reduce <i>all‐cause mortality up to 30 days</i> in people hospitalised because of symptomatic COVID‐19, while the evidence is very uncertain about the effect on <i>all‐cause mortality up to 120 days</i>. For younger people (under 70 years of age) there was a potential advantage, as well as for Black, Asian, or people of a minority ethnic group; further subgroup analyses showed no relevant effects. Evidence related to the most effective type, dose, or timing of systemic corticosteroids remains immature. Currently, there is no evidence on asymptomatic or mild disease (non‐hospitalised participants). Due to the low to very low certainty of the current evidence, we cannot assess safety adequately to rule out harmful effects of the treatment, therefore there is an urgent need for good‐quality safety data. Findings of equity‐related subgroup analyses should be interpreted with caution because of their explorative nature, low precision, and missing data. </p> <p>We identified 42 ongoing and 23 completed studies lacking published results or relevant information on the study design, suggesting there may be possible changes of the effect estimates and certainty of the evidence in the future. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014963-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014963-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD014963-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD014963-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014963-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014963-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD014963-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014963-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014963-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014963-abs-0002" lang="en"> <h3>Are corticosteroids (anti‐inflammatory medicines) given orally or by injection an effective treatment for people with COVID‐19? </h3> <p><b>Key messages</b> </p> <p>• Corticosteroids (anti‐inflammatory medicines) given orally or by injection (systemic) are evaluated for the treatment of coronavirus disease 2019 (COVID‐19). </p> <p>• Corticosteroids are effective in reducing mortality slightly.</p> <p>• We do not know whether a specific type or dose of corticosteroid is effective.</p> <p>• There are no data for people who were not hospitalised.</p> <p>• We found 42 ongoing and 23 completed studies lacking published results or relevant information on the study design, so our findings may change in the future. </p> <p><b>What are corticosteroids?</b> </p> <p>Corticosteroids are anti‐inflammatory drugs that reduce redness and swelling that arises due to an insult (e.g. injury, irritation) to the body. They also reduce the activity of the immune system, which defends the body against disease and infection. Corticosteroids are used to treat a variety of conditions, such as asthma, eczema, joint strains, and rheumatoid arthritis. Systemic corticosteroids can be swallowed or taken as an injection to treat problems anywhere in the body. Short‐term intake of high doses can increase the risk of further infections (including fungal infections) as well as high blood sugar and blood pressure. Furthermore, it can cause swelling of the body and psychiatric side effects such as steroid psychosis and delirium. </p> <p><b>Why are corticosteroids possible treatments for COVID‐19?</b> </p> <p>COVID‐19 affects the lungs and airways. As the immune system fights the virus, the lungs and airways become injured and inflamed, causing breathing difficulties, and hinder oxygen transport to other vital organs. Some patients’ immune systems overreact against the invading virus causing further inflammation and tissue damage in the whole body; corticosteroids may help to control this response. </p> <p><b>We wanted to know:</b> </p> <p>• whether and in which doses systemic corticosteroids are an effective treatment for people with COVID‐19; </p> <p>• whether they cause unwanted effects; and</p> <p>• whether the benefits and harms differ with respect to equity‐related aspects (e.g. age, sex, ethnicity, income by country). </p> <p><b>We were interested in:</b> </p> <p>• deaths from any cause up to 30 and 120 days after treatment start;</p> <p>• whether people got better or worse after treatment;</p> <p>• unwanted effects, for example infections caught in hospital.</p> <p><b>What did we do?</b> </p> <p>We looked for studies that investigated systemic corticosteroids for people with COVID‐19. People could be of any age, sex, or ethnicity. </p> <p>Studies could compare corticosteroids:</p> <p>• plus usual care versus usual care with or without placebo (sham medicine);<br/>• versus another type of corticosteroid;<br/>• versus a different medicine;<br/>• in different doses;<br/>• given as early versus late treatment. </p> <p>We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 16 studies with 9549 people. About 4532 people received corticosteroids, mostly dexamethasone (3766 people). These studies included participants mostly older than 50 years, male, and from high‐income countries. </p> <p>We also found 42 ongoing and 23 completed studies lacking published results or relevant information on the study design. </p> <p><b>Main results</b> </p> <p>Eleven studies compared corticosteroids plus usual care versus usual care with or without a placebo. Only one study compared two types of corticosteroids. Four studies compared different dosing of a corticosteroid named dexamethasone. The studies included only hospitalised people with confirmed or suspected COVID‐19. No studies looked at non‐hospitalised people or different timing of treatment. </p> <p><b>Systemic corticosteroids plus usual care compared to usual care with or without placebo:</b> </p> <p>• probably reduce the number of deaths from any cause slightly, up to 30 days after treatment; </p> <p>• may slightly increase the chance of being discharged alive from hospital and may slightly decrease the risk of needing breathing support or dying; </p> <p>• we don't know if corticosteroids increase or decrease the number of deaths from any cause up to 120 days after treatment, any unwanted effects, or infections caught in the hospital. </p> <p><b>Methylprednisolone versus dexamethasone:</b> </p> <p>The evidence for the number of deaths up to 30 days is very uncertain (one small study only). </p> <p><b>High‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8 mg)</b> </p> <p>High‐dose dexamethasone:</p> <p>• may reduce the number of deaths from any cause up to 30 days after treatment;<br/>• may make little to no difference to the chance of being discharged alive from hospital;<br/>• we don't know if high‐dose dexamethasone increases or decreases the number of deaths from any cause up to 120 days after treatment, any unwanted effects, or infections caught in the hospital. </p> <p><b>Equity‐related subgroup analyses</b> </p> <p>We examined the following equity‐related aspects: ethnicity (Black, Asian or other versus White versus unknown) and place of residence (high‐income versus low‐ and middle‐income countries). For most of the subgroups, except for age and ethnicity, no evidence for differences could be identified. For death from any cause up to 30 days, participants younger than 70 years seem to benefit from corticosteroids in contrast to participants who were aged 70 years and older. Furthermore, the few participants from a Black, Asian, or minority ethnic group had a larger estimated effect than the many White participants, but these subgroup results need cautious interpretation. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are moderately confident in the evidence about the effect of corticosteroids on deaths from any cause within 30 days after treatment. However, our confidence in the other evidence is low to very low, because studies did not use the most robust methods, and the way results were recorded and reported differed across studies. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>This review updates our previous review. The evidence is up‐to‐date to 6 January 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014963-sec-0146" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014963-sec-0146"></div> <h3 class="title" id="CD014963-sec-0147">Implications for practice</h3> <section id="CD014963-sec-0147"> <p>Based on the current evidence, we are moderately certain that systemic corticosteroids probably slightly reduce <i>All‐cause mortality up to 30 days</i> amongst hospitalised, symptomatic COVID‐19 patients while level of respiratory support might play a critical role in patient selection. This finding is supported by low‐certainty evidence for a slightly increased chance of clinical improvement and a slightly decreased risk of worsening. Subgroup analyses suggest that the beneficial effect of the intervention might vanish for patients aged 70 years and older, but could be stronger in patients of Black, Asian, or other non‐White ethnicity. Long‐term survival data up to 120 days is of very low certainty and hence inconclusive. </p> <p>Direct evidence on types of corticosteroids in the second comparison is of very low certainty and hence also inconclusive. Dose escalation may add to the slight benefit on <i>All‐cause mortality up to 30 days</i>, but the certainty of the evidence is low. It is most important to state that evidence on safety throughout the comparisons is of very low certainty because of underreporting and missing adjustment for competing risk of death. </p> <p>The applicability of the data is limited. Data primarily came from European high‐income countries and are therefore limited in their applicability to settings different from that with regard to resources, climate, and other infectious diseases. Our own subgroup analyses are inconclusive in that regard but non‐RCT data raise suspicion of a potential for harm. Moreover, even in this update of the review the data were generated from unvaccinated participants and before the first occurrence of the recent variants of SARS‐CoV‐2, so the evidence may not be fully transferable to patients in 2022 and beyond. </p> <p>Currently, there is no evidence to characterise the benefits and harms of corticosteroids in patients with asymptomatic or mild disease (non‐hospitalised) and regarding timing of the intervention. </p> </section> <h3 class="title" id="CD014963-sec-0148">Implications for research</h3> <section id="CD014963-sec-0148"> <p>To address large uncertainties in the already existing analyses, we would prioritise the following: </p> <p> <ul id="CD014963-list-0136"> <li> <p>Applicability: RCT data from low‐ and middle‐income countries and diverse environments is needed. All publishers should support timely and adequate reporting of already completed studies. </p> </li> <li> <p>Safety data (adverse events/serious adverse events, detailed reporting of secondary infections): study authors should consistently measure and report adverse events, serious adverse events, and infections for both study arms. </p> </li> <li> <p>Survival data: there is an urgent need for more long‐term data (up to 120 days and beyond) to improve the certainty of the evidence. </p> </li> <li> <p>Patient‐centred outcomes: quality of life, neurological function, and independence in daily activities should be examined and reported. </p> </li> <li> <p>Regimens: treatment dosing and duration are likely to influence both benefits and harms and the latter remains unaddressed in RCTs. </p> </li> </ul> </p> <p>Interpretation of the current evidence warrants a call for new RCTs in the main comparison of systemic steroids plus standard care to standard care alone (plus/minus placebo) directly investigating the following: </p> <p> <ul id="CD014963-list-0137"> <li> <p>Age: as there are some hints in the subgroup analysis that older people (above 70 years) might benefit less, study authors should report subgroup analyses for different age groups. </p> </li> <li> <p>Immunological effects of recent variants and vaccination: re‐applying study designs from 2020 in contemporary and vaccinated populations. </p> </li> </ul> </p> <p>We identified 42 ongoing and 23 completed RCTs lacking publication or important information in trials registries and databases, which will probably increase the certainty of the evidence in the future. In accordance with the living systematic review approach, we will continually update our search and include eligible trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014963-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014963-sec-0008"></div> <div class="table" id="CD014963-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Corticosteroids plus standard care compared to standard care (plus/minus placebo) for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Corticosteroids plus standard care compared to standard care (plus/minus placebo) for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19<br/><b>Setting:</b> inpatient, ICU<br/><b>Intervention:</b> corticosteroids plus standard care<br/><b>Comparison:</b> standard care (plus/minus placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care (plus/minus placebo)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with corticosteroids plus standard care</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>274 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b><br/>(230 to 265) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b><br/>(0.84 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7898<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic corticosteroids probably reduce all‐cause mortality up to 30 days slightly.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 120 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>402 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>298 per 1000</b><br/>(93 to 942) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b><br/>(0.23 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of systemic corticosteroids on all‐cause mortality up to 120 days. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: discharged alive (follow‐up: 28 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>664 per 1000</b><br/>(639 to 688) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b><br/>(1.03 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6786<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic corticosteroids may slightly increase the chance of clinical improvement: discharged alive. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: new need for invasive mechanical ventilation or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>282 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b><br/>(237 to 285) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b><br/>(0.84 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5586<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic corticosteroids may slightly decrease the risk of clinical deterioration: new need for invasive mechanical ventilation or death. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias, heterogeneous definitions, and underreporting. Therefore, we only present descriptive statistics: Angus 2020 shock‐dependent hydrocortisone: RR 4.11 (95% CI 0.23 to 72.98); Angus 2020 fixed‐dose hydrocortisone: RR 1.43 (95% CI 0.16 to 12.49); Tomazini 2020: RR 0.54 (95% CI 0.19 to 1.59). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>678<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of systemic corticosteroids on serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any grade) (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias, heterogeneous definitions, and underreporting. We only present descriptive statistics: Edalatifard 2020: RR 0.82 (95% CI 0.12 to 5.48); Tang 2021: RR 0.63 (95% CI 0.22 to 1.76); Tomazini 2020: RR 0.99 (95% CI 0.89 to 1.10). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of systemic corticosteroids on adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐acquired infections (follow up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias, heterogeneous definitions, and underreporting. We present descriptive statistics only: Corral‐Gudino 2021: RR 4.14 (95% CI 0.51 to 33.49); Dequin 2020: RR 0.90 (95% CI 0.60 to 1.34); Tang 2021: RR 2.00 (95% CI 0.19 to 21.24); Tomazini 2020: RR 0.75 (95% CI 0.50 to 1.15). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>598<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of systemic corticosteroids on hospital‐acquired infections. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive fungal infections (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We present descriptive statistics only because of high risk of bias: Corral‐Gudino 2021: RR 2.50 (95% CI 0.11 to 59.15). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of systemic corticosteroids on invasive fungal infections. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424096272361428897" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424096272361428897</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> We downgraded one level for serious risk of bias (partly deviations from the intended intervention, selection of the reported results, missing information about the allocation concealment, baseline differences)<br/><sup>b</sup> We downgraded one level for serious risk of bias (partly deviations from the intended intervention, selection of the reported results, missing information about the allocation concealment), one level for serious inconsistency and one level for serious imprecision (wide confidence interval, low number of participants)<br/><sup>c</sup> We downgraded one level for serious risk of bias (partly deviations from the intended intervention, selection of the reported results, missing information about the allocation concealment) and one level for serious inconsistency.<br/><sup>d</sup> We downgraded one level for serious risk of bias (deviations from the intended intervention, measurement of the outcome) and one level for serious inconsistency.<br/><sup>e</sup> We downgraded two levels for very serious risk of bias (deviations from the intended intervention, missing adjustment for competing risk of death, reporting bias (the safety‐relevant outcome was not reported)) and one level for serious imprecision (fewer than 500 events).<br/><sup>f</sup> We downgraded two levels for very serious risk of bias (deviations from the intended intervention, missing adjustment for competing risk of death, missing information about the allocation concealment, reporting bias (the safety‐relevant outcome was not reported) and one level for serious imprecision (fewer than 500 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014963-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Methylprednisolone compared to dexamethasone for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Methylprednisolone compared to dexamethasone for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19<br/><b>Setting:</b> inpatient, ICU<br/><b>Intervention:</b> methylprednisolone<br/><b>Comparison:</b> dexamethasone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with dexamethasone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with methylprednisolone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>357 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b><br/>(86 to 382) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.51</b><br/>(0.24 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of methylprednisolone on all‐cause mortality up to 30 days. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 120 days ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: discharged alive ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: new need for invasive mechanical ventilation or death ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐acquired infections ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive fungal infections ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424391243004646489" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424391243004646489</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> We downgraded one level for serious risk of bias for missing pre‐specification/protocol/statistical analysis plan and two levels for very serious imprecision (fewer than 50 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014963-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) compared to low‐dose dexamethasone (6 mg to 8 mg) for hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High‐dose dexamethasone (12 mg or higher) compared to low‐dose dexamethasone (6 mg to 8 mg) for hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19<br/><b>Setting:</b> inpatient<br/><b>Intervention:</b> high‐dose dexamethasone (12 mg or higher)<br/><b>Comparison:</b> low‐dose dexamethasone (6 mg to 8 mg) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with low‐dose dexamethasone (6 mg to 8 mg)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with high‐dose dexamethasone (12 mg or higher)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>285 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>248 per 1000</b><br/>(208 to 297) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b><br/>(0.73 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1269<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose dexamethasone may further reduce all‐cause mortality up to 30 days compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 120 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>329 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>306 per 1000</b><br/>(260 to 355) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b><br/>(0.79 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1383<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of high‐dose dexamethasone (12 mg or higher) on all‐cause mortality up to 120 days compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: discharged alive (follow‐up: 28 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>882 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>865 per 1000</b><br/>(785 to 962) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b><br/>(0.89 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose dexamethasone (12 mg or higher) may have little or no impact on the chance of clinical improvement: discharged alive compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: new need for invasive mechanical ventilation or death ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias arising from the missing adjustment for competing risk of death. We present descriptive data only: Munch 2021b: RR 0.80 (95% CI 0.60 to 1.07); Maskin 2021: RR 1.05 (95% CI 0.88 to 1.25). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1080<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of high‐dose dexamethasone (12 mg or higher) on serious adverse events compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any grade) (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias arising from the missing adjustment for competing risk of death. We present descriptive data only: Maskin 2021: RR 1.02 (95% CI 0.96 to 1.08). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of high‐dose dexamethasone (12 mg or higher) on adverse events compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐acquired infections (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias arising from the missing adjustment for competing risk of death. We present descriptive data only: Maskin 2021: RR 0.89 (95% CI 0.70 to 1.14); Munch 2021b: RR 0.80 (95% CI 0.56 to 1.14). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1080<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of high‐dose dexamethasone (12 mg or higher) on hospital‐acquired infections compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive fungal infections (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias arising from the missing adjustment for competing risk of death. We present descriptive data only: Munch 2021b: RR 0.70 (95% CI 0.36 to 1.34); Maskin 2021: RR 1.00 (95% CI 0.21 to 4.71). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1080<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of high‐dose dexamethasone (12 mg or higher) on invasive fungal infections compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431226044092715996" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431226044092715996</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> We downgraded one level for serious risk of bias (deviations from the intended intervention, no information about the allocation concealment) and one level for serious imprecision (wide confidence interval, low number of participants/events). <br/><sup>b</sup> We downgraded one level for serious risk of bias (no information about the allocation concealment; deviations from the protocol), one level for serious imprecision (wide confidence interval, low number of participants/events) and one level for serious inconsistency (Toroghi 2021 differs from the other studies). <br/><sup>c</sup> We downgraded one level for serious risk of bias (no information about the allocation concealment) and one level for serious imprecision (wide confidence interval, low number of participants/events). <br/><sup>d</sup> We downgraded one level for serious risk of bias (missing adjustment of competing risk of death) and two levels for very serious imprecision (very low number of events/participants).<br/><sup>e</sup> We downgraded one level for serious risk of bias (missing adjustment for competing risk of death, deviations from the intended intervention), two levels for very serious imprecision (very low number of events/participants).<br/><sup>f</sup> We downgraded one level for serious risk of bias (missing adjustment for competing risk of death, protocol deviations, measurement of the outcome, no information about the allocation concealment), two levels for very serious imprecision (very low number of events/participants). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014963-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014963-sec-0009"></div> <p>This work is part of a series of Cochrane Reviews investigating treatments and therapies for coronavirus disease 2019 (COVID‐19). Reviews in this series share information in the background section and methodology with the first published reviews about monoclonal antibodies (<a href="./references#CD014963-bbs2-0149" title="KreuzbergerN , HirschC , ChaiKL , TomlinsonE , KhosraviZ , PoppM , et al. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 9. Art. No: CD013825. [DOI: 10.1002/14651858.CD013825]">Kreuzberger 2021</a>), and convalescent plasma (<a href="./references#CD014963-bbs2-0171" title="PiechottaV , IannizziC , ChaiKL , ValkSJ , KimberC , DorandoE , et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub4]">Piechotta 2021</a>). </p> <section id="CD014963-sec-0010"> <h3 class="title" id="CD014963-sec-0010">Description of the condition</h3> <p>COVID‐19 is a rapidly spreading infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (<a href="./references#CD014963-bbs2-0201" title="World Health Organization. Report of the WHO‐China joint mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 22 March 2021).">WHO 2020a</a>). On 11 March 2020, the World Health Organization (WHO) declared the current COVID‐19 outbreak a pandemic, which is unprecedented in comparison to previous coronavirus outbreaks (severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which each caused fewer than 1000 deaths; <a href="./references#CD014963-bbs2-0199" title="World Health Organization. Cumulative number of reported probable cases of SARS. www.who.int/csr/sars/country/2003_07_11/en (accessed 22 March 2021).">WHO 2007</a>; <a href="./references#CD014963-bbs2-0200" title="World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). www.who.int/emergencies/mers-cov/en (accessed 22 March 2021).">WHO 2019</a>). Despite intensive international efforts to contain its spread, SARS‐CoV‐2 has resulted in an ongoing increase of new weekly cases and deaths in several regions around the globe (<a href="./references#CD014963-bbs2-0204" title="World Health Organization. Weekly epidemiological update - 23 February 2021. www.who.int/publications/m/item/weekly-epidemiological-update---23-february-2021 (accessed 1 March 2021).">WHO 2021a</a>; <a href="./references#CD014963-bbs2-0207" title="World Health Organization. WHO coronavirus disease (COVID-19) dashboard. covid19.who.int (accessed 31 March 2022).">WHO 2022a</a>). In the meantime, the emergence of SARS‐CoV‐2 variants, with the potential for altered transmission or disease characteristics, or to impact the effectiveness of vaccines, therapeutics, diagnostics, or public health and social measures, challenge strategies to control disease spread (<a href="./references#CD014963-bbs2-0208" title="World Health Organization. SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed 4 April 2022).">WHO 2022b</a>). </p> <p>Apart from age and co‐morbidities, vaccination status substantially influences the risk of a severe course of disease, hospitalisation, and mortality. In patients without effective immunisation (individuals who are unvaccinated, incompletely vaccinated, or individuals who fail to develop an immunological response despite being fully vaccinated) this risk is higher among those aged 65 years or older, smokers and those with certain underlying medical conditions such as cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), heart conditions, immunocompromised state, obesity, sickle cell disease or type 2 diabetes mellitus (<a href="./references#CD014963-bbs2-0146" title="HuangC , WangY , LiX , RenL , ZhaoJ , HuY , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020;395(10223):497-506. [DOI: 10.1016/S0140-6736(20)30183-5]">Huang 2020</a>; <a href="./references#CD014963-bbs2-0153" title="LiangW , GuanW , ChenR , WangW , LiJ , XuK , et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology2020;21(3):335-7. [DOI: 10.1016/S1470-2045(20)30096-6]">Liang 2020</a>; <a href="./references#CD014963-bbs2-0201" title="World Health Organization. Report of the WHO‐China joint mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 22 March 2021).">WHO 2020a</a>; <a href="./references#CD014963-bbs2-0209" title="WilliamsonE , WalkerAJ , BhaskaranKJ , BaconS , BatesC , MortonCE , et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature2020;584:430-6. [DOI: 10.1038/s41586-020-2521-4]">Williamson 2020</a>). COVID‐19 case fatality ratios vary widely between countries and reporting periods, from 0.0% to more than 18% (<a href="./references#CD014963-bbs2-0147" title="Johns Hopkins University. Mortality analyses. coronavirus.jhu.edu/data/mortality (accessed 4 April 2022).">Johns Hopkins University 2022</a>). However, these numbers may be misleading as variability in reporting and testing certainly contributed to inaccuracy in case fatality ratios due to varying testing frequency, a lack of reporting dates, and variations in case definitions, especially at the beginning of the pandemic when the main focus was on severe cases (<a href="./references#CD014963-bbs2-0202" title="World Health Organization. Estimating mortality from COVID-19 - scientific brief. www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1 (accessed 22 March 2021).">WHO 2020b</a>). </p> <p>The median incubation time and time to symptom onset depends on the virus variant and is estimated to be three days (range zero to eight days) in the case of the Omicron variant of concern, which is shorter compared with previous reports for the Delta variant and other previously circulating non‐Delta SARS‐CoV‐2 (five to six days) (<a href="./references#CD014963-bbs2-0122" title="BrandalLT , MacDonaldE , VenetiL , RavloT , LangeH , NaseerU , et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. European Surveillance2021;26(50):2101147. [DOI: 10.2807/1560-7917.ES.2021.26.50.2101147]">Brandal 2021</a>; <a href="./references#CD014963-bbs2-0150" title="LauerSA , GrantzKH , BiQ , JonesFK , ZhengQ , MeredithHR , et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine2020;172(9):577–82.">Lauer 2020</a>). Sore throat, cough, fever, headache, fatigue, and myalgia or arthralgia are the most commonly reported symptoms (<a href="./references#CD014963-bbs2-0122" title="BrandalLT , MacDonaldE , VenetiL , RavloT , LangeH , NaseerU , et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. European Surveillance2021;26(50):2101147. [DOI: 10.2807/1560-7917.ES.2021.26.50.2101147]">Brandal 2021</a>; <a href="./references#CD014963-bbs2-0188" title="StruyfT , DeeksJJ , DinnesJ , TakwoingiY , DavenportC , LeeflangMM , et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013665. [DOI: 10.1002/14651858.CD013665]">Struyf 2020</a>). Other symptoms include dyspnoea, chills, nausea or vomiting, diarrhoea, and nasal congestion (<a href="./references#CD014963-bbs2-0201" title="World Health Organization. Report of the WHO‐China joint mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 22 March 2021).">WHO 2020a</a>). The reported frequency of asymptomatic infections varies greatly, depending on the time of the investigation, the cohort investigated, and the virus variant, and ranges between 6% and 96% (<a href="./references#CD014963-bbs2-0124" title="Buitrago-GarciaD , Egli-GanyD , CounotteMJ , HossmannS , ImeriH , Ipekci AzizM , et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLOS Medicine2020;17(9):e1003346.">Buitrago‐Garcia 2020</a>; <a href="./references#CD014963-bbs2-0135" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance2021;26(16):2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD014963-bbs2-0151" title="LewnardJA , HongVX , PatelMM , KahnR , LipsitchM , TartofSY . Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. Preprint server MedRxiv2022. [DOI: 10.1101/2022.01.11.22269045]">Lewnard 2022</a>; <a href="./references#CD014963-bbs2-0166" title="OranDP , TopolEJ . Prevalence of Asymptomatic SARS-CoV-2 Infection. Annals of Internal Medicine2020;173(5):362-7. [DOI: 10.7326/M20-3012]">Oran 2020</a>; <a href="./references#CD014963-bbs2-0210" title="WolterN , JassatW , WalazaS , WelchR , MoultrieH , GroomeM , et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet2022;399(10323):437-46. [DOI: 10.1016/S0140-6736(22)00017-4]">Wolter 2022</a>). </p> <p>A smaller proportion of people are affected by severe (approximately 11% to 20%) or critical (approximately 1% to 5%) disease with hospitalisation and intensive care unit (ICU) admission due to respiratory failure, septic shock, or multiple organ dysfunction syndrome (<a href="./references#CD014963-bbs2-0134" title="FergusonN , GhaniA , HinsleyW , VolzE . Hospitalisation risk for Omicron cases in England. Imperial College London2021;www.gov.uk:1-12. [DOI: 10.25561/93035]">Ferguson 2021</a>; <a href="./references#CD014963-bbs2-0135" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance2021;26(16):2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD014963-bbs2-0151" title="LewnardJA , HongVX , PatelMM , KahnR , LipsitchM , TartofSY . Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. Preprint server MedRxiv2022. [DOI: 10.1101/2022.01.11.22269045]">Lewnard 2022</a>; <a href="./references#CD014963-bbs2-0210" title="WolterN , JassatW , WalazaS , WelchR , MoultrieH , GroomeM , et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet2022;399(10323):437-46. [DOI: 10.1016/S0140-6736(22)00017-4]">Wolter 2022</a>; <a href="./references#CD014963-bbs2-0212" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). In one systematic review and meta‐analysis of international studies, the proportion of patients who died among those treated in the ICU was estimated to be 34% and for those who received invasive mechanical ventilation it was 83% (<a href="./references#CD014963-bbs2-0172" title="PotereN , ValerianiE , CandeloroM , TanaM , PorrecaE , AbbateA , et al. A higher mortality rate and long ventilation times differentiate COVID-19 from severe respiratory infections in flu waves [Eine höhere Letalität und lange Beatmungsdauer unterscheiden COVID-19 von schwer verlaufenden Atemwegsinfektionen in Grippewellen]. Critical Care2020;24(1):389. [DOI: 10.25646/7111]">Potere 2020</a>). However, the hospitalisation and ICU treatment rates seem to depend on the virus variant. Analyses from the United Kingdom show a significant reduction in the relative risk of hospitalisation for adult Omicron cases compared to Delta (<a href="./references#CD014963-bbs2-0134" title="FergusonN , GhaniA , HinsleyW , VolzE . Hospitalisation risk for Omicron cases in England. Imperial College London2021;www.gov.uk:1-12. [DOI: 10.25561/93035]">Ferguson 2021</a>). There may also have been a different threshold for admission to hospital or ICU during the course of the pandemic. Depending on the local pressure on ICU resources, some normal wards will have learned to provide continuous positive airway pressure (CPAP) therapy equivalent to ICU support in other healthcare systems. It is unclear whether triage criteria in some healthcare systems may have influenced admission to hospital or ICU (or both). </p> <p>As the evidence on many of the substances that were investigated for the treatment of COVID‐19 increased over the course of the pandemic, national and international guidelines emerged to support daily clinical decisions (<a href="./references#CD014963-bbs2-0163" title="NICE. COVID-19 rapid guideline: managing COVID-19. https://www.nice.org.uk/guidance/ng191/resources/covid19-rapid-guideline-managing-covid19-pdf-51035553326.">NICE 2021</a>; <a href="./references#CD014963-bbs2-0164" title="COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/.">NIH 2021</a>; <a href="./references#CD014963-bbs2-0205" title="World Health Organization. Therapeutics and COVID-19: living guideline. 6 July 2021. 6. Who do the recommendations apply to?www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.">WHO 2021b</a>). However, so far there are only a few substances with clearly proven benefits and clear recommendations as well as approval by national and international authorities for the treatment of COVID‐19 (<a href="./references#CD014963-bbs2-0132" title="European Medicines Agency (EMA). COVID-19 treatments. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments (accessed 12 December 2021).">EMA 2022</a>; <a href="./references#CD014963-bbs2-0133" title="FDA US Food &amp; Drug Administration. Coronavirus Disease 2019 (COVID-19). Available at: https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19 (accessed 12 December 2021).">FDA 2022</a>; <a href="./references#CD014963-bbs2-0205" title="World Health Organization. Therapeutics and COVID-19: living guideline. 6 July 2021. 6. Who do the recommendations apply to?www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.">WHO 2021b</a>; <a href="./references#CD014963-bbs2-0206" title="WHO. Therapeutics and COVID-19: living guideline. 6 July 2021. 7. Recommendations for therapeutics. 7.6 Systemic corticosteroids (published 2 September 2020). www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2.">WHO 2021c</a>). In light of the extent of the COVID‐19 pandemic and the scarcity of effective treatments, there is still an urgent need for effective therapies to save lives and to reduce the high burden on healthcare systems (either with a high workload caused by COVID‐19 or staff shortages due to infected health care providers), especially in the face of evolving variants of the virus with the potential for increased transmissibility and the limited global availability of vaccines. </p> </section> <section id="CD014963-sec-0011"> <h3 class="title" id="CD014963-sec-0011">Description of the intervention</h3> <p>Corticosteroids are a group of stress hormones produced from the adrenal cortex. In addition to their stress‐mediated mechanisms for generating energy substrates, corticosteroids have anti‐inflammatory and immunosuppressive properties in higher doses and are applied in a wide variety of ways in almost all fields of medicine (<a href="./references#CD014963-bbs2-0118" title="BarnesPJ . How corticosteroids control inflammation: quintiles prize lecture. British Journal of Pharmacology2005;148(3):245-54. [DOI: 10.1038/sj.bjp.0706736]">Barnes 2006</a>; <a href="./references#CD014963-bbs2-0177" title="RhenT , CidlowskiJA . Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. New England Journal of Medicine2005;353(16):1711-23. [DOI: 10.1056/NEJMra050541]">Rhen 2005</a>). For example, corticosteroids are used at high doses of more than 6 mg/kg up to 30 mg/kg methylprednisolone corresponding to more than 30 mg/kg up to 150 mg/kg hydrocortisone equivalents daily for short‐term, high‐dose pulse therapy against solid organ transplant rejection, or about 0.5 mg/kg hydrocortisone equivalents daily for prolonged therapy in different inflammatory lung diseases. A major representative of synthetic corticosteroids is the long‐acting compound dexamethasone. Examples of other synthetic corticosteroids with weaker and shorter activity are methylprednisolone and hydrocortisone (<a href="./references#CD014963-bbs2-0121" title="BourdeauI , StratakisCA . Glucocorticoids, Pharmacology of. In: HenryH , NormanA , editors(s). Encyclopedia of Hormones. Cambridge, MA: Academic Press, 2003:142-50. [DOI: https://doi.org/10.1016/B0-12-341103-3/00122-4]">Bourdeau 2003</a>). To obtain comparable effects, dosage equivalents are needed for the different corticosteroids. However, patients may have a higher risk of infections (including fungal infections) and can suffer from blood glucose problems, hypertension, oedema, and psychiatric side effects such as steroid psychosis and delirium (<a href="./references#CD014963-bbs2-0180" title="SchreiberMP , ColantuoniE , BienvenuOJ , NeufeldKJ , ChenKF , ShanholtzC , et al. Corticosteroids and transition to delirium in patients with acute lung injury. Critical Care Medicine2014;42(6):1480-6. [DOI: 10.1097/CCM.0000000000000247]">Schreiber 2014</a>; <a href="./references#CD014963-bbs2-0195" title="WaljeeAK , RogersMAM , LinP , SingalAG , SteinJD , MarksRM , et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ2017;357(j1415):1-8. [DOI: 10.1136/bmj.j1415]">Waljee 2017</a>). The therapeutic use of higher doses of corticosteroids over a longer time suppresses the hypothalamic‐pituitary‐adrenal axis such that dosage‐tapering may be needed (<a href="./references#CD014963-bbs2-0189" title="TavesMD , Gomez-SanchezCE , SomaKK . Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation and function. American Journal of Physiology - Endocrinology and Metabolism2011;301(1):E11-24. [DOI: 10.1152/ajpendo.00100.2011]">Taves 2011</a>; <a href="./references#CD014963-bbs2-0213" title="YasirM , GoyalA , SonthaliaS . Corticosteroid adverse effects. StatPearls Publishing2022. [https://www.ncbi.nlm.nih.gov/books/NBK531462/]">Yasir 2022</a>).  </p> </section> <section id="CD014963-sec-0012"> <h3 class="title" id="CD014963-sec-0012">How the intervention might work</h3> <p>It has been proposed that corticosteroids could be clinically effective against severe and critical COVID‐19. A substantial percentage of patients develop severe and critical COVID‐19 that requires hospitalisation, with dyspnoea, hypoxia, or relevant lung involvement based on imaging, as well as respiratory failure, shock, or multi‐organ dysfunction requiring ventilator support (<a href="./references#CD014963-bbs2-0190" title="ThibeaultC , MühlemannB , HelbigET , MittermaierM , LingscheidT , Tober-LauP , et al. Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. Infection2021;49(4):703-14.">Thibeault 2021</a>; <a href="./references#CD014963-bbs2-0212" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). In COVID‐19, an insufficient host defence and unbalanced inflammation is thought to play a key role in the pathophysiology of hypoxaemic respiratory failure (<a href="./references#CD014963-bbs2-0181" title="Schulte-SchreppingJ , ReuschN , PaclikD , BaßlerK , SchlickeiserS , ZhangB , et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell2020;182(6):1419-40.">Schulte‐Schrepping 2020</a>). A systemic inflammatory response with the excessive release of cytokines and inflammation mediators can lead to lung injury with the development of acute respiratory distress syndrome (ARDS). The potent anti‐inflammatory effects of corticosteroids might prevent or mitigate these deleterious effects by modulating cytokine release (<a href="./references#CD014963-bbs2-0194" title="VillarJ , FerrandoC , MartínezD , AmbrósA , MuñozT , SolerJA , et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respiratory Medicine2020;8(3):267-76.">Villar 2020</a>). Corticosteroids have been widely used in syndromes closely related to COVID‐19, including SARS, MERS, severe influenza, and community‐acquired pneumonia. The evidence to support or discourage the use of corticosteroids under these conditions has been weak. Corticosteroids can induce harm through immunosuppressive effects during the treatment of infection. In SARS‐CoV‐2 infection, viral shedding appears early in the illness and declines thereafter. The effect of corticosteroid therapy on virus clearance in COVID‐19 needs to be taken into consideration as well as the unwanted adverse events. In acutely critically ill people, dexamethasone has comparatively few side effects (<a href="./references#CD014963-bbs2-0178" title="RochwergB , OczkowskiSJ , SiemieniukRA , AgoritsasT , Belley-CoteE , D'AragonF , et al. Corticosteroids in sepsis: an updated systematic review and meta-analysis. Critical Care Medicine2018;46(9):1411-20. [PMID: 29979221]">Rochwerg 2018</a>). However, patients may suffer from blood glucose variations and potential invasive fungal infections. The therapeutic use of higher doses of corticosteroids over a longer time (more than 21 days) suppresses the hypothalamic‐pituitary‐adrenal axis such that dosage‐tapering may be needed. </p> </section> <section id="CD014963-sec-0013"> <h3 class="title" id="CD014963-sec-0013">Why it is important to do this review</h3> <p>Systemic corticosteroids are now part of the standard therapy for COVID‐19 in patients having additional oxygen supply and/or mechanical ventilation, and are recommended in national and international guidelines (<a href="./references#CD014963-bbs2-0163" title="NICE. COVID-19 rapid guideline: managing COVID-19. https://www.nice.org.uk/guidance/ng191/resources/covid19-rapid-guideline-managing-covid19-pdf-51035553326.">NICE 2021</a>; <a href="./references#CD014963-bbs2-0164" title="COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/.">NIH 2021</a>; <a href="./references#CD014963-bbs2-0205" title="World Health Organization. Therapeutics and COVID-19: living guideline. 6 July 2021. 6. Who do the recommendations apply to?www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.">WHO 2021b</a>), based on systematic reviews regarding interventions for COVID‐19, including corticosteroids. For example, several systematic reviews investigated the association between the use of corticosteroids and COVID‐19‐related mortality based on randomised controlled trials (RCTs) and non‐randomised studies (e.g. <a href="./references#CD014963-bbs2-0126" title="ChaudhuriD , SasakiK , KarkarA , SharifS , LewisK , MammenMJ , et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Medicine2021;47:521–37. [DOI: https://doi.org/10.1007/s00134-021-06394-2]">Chaudhuri 2021</a>; <a href="./references#CD014963-bbs2-0186" title="SterneJA . Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA2020;324(13):1330-41.">Sterne 2020</a>; <a href="./references#CD014963-bbs2-0193" title="Van PaassenJ , VosJS , HoekstraEM , NeumannKM , BootPC , ArbousSM . Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Critical Care2020;24(696):1-22.">Van Paassen 2020</a>). Comparison of different corticosteroids, dosages, and time points of administration in terms of clinical progression, or comparison with other active substances, especially other anti‐inflammatory substances, appears necessary in order to define the role of corticosteroids in the treatment of COVID‐19. This not only relates to effectiveness but also the risk profile, especially with regard to a potential risk of systemic fungal infections. This, moreover, is interconnected with the equity considerations that this updated systematic review is addressing: do participant characteristics such as age, sex, place of residence, or ethnicity stratify clinical outcomes and influence how large a benefit a participant can expect in terms of mortality reduction, or should certain subgroups not receive systemic corticosteroids at all?  </p> <p>We were encouraged by <a href="./references#CD014963-bbs2-0192" title="TomlinsonE , PetkovicJ , WelchV , TugwellP . It's time to increase the global relevance of Cochrane Reviews by applying an ‘equity lens’. Cochrane Database of Systematic Reviews2021;8. [DOI: https://doi.org/10.1002/14651858.ED000155]">Tomlinson 2021</a> to not only present the baseline characteristics of participants but also to analyse outcome data with respect to equity‐related aspects. We aimed to perform subgroup analyses stratified by age group, sex, income group of the country of origin, and ethnicity for mortality outcomes in all comparisons. We used PROGRESS‐Plus to consider the equity‐related stratifying factors below (<a href="./references#CD014963-bbs2-0198" title="WelchV , PetticrewM , TugwellP , MoherD , O'NeillJ , WatersE , et al. PRISMA-equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. PLOS Medicine2012;9(10):e1001333. [DOI: 10.1371/journal.pmed.1001333]">Welch 2012</a>): </p> <p> <ul id="CD014963-list-0001"> <li> <p>Sex: sex of study participants might influence the outcome and potentially access to care (<a href="./references#CD014963-bbs2-0111" title="AhrenfeldtLJ , OtavovaM , ChristensenK , Lindahl-JacobsenR . Sex and age differences in COVID-19 mortality in Europe. Wiener Klinische Wochenschrift2021;133:393-8.">Ahrenfeldt 2020</a>). </p> </li> <li> <p>Age: age is a known risk factor for severe disease and potentially access to care (<a href="./references#CD014963-bbs2-0111" title="AhrenfeldtLJ , OtavovaM , ChristensenK , Lindahl-JacobsenR . Sex and age differences in COVID-19 mortality in Europe. Wiener Klinische Wochenschrift2021;133:393-8.">Ahrenfeldt 2020</a>). </p> </li> <li> <p>Ethnicity: existing studies have indicated that some ethnicities might have a worse outcome (e.g. people of colour, including in a high‐income country), therefore it is important to evaluate whether intervention effects are consistent across all ethnicities (<a href="./references#CD014963-bbs2-0162" title="NavarAM , PurintonSN , HouQ , TaylorRJ , PetersonED . The impact of race and ethnicity on outcomes in 19,584 adults hospitalised with COVID-19. PLOS One2021;16(7):e0254809.">Navar 2021</a>). </p> </li> <li> <p>Place of residence: we did not evaluate at country‐level, but by income ranking (low‐ and middle‐income versus high‐income countries). One reason for this was to see whether this effective treatment has also been evaluated in low‐ and middle‐income countries and whether the results are comparable, as this intervention is cheap and available almost everywhere (<a href="./references#CD014963-bbs2-0165" title="OkeJ , HeneghanC . Global Covid-19 case fatality rates. https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/ (accessed 17 August 2022).">Oke 2020</a>). </p> </li> </ul> </p> <p>The 'living' approach in evidence synthesis is necessary in order to incorporate new knowledge into the data evaluation, to keep the evidence assessment up‐to‐date and thus to offer a better basis for recommendations and everyday clinical decisions. This Cochrane Review is the first update of our published review (<a href="./references#CD014963-bbs2-0214" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 16 August 2021, Issue 8. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Wagner 2021a</a>). The update was necessary because important new studies have been published in the meantime. It will fill current evidence gaps by identifying, describing, evaluating, and meta‐analysing RCTs of systemic corticosteroids in relation to clinical outcomes in COVID‐19. Unlike other systematic reviews in this field, it considers the outcome clinical improvement (defined as <i>Discharged alive</i> ) and worsening (defined as a combined endpoint <i>New need for invasive ventilation or death</i>), and provides equity‐relevant subgroup analyses and methodologically critical sensitivity analyses. This living systematic review will be updated once new evidence becomes available. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014963-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014963-sec-0014"></div> <p>To assess whether and at which doses systemic corticosteroids are effective and safe in the treatment of people with COVID‐19, and to keep up‐to‐date with the evolving evidence base using a living systematic review approach. Apart from adding newly published evidence to existing and new comparisons, we would like to assess equity‐related aspects quantitatively in subgroup analyses where possible. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014963-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014963-sec-0015"></div> <section id="CD014963-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014963-sec-0017"> <h4 class="title">Types of studies</h4> <p>The main description of methods is based on Cochrane Haematology's standard template and is in line with a series of Cochrane Reviews investigating treatments and therapies against COVID‐19. We made specific adaptations related to the research question if necessary. The protocol for this review was registered with PROSPERO on 21 December 2020 (<a href="./references#CD014963-bbs2-0215" title="WagnerC , GrieselM , MicholajewskaA , FichtnerF , SkoetzN . Corticosteroids for the treatment of COVID-19 (part of German Ecosystem CEO-Sys). PROSPERO 1 February 2021 (available from www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=227450). [PROSPERO: CRD42020227450]">Wagner 2021b</a>). </p> <p>To assess the efficacy and safety of systemic corticosteroids against COVID‐19, we included RCTs, as this study design, if performed appropriately, provides the best evidence for experimental therapies in highly controlled therapeutic settings. We used the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014963-bbs2-0141" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from: training.cochrane.org/handbook2022.">Higgins 2022a</a>). We would also have accepted cluster‐randomised trials for inclusion, if we had found any. </p> <p>We included the following formats if sufficient information was available on study design, characteristics of participants, interventions, and outcomes: </p> <p> <ul id="CD014963-list-0002"> <li> <p>full‐text publications;</p> </li> <li> <p>preprint articles.</p> </li> </ul> </p> <p>For our previous version of the review (<a href="./references#CD014963-bbs2-0214" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 16 August 2021, Issue 8. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Wagner 2021a</a>), we included preprints for a complete overview of ongoing research activity, especially for tracking newly emerging studies about the use of systemic corticosteroids against COVID‐19, but in this updated version all studies that contributed to data/analyses are peer‐reviewed RCTs.  </p> <p>We did not apply any limitation with respect to the length of follow‐up. The types of study designs remained the same as in the first version of this review, and we did not include any additional study designs that may be more suited for conducting equity‐related analyses. </p> </section> <section id="CD014963-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adults with a suspected or confirmed diagnosis of COVID‐19 (as described in the study) and we did not exclude any studies based on sex, ethnicity, disease severity, or setting. </p> <p>We excluded studies evaluating the use of corticosteroids against coronavirus diseases such as SARS or MERS, or other viral diseases, such as influenza. If studies enrolled populations with or exposed to mixed viral diseases, we had planned to only include these if the study authors provided subgroup data for SARS‐CoV‐2 infection. </p> </section> <section id="CD014963-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included the following interventions:</p> <p> <ul id="CD014963-list-0003"> <li> <p>any type or dose of systemic corticosteroids;</p> </li> <li> <p>oral or intravenous application.</p> </li> </ul> </p> <p>We had planned to include the following comparisons:</p> <p> <ul id="CD014963-list-0004"> <li> <p>systemic corticosteroids plus standard care versus standard care (plus/minus placebo);</p> </li> <li> <p>dose comparisons;</p> </li> <li> <p>timing comparisons (early versus late);</p> </li> <li> <p>different types of corticosteroids;</p> </li> <li> <p>systemic corticosteroid versus other active substances.</p> </li> </ul> </p> <p>However, comparisons of different timings (early versus late) and systemic corticosteroids versus other active substances were not available. </p> <p>Standard care in both arms should be similar.</p> <p>We excluded the following interventions:</p> <p> <ul id="CD014963-list-0005"> <li> <p>corticosteroid plus other active substance versus standard care;</p> </li> <li> <p>topical corticosteroids;</p> </li> <li> <p>inhaled corticosteroids;</p> </li> <li> <p>corticosteroids for long‐COVID treatment.</p> </li> </ul> </p> </section> <section id="CD014963-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We evaluated core outcomes in accordance with the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for COVID‐19 patients (<a href="./references#CD014963-bbs2-0129" title="Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 2 November 2020).">COMET 2020</a>; <a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>), and additional outcomes that have been prioritised by consumer representatives and the panel of the German 'National Treatment Guidance for Hospitalised COVID‐19 Patients' (<a href="./references#CD014963-bbs2-0148" title="KlugeS , JanssensU , WelteT , Weber-CarstensS , SchälteG , SpinnerCD , et al. S3 Guideline – recommendations for inpatient therapy of patients with COVID-19 [S3-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19]. www.awmf.org/uploads/tx_szleitlinien/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2022-03.pdf (accessed 7 April 2022).">Kluge 2022</a>). </p> <p>We defined this outcome set for hospitalised individuals with a confirmed or suspected diagnosis of COVID‐19 and moderate to severe disease, according to the WHO clinical progression scale stage 4 to 9 (<a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>); that is, all patients who were hospitalised because of symptomatic COVID‐19 treated with all different levels of respiratory support (no additional oxygen, low‐flow oxygen prongs or mask ('low‐flow oxygen' only hereafter), high‐flow oxygen or non‐invasive ventilation (NIV), invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO)), and individuals with a confirmed or suspected diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease, according to the WHO clinical progression scale (<a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>). Of note, readers may encounter respiratory support both as a baseline characteristic and as an outcome measure ‐ in the latter case we used changes in the level of support. </p> <section id="CD014963-sec-0021"> <h5 class="title">Individuals with a suspected or confirmed diagnosis of COVID‐19 and moderate to severe disease </h5> <section id="CD014963-sec-0022"> <h6 class="title">Prioritised outcomes (included in the summary of findings tables)</h6> <p> <ul id="CD014963-list-0006"> <li> <p>Mortality: </p> <ul id="CD014963-list-0007"> <li> <p>All‐cause mortality</p> <ul id="CD014963-list-0008"> <li> <p>Up to day 30 (from here on for simplicity in this version of the review <i>All‐cause mortality up to 30 days</i>) </p> </li> <li> <p>Any longer observation period from day 31 on (from here on <i>All‐cause mortality up to 120 days</i>) </p> </li> </ul> </li> </ul> </li> <li> <p>Improvement of clinical status during the longest observation period available:</p> <ul id="CD014963-list-0009"> <li> <p>Participants discharged alive (without clinical worsening or death)</p> </li> </ul> </li> <li> <p>Worsening of clinical status during the longest observation period available:</p> <ul id="CD014963-list-0010"> <li> <p>New need for invasive mechanical ventilation or death</p> </li> </ul> </li> <li> <p>Serious adverse events, defined as the number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events)) </p> </li> <li> <p>Adverse events (any grade), defined as the number of participants with any adverse event </p> </li> <li> <p>Specific adverse events: hospital‐acquired infections, defined as the number of participants with an event </p> </li> <li> <p>Specific adverse events: invasive fungal infections, defined as the number of participants with an event </p> </li> </ul> </p> </section> <section id="CD014963-sec-0023"> <h6 class="title">Prioritised outcomes (not included in the summary of findings tables):</h6> <p> <ul id="CD014963-list-0011"> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) during the longest period available </p> </li> </ul> </p> </section> <section id="CD014963-sec-0024"> <h6 class="title">Additional outcomes (not included in the summary of findings tables)</h6> <p> <ul id="CD014963-list-0012"> <li> <p>New need for dialysis during the longest period available</p> </li> <li> <p>Viral clearance, assessed with reverse transcription polymerase chain reaction (RT‐PCR) test for SARS‐CoV‐2 at baseline, up to 3, 7, and 15 days </p> </li> </ul> </p> </section> </section> <section id="CD014963-sec-0025"> <h5 class="title">Individuals with a suspected or confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease </h5> <section id="CD014963-sec-0026"> <h6 class="title">Prioritised outcomes (included in the summary of findings tables)</h6> <p> <ul id="CD014963-list-0013"> <li> <p>Mortality: all‐cause mortality up to day 30 or any longer observation period</p> </li> <li> <p>Admission to hospital or death within 28 days</p> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) during the longest period available </p> </li> <li> <p>Serious adverse events, defined as the number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events) </p> </li> <li> <p>Adverse events (any grade), defined as the number of participants with any adverse event </p> </li> <li> <p>Specific adverse events: infections, defined as the number of participants with an event </p> </li> <li> <p>Specific adverse events: invasive fungal infections, defined as the number of participants with an event </p> </li> </ul> </p> </section> <section id="CD014963-sec-0027"> <h6 class="title">Additional outcomes (not included in the summary of findings tables)</h6> <p> <ul id="CD014963-list-0014"> <li> <p>Viral clearance, assessed with RT‐PCR test for SARS‐CoV‐2 at baseline, up to 3, 7, and 15 days </p> </li> </ul> </p> </section> </section> <section id="CD014963-sec-0028"> <h5 class="title">Timing of outcome measurement</h5> <p>In the case of time‐to‐event analysis, for example, for time to clinical improvement, we included the outcome measure based on the longest follow‐up time. We also collected information on outcomes from all other time points reported in the publications. </p> </section> </section> </section> <section id="CD014963-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD014963-sec-0030"> <h4 class="title">Electronic searches</h4> <p>Our information specialist (MIM) conducted systematic searches in the following sources from the inception of each database to 6 January 2022 (search date for all databases) and did not place restrictions on the language of publication. </p> <p> <ul id="CD014963-list-0015"> <li> <p>Cochrane COVID‐19 Study Register (CCSR) (<a href="https://covid-19.cochrane.org/" target="_blank">www.covid-19.cochrane.org</a>), comprising: </p> <ul id="CD014963-list-0016"> <li> <p>MEDLINE (PubMed), weekly updates;</p> </li> <li> <p>Embase.com, weekly updates;</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), daily updates; </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch</a>), weekly updates; </p> </li> <li> <p>medRxiv (<a href="https://www.medrxiv.org" target="_blank">www.medrxiv.org</a>), weekly updates; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), monthly updates.</p> </li> </ul> </li> <li> <p>Web of Science Core Collection (Clarivate), from 1 January 2020 onwards:</p> <ul id="CD014963-list-0017"> <li> <p>Science Citation Index Expanded (1945 to present);</p> </li> <li> <p>Emerging Sources Citation Index (2015 to present).</p> </li> </ul> </li> <li> <p>WHO COVID‐19 Global literature on coronavirus disease (<a href="https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/" target="_blank">search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/</a>). </p> </li> </ul> </p> <p>Database search results for Web of Science were restricted to publications from 2020 to the present date, as no treatment studies on COVID‐19 were registered prior to January 2020. For detailed search strategies, see <a href="./appendices#CD014963-sec-0152">Appendix 1</a> (previous review version) and <a href="./appendices#CD014963-sec-0153">Appendix 2</a> (current review version). </p> <p>We did not conduct separate searches of the databases required by the Methodological Expectations of Cochrane Intervention Reviews (MECIR) standards (<a href="./references#CD014963-bbs2-0140" title="HigginsJP , LassersonT , ChandlerJ , ToveyD , ThomasJ , FlemyngE , et al. Methodological expectations of Cochrane intervention reviews. www.community.cochrane.org/mecir-manual/ (accessed 6 January 2022).">Higgins 2022</a>), since these databases are already being regularly searched for the production of the CCSR. </p> </section> <section id="CD014963-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We identified other potentially eligible studies or ancillary publications by searching the reference lists of included studies and systematic reviews. </p> </section> </section> <section id="CD014963-sec-0032"> <h3 class="title" id="CD014963-sec-0032">Data collection and analysis</h3> <section id="CD014963-sec-0033"> <h4 class="title">Selection of studies</h4> <p>Two out of three review authors (MSp, CW, ALF) independently screened the results of the search strategies for eligibility for the review by reading the titles and abstracts using <a href="./references#CD014963-bbs2-0167" title="OuzzaniM , HammadyH , FedorowiczZ , ElmagarmidA . Rayyan — a web and mobile app for systematic reviews. Systematic Reviews2016;5(1):210. [DOI: 10.1186/s13643-016-0384-4]">Ouzzani 2016</a>. We coded the abstracts as either 'include' or 'exclude'. In the case of disagreement or if it was unclear whether we should retrieve the abstract or not, we obtained the full‐text publication for further discussion. Two review authors assessed the full‐text articles of selected studies. If the two review authors were unable to reach a consensus, they consulted a senior review author to reach a final decision. </p> <p>We documented the study selection process in a flow chart, as recommended in the PRISMA statement (<a href="./references#CD014963-bbs2-0160" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>), and showed the total numbers of retrieved references and the numbers of included and excluded studies. We listed all studies that we excluded after full‐text assessment and the reasons for their exclusion in the <a href="./references#CD014963-sec-0174" title="">Characteristics of excluded studies</a> section. </p> </section> <section id="CD014963-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>We conducted data extraction according to the guidelines proposed by Cochrane (<a href="./references#CD014963-bbs2-0152" title="LiT , HigginsJP , Deeks JJ (editors). Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Li 2021</a>). Two out of five review authors (CW, MSp, JD, ALF, MG) extracted data independently and in duplicate, using a customised data extraction form developed in Microsoft Excel (<a href="./references#CD014963-bbs2-0158" title="Microsoft Excel. Microsoft Corporation. Microsoft Corporation, 2018. office.microsoft.com/excel.">Microsoft 2018</a>). We resolved disagreements by discussion. If we were unable to reach agreement, we involved a third review author. </p> <p>Two review authors (CW, MSp) independently assessed eligible studies obtained in the process of study selection (as described above) for methodological quality and risk of bias. If the review authors were unable to reach a consensus, they consulted a third review author. </p> <p>We extracted the following information if reported:</p> <p> <ul id="CD014963-list-0018"> <li> <p>General information: author, title, source, publication date, country, language, duplicate publications </p> </li> <li> <p>Study characteristics: trial design, setting and dates, source of participants, inclusion/exclusion criteria, comparability of groups, treatment cross‐overs, compliance with assigned treatment, length of follow‐up </p> </li> <li> <p>Participant characteristics: age, sex, ethnicity, number of participants recruited/allocated/evaluated, number of participants with positive, negative or unknown RT‐PCR test result, additional diagnoses, severity of disease, previous treatments, concurrent treatments, co‐morbidities (e.g. diabetes, immunosuppression), vaccination status </p> </li> <li> <p>Interventions: type of corticosteroid, dose, frequency, timing, duration and route of administration, setting (e.g. inpatient, outpatient), duration of follow‐up </p> </li> <li> <p>Control interventions: placebo, no treatment or other intervention; dose, frequency, timing, duration and route of administration, setting, duration of follow‐up </p> </li> <li> <p>Outcomes: as specified under <a href="#CD014963-sec-0020">Types of outcome measures</a> </p> </li> <li> <p>Risk of bias assessment: randomisation process, deviations from the intended interventions, missing outcome data, measurement of the outcome, selection of the reported results </p> </li> <li> <p>Equity‐related aspects as per the PROGRESS‐Plus approach (<a href="./references#CD014963-bbs2-0198" title="WelchV , PetticrewM , TugwellP , MoherD , O'NeillJ , WatersE , et al. PRISMA-equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. PLOS Medicine2012;9(10):e1001333. [DOI: 10.1371/journal.pmed.1001333]">Welch 2012</a>): place of residence, race/ethnicity, occupation, sex, religion, education, socioeconomic status, social capital and personal characteristics associated with discrimination (e.g. age, disability); features of relationships; time‐dependent relationships  </p> <ul id="CD014963-list-0019"> <li> <p>Countries were classified socio‐economically based on the World Bank's latest version of the Country and Lending Groups (<a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]">World Bank 2021</a>) </p> </li> </ul> </li> </ul> </p> </section> <section id="CD014963-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the RoB 2 tool (version of 22 August 2019) to analyse the risk of bias of study results (<a href="./references#CD014963-bbs2-0185" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweN , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). Of interest for this review is the effect of the assignment to the intervention (the intention‐to‐treat (ITT) effect); thus, we performed all assessments with RoB 2 on this effect. The outcomes that we assessed are those specified for inclusion in the summary of findings table. </p> <p>Two out of six review authors (CW, MSp, MG, ALF, AAN, JD) independently assessed the risk of bias for each outcome. In case of discrepancies among their judgements and inability to reach consensus, we consulted the third review author to reach a final decision. We assessed the following types of bias as outlined in Chapter 8 (<a href="./references#CD014963-bbs2-0142" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022b</a>) and for cluster‐RCTs as outlined in Chapter 23 (Table 23.1.a; <a href="./references#CD014963-bbs2-0143" title="HigginsJ , EldridgeS , LiT . Chapter 23: Including variants on randomised trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 202s). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022c</a>) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>: </p> <p>For RCTs:</p> <p> <ul id="CD014963-list-0020"> <li> <p>bias arising from the randomisation process;</p> </li> <li> <p>bias due to deviations from the intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome;</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ul> </p> <p>For cluster‐RCTs:</p> <p> <ul id="CD014963-list-0021"> <li> <p>bias arising from the randomisation process;</p> </li> <li> <p>bias arising from the timing of identification and recruitment of participants;</p> </li> <li> <p>bias due to deviations from intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome;</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ul> </p> <p>To address these types of bias we used the signalling questions recommended in RoB 2 and made a judgement using the following options. </p> <p> <ul id="CD014963-list-0022"> <li> <p>'Yes': if there is firm evidence that the question is fulfilled in the study (i.e. the study is at low or high risk of bias for the given the direction of the question). </p> </li> <li> <p>'Probably yes': a judgement has been made that the question is fulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'No': if there is firm evidence that the question is unfulfilled in the study (i.e. the study is at low or high risk of bias for the given the direction of the question). </p> </li> <li> <p>'Probably no': a judgement has been made that the question is unfulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'No information': if the study report does not provide sufficient information to allow any judgement. </p> </li> </ul> </p> <p>We used the algorithms proposed by RoB 2 to assign each domain one of the following levels of bias: </p> <p> <ul id="CD014963-list-0023"> <li> <p>low risk of bias;</p> </li> <li> <p>some concerns;</p> </li> <li> <p>high risk of bias.</p> </li> </ul> </p> <p>Subsequently, we derived an overall risk of bias rating for each pre‐specified outcome in each study in accordance with the following suggestions. </p> <p> <ul id="CD014963-list-0024"> <li> <p>'Low risk of bias': we judge the trial to be at low risk of bias for all domains for this result. </p> </li> <li> <p>'Some concerns': we judge the trial to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain. </p> </li> <li> <p>'High risk of bias': we judge the trial to be at high risk of bias in at least one domain for the result, or we judge the trial to have some concerns for multiple domains in a way that substantially lowers confidence in the results. </p> </li> </ul> </p> <p>We used the RoB 2 Excel tool to implement RoB 2 (available on the <a href="https://www.riskofbias.info/" target="_blank">riskofbias.info</a> website), and stored and presented our detailed RoB 2 assessments in the analyses section and as supplementary online material. </p> <p>As we collected the data from the studies and assessed RoB 2, we noticed an issue with competing risk of death (<a href="./references#CD014963-bbs2-0128" title="Competing Risk Analysis. Columbia University Mailman School of Public Health Website. Available from www.publichealth.columbia.edu/research/population-health-methods/competing-risk-analysis (accessed 13 July 2021). [ACCESSED JULY 13 2021: https://www.publichealth.columbia.edu/research/population-health-methods/competing-risk-analysis]">Columbia Public Health 2021</a> as easily accessible introduction), which we discussed in <a href="#CD014963-sec-0135">Quality of the evidence</a> of the first version of the review. We dealt with this issue within domain 3 of RoB 2 (<a href="./references#CD014963-bbs2-0139" title="HigginsJP , SavovicJ , PageMJ , SterneJA . Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2 (accessed 7 July 2021).">Higgins 2019</a>). For risk of bias in the subgroup analyses of mortality we applied the same assessments as for the respective studies' main mortality result, irrespective of whether data were primarily published or sent in upon request. </p> <p>Additionally, we pioneered critical appraisal of specific sources of bias in platform trials using the <a href="./references#CD014963-bbs2-0168" title="ParkJJ , HarariO , DronL , LesterRT , ThorlundK , MillsEJ . An overview of platform trials with a checklist for clinical readers. Journal of Clinical Epidemiology2020;125:1-8. [DOI: 10.1016/j.jclinepi.2020.04.025]">Park 2020</a> checklist. Sources of bias were not assessed on result but at study level and this did not have a direct impact on GRADEing of the evidence. </p> </section> <section id="CD014963-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous outcomes, we recorded the mean, standard deviation (SD), and total number of participants in both treatment and control groups. Where continuous outcomes used the same scale, we performed analyses using the mean difference (MD) with 95% confidence intervals (CIs). For continuous outcomes measured with different scales, we had planned to perform analyses using the standardised mean difference (SMD). For interpreting SMDs, we would have re‐expressed SMDs in the original units of a particular scale with the most clinical relevance and impact. </p> <p>For dichotomous outcomes, we recorded the number of events and total number of participants in both treatment and control groups. We reported the pooled risk ratio (RR) with a 95% CI (<a href="./references#CD014963-bbs2-0130" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). </p> <p>If available, we had planned to extract and report hazard ratios (HRs) for time‐to‐event outcomes (e.g. time to liberation from invasive ventilation), but we did not find data to estimate them using the methods proposed by Parmar and Tierney (<a href="./references#CD014963-bbs2-0169" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>; <a href="./references#CD014963-bbs2-0191" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [DOI: 10.1186/1745-6215-8-16]">Tierney 2007</a>). </p> </section> <section id="CD014963-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>The aim of this review is to summarise studies that analyse data at the level of the individual. We would also have accepted cluster‐randomised trials for inclusion, if we had found any. We collated multiple reports of one study so that the study, and not the report, is the unit of analysis. In case of adverse events, serious adverse events, hospital‐acquired infections, and invasive fungal infections only the number of events and not the number of participants are counted in most of the studies. We therefore asked the authors if they could provide us with the data as the number of participants with at least one event, i.e. as dichotomous data. </p> <section id="CD014963-sec-0038"> <h5 class="title">Studies with multiple treatment groups</h5> <p>As recommended in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014963-bbs2-0144" title="HigginsJP , LiT , DeeksJJ , editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022d</a>), for studies with multiple treatment groups of the same intervention (i.e. dose, route of administration), we planned to evaluate whether study arms were sufficiently homogeneous to be combined. If arms could not be pooled, we planned to compare each arm with the common comparator separately. For pair‐wise meta‐analysis, we planned to split the ‘shared’ group into two or more groups with smaller sample size, and include two or more (reasonably independent) comparisons. For this purpose, for dichotomous outcomes, we planned to divide both the number of events and the total number of participants, and for continuous outcomes, we planned to divide the total number of participants with unchanged means and SDs. </p> </section> </section> <section id="CD014963-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> suggests a number of potential sources for missing data, which we took into account at study level, at outcome level, and at summary data level (<a href="./references#CD014963-bbs2-0130" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). At all levels, it is important to differentiate between data 'missing at random', which may often be unbiased, and 'not missing at random', which may bias study and thus review results. </p> <p>Missing outcome data on general safety and corticosteroid‐specific safety, and missing adjustment for competing risk of death, had a negative impact on the certainty of the evidence in the first version of this review. Moreover, the influence of equity‐related aspects on mortality had not been examined quantitatively. Therefore, we requested from all corresponding authors data for <i>Serious adverse events</i> , <i>Adverse events</i> , <i>Hospital‐acquired infections</i> , and <i>Invasive fungal infections</i> standardised on the nominal scale as a dichotomous outcome, <i>Participants with at least one event/patients at risk</i>. Additionally, we requested safety data adjusted for competing risk of death and mortality data stratified by age group, sex, and ethnicity to explore equity‐related aspects. Finally, we asked corresponding authors of studies awaiting classification to clarify registration, protocol, and randomisation issues (<a href="./references#CD014963-bbs2-0050" title="GautamPB , KumarA , KannojiaBL , ChaudharyR . A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease. Asian Journal of Medical Sciences2021;12(12):17-22. [DOI: 10.3126/ajms.v12i12.39294]">Gautam 2021</a>; <a href="./references#CD014963-bbs2-0051" title="GhaneiM , Solaymani‑DodaranM , QazviniA , Ghazale AH, SetarehdanSA , SaadatSH , et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respiratory Research2021;22(245):1-14. [DOI: 10.1186/s12931-021-01833-6]">Ghanei 2021</a>; <a href="./references#CD014963-bbs2-0066" title="NCT04519385. Tocilizumab versus dexamethasone in severe COVID19 cases. clinicaltrials.gov/show/NCT04519385 (first received 19 August 2020). RashadA , MousaS , Nafady‑HegoH , NafadyA , ElgendyH . Short term survival of critically ill COVID‑19 Egyptian patients on assisted ventilation treated by either dexamethasone or tocilizumab. Scientific Reports2021;11(8816):1-7. [DOI: 10.1038/s41598-021-88086-x]">Rashad 2021</a>), and make available the manuscript where only an abstract was published (<a href="./references#CD014963-bbs2-0058" title="MontalvanE , CarcamoB , PalacionD , RiveraS , EstevezR , NorwoodD , et al. High-dose vs low-dose dexamethasone in patients with COVID-19 in a tertiary hospital in Western Honduras. Chest2021;160(4):A1117-8. [DOI: 10.1016/j.chest.2021.07.1027]">Montalvan 2021</a>). </p> </section> <section id="CD014963-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of treatment effects between trials using a Chi² test with a significance level at P &lt; 0.1. We used the I² statistic (<a href="./references#CD014963-bbs2-0138" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), and visual examination, to assess possible heterogeneity (I² statistic &gt; 30% to signify moderate heterogeneity, I² statistic &gt; 75% to signify considerable heterogeneity; <a href="./references#CD014963-bbs2-0130" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). If the I² statistic was above 80%, we had planned to explore potential causes through sensitivity and subgroup analyses (see <a href="#CD014963-sec-0044">Sensitivity analysis</a> and <a href="#CD014963-sec-0043">Subgroup analysis and investigation of heterogeneity</a>). For future updates, if we cannot identify reasons for heterogeneity in subgroup or sensitivity analysis, we will not perform a meta‐analysis but, instead, provide outcome data for all studies without an overall effect estimate. </p> </section> <section id="CD014963-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>As mentioned above, we searched trials registries to identify completed studies that have not been published elsewhere, to minimise or determine publication bias. We intended to explore potential publication bias by generating a funnel plot and statistically testing this by conducting a linear regression test for meta‐analyses involving at least 10 trials (<a href="./references#CD014963-bbs2-0185" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweN , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). We considered P &lt; 0.1 as significant for this test. We planned to generate a funnel plot, but had fewer than 10 studies reporting a comparable outcome. </p> </section> <section id="CD014963-sec-0042"> <h4 class="title">Data synthesis</h4> <p>If the clinical and methodological characteristics of individual studies were sufficiently homogeneous, we pooled the data in a meta‐analysis. We performed analyses according to the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014963-bbs2-0130" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). Additionally, we analysed studies that included different severities of disease separately, grouping them with respect to disease severity according to need for respiratory support at randomisation (see <a href="#CD014963-sec-0020">Types of outcome measures</a>). We treated placebo and standard care as the same intervention, as well as standard care at different institutions and time points. </p> <p>We used Review Manager Web (RevMan Web) software for analyses (<a href="./references#CD014963-bbs2-0176" title="Review Manager Web (RevMan Web). The Cochrane Collaboration, 2019. revman.cochrane.org.">RevMan Web 2019</a>). One review author entered the data into RevMan Web, and a second review author checked the data for accuracy. For most of our analyses we used the random‐effects model as planned and as required to take into account differences, for example, in settings, disease severity, and co‐medications. However, in rare cases (i.e. <a href="./references#CD014963-fig-0005" title="">Analysis 1.3</a>; <a href="./references#CD014963-fig-0006" title="">Analysis 1.4</a>; <a href="./references#CD014963-fig-0026" title="">Analysis 9.2</a>), we decided to report the fixed‐effect model as the primary analysis so that very small studies with few events did not receive extraordinary weight compared to very large studies with many events. If we deemed meta‐analysis inappropriate for a certain outcome because of heterogeneity of the included studies both statistically or conceptually or due to too high a risk of bias, we presented descriptive statistics only. </p> <p>If meta‐analysis was possible, we assessed the effects of potential biases in sensitivity analyses (see <a href="#CD014963-sec-0044">Sensitivity analysis</a>). For binary outcomes, we based the estimation of the between‐study variance on the Mantel‐Haenszel method. We explored heterogeneity above 80% with subgroup and sensitivity analyses. </p> </section> <section id="CD014963-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Our focus was on both clinical relevance and equity, therefore we performed subgroup analyses for all‐cause mortality based on participant characteristics that may stratify health outcomes for every comparison in which data were available, irrespective of observed statistical heterogeneity. </p> <p><b>Clinical relevance</b> </p> <p> <ul id="CD014963-list-0025"> <li> <p>Respiratory support at randomisation</p> </li> <li> <p>Type of systemic corticosteroid: dexamethasone versus (methyl‐)prednisolone versus hydrocortisone </p> </li> </ul> </p> <p><b>Equity‐related aspects</b> </p> <p> <ul id="CD014963-list-0026"> <li> <p>Sex: female versus male</p> </li> <li> <p>Age: &lt; 70 years versus ≥ 70 years</p> </li> <li> <p>Ethnicity: Black, Asian, or other versus White versus unknown</p> </li> <li> <p>Place of residence: high‐income countries (HIC) versus low‐ and middle‐income countries (LMIC) </p> </li> </ul> </p> <p>We also performed subgroup analyses for clinical improvement (discharged alive) because the I² statistic was found to be above 80%. We made our decision on subgroup definitions before performing the first analyses. For future updates, if the I² statistic is found to be above 80% for the other outcomes, we will also conduct subgroup analyses for these outcomes (see also <a href="#CD014963-sec-0040">Assessment of heterogeneity</a>). </p> </section> <section id="CD014963-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We performed the following sensitivity analysis for all‐cause mortality up to 30 and 120 days as well as for clinical improvement (discharged alive) because I² statistic for the latter was found to be above 80%: </p> <p> <ul id="CD014963-list-0027"> <li> <p>Risk of bias assessment components (studies with a low risk of bias or some concerns versus studies with a high risk of bias). </p> </li> <li> <p>Platform trials versus no platform trials.</p> </li> <li> <p>Fixed‐effect model versus random‐effects model.</p> </li> <li> <p>Preprint versus journal publication.</p> </li> </ul> </p> </section> <section id="CD014963-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the certainty of the evidence for the following outcomes, and prepared one summary of findings table per population. </p> <section id="CD014963-sec-0046"> <h5 class="title">Summary of findings</h5> <p>We used the <a href="./references#CD014963-bbs2-0136" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 18 July 2021. Available at gradepro.org.">GRADEpro GDT</a> software to create summary of findings tables. For time‐to‐event outcomes, we would have calculated absolute effects at specific time points, as recommended in the GRADE guidance (<a href="./references#CD014963-bbs2-0184" title="SkoetzN , GoldkuhleM , Van DalenEC , AklEA , TrivellaM , MustafaRA , et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles. Journal of Clinical Epidemiology2020;118:124-31.">Skoetz 2020</a>). </p> <p>According to Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, the “most critical and/or important health outcomes, both desirable and undesirable, limited to seven or fewer outcomes” should be included in the summary of findings table(s) (<a href="./references#CD014963-bbs2-0182" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>). We included outcomes prioritised according to the core outcome sets for studies for the treatment of patients with confirmed or suspected COVID‐19 (<a href="./references#CD014963-bbs2-0129" title="Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 2 November 2020).">COMET 2020</a>), and patient relevance. These outcomes were as follows. </p> <section id="CD014963-sec-0047"> <h6 class="title">Individuals with a suspected or confirmed diagnosis of COVID‐19 and moderate to severe disease </h6> <p> <ul id="CD014963-list-0028"> <li> <p>All‐cause mortality</p> <ul id="CD014963-list-0029"> <li> <p>Up to day 30 (from here on for simplicity in this version of the review <i>All‐cause mortality up to 30 days</i>) </p> </li> <li> <p>Any longer observation period from day 31 on (from here on for simplicity in this version of the review <i>All‐cause mortality up to 120 days</i>) </p> </li> </ul> </li> <li> <p>Improvement of clinical status during the longest observation period available:</p> <ul id="CD014963-list-0030"> <li> <p>Participants discharged alive (without clinical worsening or death)</p> </li> </ul> </li> <li> <p>Worsening of clinical status during the longest observation period available:</p> <ul id="CD014963-list-0031"> <li> <p>New need for invasive mechanical ventilation or death; that is, transition to WHO 7 to 9 if 6 or lower at baseline (<a href="#CD014963-fig-0001">Figure 1</a>) </p> </li> </ul> </li> <li> <p>Serious adverse events, defined as the number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events) </p> </li> <li> <p>Adverse events (any grade), defined as the number of participants with any adverse event </p> </li> <li> <p>Specific adverse events: hospital‐acquired infections</p> </li> <li> <p>Specific adverse events: invasive fungal infections</p> </li> </ul> </p> <div class="figure" id="CD014963-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="WHO Clinical Progression Scale (Marshall 2020). Copyright © 2020 Elsevier Ltd. All rights reserved: reproduced with permission.ECMO = extracorporeal membrane oxygenation; FiO2 = fraction of inspired oxygen; NIV = non‐invasive ventilation; pO2 = partial pressure of oxygen; RNA = ribonucleic acid; SpO2 = oxygen saturation.*If hospitalised for isolation only, record status for ambulatory patients." data-id="CD014963-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>WHO Clinical Progression Scale (<a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>). Copyright © 2020 Elsevier Ltd. All rights reserved: reproduced with permission. </p> <p>ECMO = extracorporeal membrane oxygenation; FiO<sub>2</sub> = fraction of inspired oxygen; NIV = non‐invasive ventilation; pO<sub>2</sub> = partial pressure of oxygen; RNA = ribonucleic acid; SpO<sub>2</sub> = oxygen saturation. </p> <p>*If hospitalised for isolation only, record status for ambulatory patients.</p> </div> </div> </div> </section> <section id="CD014963-sec-0048"> <h6 class="title">Individuals with a suspected or confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease </h6> <p> <ul id="CD014963-list-0032"> <li> <p>All‐cause mortality</p> <ul id="CD014963-list-0033"> <li> <p>Up to day 30</p> </li> <li> <p>Any longer observation period</p> </li> </ul> </li> <li> <p>Admission to hospital or death within 28 days</p> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) during the longest period available </p> </li> <li> <p>Serious adverse events, defined as the number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events) </p> </li> <li> <p>Adverse events (any grade), defined as the number of participants with any adverse event </p> </li> <li> <p>Specific adverse events: infections</p> </li> </ul> </p> </section> </section> <section id="CD014963-sec-0049"> <h5 class="title">Assessment of the certainty of the evidence</h5> <p>We used the GRADE approach to assess the certainty of the evidence for the outcomes listed in the previous section. </p> <p>The GRADE approach uses five domains (risk of bias, inconsistency, imprecision, indirectness, and publication bias) to assess certainty in the body of evidence for each prioritised outcome. </p> <p>We downgraded our certainty of the evidence for:</p> <p> <ul id="CD014963-list-0034"> <li> <p>serious (‐1) or very serious (‐2) risk of bias;</p> </li> <li> <p>serious (‐1) or very serious (‐2) inconsistency;</p> </li> <li> <p>serious (‐1) or very serious (‐2) uncertainty about directness;</p> </li> <li> <p>serious (‐1) or very serious (‐2) imprecise or sparse data;</p> </li> <li> <p>serious (‐1) or very serious (‐2) probability of reporting bias.</p> </li> </ul> </p> <p>The GRADE system uses the following criteria for assigning grade of evidence.</p> <p> <ul id="CD014963-list-0035"> <li> <p>'High': we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>'Moderate': we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>'Low': our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>'Very low': we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>We followed the current GRADE guidance for these assessments in its entirety as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Chapter 14 (<a href="./references#CD014963-bbs2-0182" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>). </p> <p>We used the overall risk of bias judgement, derived from the RoB 2 Excel tool, to inform our decision on downgrading for risk of bias. We phrased the findings and certainty in the evidence as suggested in the informative statement guidance (<a href="./references#CD014963-bbs2-0179" title="SantessoN , GlentonC , DahmP , GarnerP , AklA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35.">Santesso 2020</a>). </p> </section> <section id="CD014963-sec-0050"> <h5 class="title">Methods for future updates</h5> <section id="CD014963-sec-0051"> <h6 class="title">Living systematic review considerations</h6> <p>Our Information Specialist (MIM) will provide us with new search records each week, which two review authors will screen, extract, evaluate, and integrate following the guidance for Cochrane living systematic reviews (<a href="./references#CD014963-bbs2-0155" title="Living Evidence Network. Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode (Version December 2019). Available from community.cochrane.org/review-production/production-resources/living-systematic-reviews (accessed 22 March 2021).">Living Evidence Network 2019</a>). </p> <p>We will manually check platform trials that were previously identified and listed as 'studies awaiting classification' for additional treatment arms. </p> <p>We will wait until the accumulating evidence changes our conclusions in the implications for research and practice before republishing the review. We will consider one or more of the following components to inform this decision: </p> <p> <ul id="CD014963-list-0036"> <li> <p>findings of one or more prioritised outcomes;</p> </li> <li> <p>credibility (e.g. GRADE rating) of one or more prioritised outcomes;</p> </li> <li> <p>new settings, populations, interventions, comparisons, or outcomes studied.</p> </li> </ul> </p> <p>In case of emerging policy relevance because of global controversies around the intervention, we will consider republishing an updated review even though our conclusions remain unchanged. We will review the review scope and methods approximately monthly, or more frequently if appropriate, in light of potential changes in COVID‐19 research (for example, when additional comparisons, interventions, subgroups or outcomes, or new review methods become available). </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014963-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014963-sec-0052"></div> <section id="CD014963-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD014963-sec-0054"> <h4 class="title">Results of the search</h4> <p>We searched all databases and screened the resulting records up to 6 January 2022. We identified 3552 records. After removing duplicates, we screened 2682 records based on their titles and abstracts. We excluded 2546 records that did not meet the inclusion criteria. Of the remaining 136 records, we included 105 records: </p> <p> <ul id="CD014963-list-0037"> <li> <p>16 RCTs (in 32 records) for inclusion in this review of which five were newly included in this second version (<a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>; <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>); </p> </li> <li> <p>42 RCTs (in 47 records) are ongoing;</p> </li> <li> <p>23 RCTs (in 26 records) are awaiting classification as they have been reported as being completed, but the results have not yet been published or they lack relevant information on the study design. </p> </li> </ul> </p> <p>The study flow diagram in <a href="#CD014963-fig-0002">Figure 2</a> illustrates the study selection process according to the PRISMA guidelines (<a href="./references#CD014963-bbs2-0160" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>). </p> <div class="figure" id="CD014963-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="PRISMA flow diagram illustrating our study selection process." data-id="CD014963-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram illustrating our study selection process.</p> </div> </div> </div> </section> <section id="CD014963-sec-0055"> <h4 class="title">Included studies</h4> <section id="CD014963-sec-0056"> <h5 class="title">Design and sample size</h5> <p>We included 16 RCTs, of which two were multicentre platform RCTs (<a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>; <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>), eight were multicentre RCTs (<a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>; <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>; <a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a>; <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>), and six were single‐centre RCTs (<a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a>; <a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a>; <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>; <a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a>; <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>; <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>). </p> <section id="CD014963-sec-0057"> <h6 class="title">Setting</h6> <p>Of 9549 participants in the included studies, 8418 (88%) originated from seven studies from high‐income countries (<a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>; <a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>; <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>; <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>; <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>); 1131 (12%) participants originated from nine studies from upper‐ and lower‐middle‐income countries (<a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a>; <a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a>; <a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a>; <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>; <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a>; <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>; <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>). There were no studies from low‐income countries. </p> </section> <section id="CD014963-sec-0058"> <h6 class="title">Participants</h6> <p>All participants were adults hospitalised for either acute proven COVID‐19 or, as in the case of <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>, <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>, <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>, <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>, and <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>, suspected acute COVID‐19. Positive RT‐PCR rates within the studies ranged from 100% in <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>, <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>, and <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a> to about 80% in <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>. All included participants were hospitalised because of symptomatic (suspected) COVID‐19 and were treated with different levels of respiratory support (no oxygen, low‐flow oxygen, high‐flow oxygen or non‐invasive ventilation (NIV), or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO)). Based on the different levels of respiratory support at baseline, disease severity ranged from 4 to 9 on the WHO Clinical Progression Scale (<a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>). </p> <p>Shares of female participants ranged between 20% in <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a> and 52% in <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>. Means of age ranged between 54 years (standard deviation (SD) 15) in the intervention group in <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a> and 73 years (SD 11) in the intervention group in <a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>. No explicit information could be found regarding the proportion of vaccinated participants in any included study. However, recruitment of all studies in the comparisons 1 and 2 had ended before the first human was injected a vaccine dose outside a clinical trial worldwide on 8 December 2020 so that we deem it reasonable to declare all those participants in comparison 1 and 2 (<a href="./full#CD014963-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD014963-tbl-0002">summary of findings Table 2</a>) "unvaccinated" with consequences for the applicability of the evidence today (<a href="./references#CD014963-bbs2-0197" title="WatsonOJ , BarnsleyG , ToorJ , HoganAB , WinskillP , GhaniAC . Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infectous Diseases2022;22(9):1293-302. [DOI: 10.1016/S1473-3099(22)00320-6]">Watson 2022</a>). However, recruitment in comparison 3 (<a href="./full#CD014963-tbl-0003">summary of findings Table 3</a>) took place until May 2021 so that we declared the vaccination status of these participants "unknown". </p> </section> <section id="CD014963-sec-0059"> <h6 class="title">Interventions</h6> <p>Of the included completed studies, 11 compared systemic corticosteroids, which were hydrocortisone, prednisolone, methylprednisolone, and dexamethasone, to standard care (plus/minus placebo), one compared methylprednisolone to dexamethasone (<a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a>), and four directly compared different doses of dexamethasone (<a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>; <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>). The route of administration was intravenous except in <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>, where both oral and intravenous administration were allowed, and <a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a>, with oral dose‐tapering after intravenous initiation. Doses as hydrocortisone equivalents were ≤ 200 mg/day in <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>, <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>, <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>, and <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>; 201 to 500 mg/day in <a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>, <a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a>, <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>, <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>, and <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>; 1250 mg/day hydrocortisone equivalent and more as pulse dose regimen in <a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a> and <a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a>. Durations of treatment differed between the studies, depending on the type of corticosteroid used, in a range between 3 days (methylprednisolone 250 mg/day, in <a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a>) and 14 days (hydrocortisone 200 mg/day tapered to 50 mg/day, in <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>). All the studies investigating the effects of dexamethasone reported treatment durations limited to 10 days (<a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>; <a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a>; <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>; <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>). None of the included studies stratified data analyses according to treatment duration. </p> </section> <section id="CD014963-sec-0060"> <h6 class="title">Equity‐related aspects</h6> <p>No study data were available for the following equity‐related elements: occupation, religion, education, socioeconomic status, and social capital. Data regarding place of residence, age, and sex were reported in all studies. <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>, <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>, and <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a> are the only trials reporting ethnicity. For details please see <a href="#CD014963-tbl-0004">Table 1</a>. </p> <div class="table" id="CD014963-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Equity elements of the included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study/equity‐element</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]"><b>World Bank 2021</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ethnicity (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Occupation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sex (% female)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Religion</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Education</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Socioeconomic status</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Social capital</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]"><b>Angus 2020</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Australia, Canada, France, Ireland, the Netherlands, New Zealand, UK, USA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0038"> <li> <p>Fixed‐dose intervention group: 60.4 (11.6)</p> </li> <li> <p>Shock‐dependent intervention group: 59.5 (12.7)</p> </li> <li> <p>Control group: 59.9 (14.6)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐dose intervention group:</p> <p> <ul id="CD014963-list-0039"> <li> <p>White: 79 (72.2%)</p> </li> <li> <p>Asian: 18 (16.2%)</p> </li> <li> <p>Black: 4 (3.6%)</p> </li> <li> <p>Mixed: 4 (3.6%)</p> </li> <li> <p>Other: 6 (5.4%)</p> </li> </ul> </p> <p>Shock‐dependent intervention group:</p> <p> <ul id="CD014963-list-0040"> <li> <p>White: 80 (76.2%)</p> </li> <li> <p>Asian: 11 (10.5%)</p> </li> <li> <p>Black: 7 (6.7%)</p> </li> <li> <p>Mixed: 0</p> </li> <li> <p>Other: 7 (6.7%)</p> </li> </ul> </p> <p> </p> <p>Control group:</p> <p> <ul id="CD014963-list-0041"> <li> <p>White: 45 (57%)</p> </li> <li> <p>Asian: 22 (27.9%)</p> </li> <li> <p>Black: 4 (5.1%)</p> </li> <li> <p>Mixed: 2 (2.5%)</p> </li> <li> <p>Other: 6 (7.6%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0042"> <li> <p>Fixed‐dose intervention group: 39 (28.5%)</p> </li> <li> <p>Shock‐dependent intervention group: 43 (29.5%)</p> </li> <li> <p>Control group: 29 (28.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]"><b>Corral‐Gudino 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0043"> <li> <p>Intervention group: 73 (11)</p> </li> <li> <p>Control group: 66 (12)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0044"> <li> <p>Intervention group: 11 (32%)</p> </li> <li> <p>Control group: 13 (45%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]"><b>Dequin 2020</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0045"> <li> <p>Intervention group: 63.1 (51.5 to 70.8)</p> </li> <li> <p>Control group: 66.3 (53.5 to 72.7)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0046"> <li> <p>Intervention group: 22 (28.9%)</p> </li> <li> <p>Control group: 23 (31.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]"><b>Edalatifard 2020</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0047"> <li> <p>Intervention group: 55.8 (16.35)</p> </li> <li> <p>Control group: 61.7 (16.62)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0048"> <li> <p>Intervention group: 10 (29.4%)</p> </li> <li> <p>Control group: 13 (46.4%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]"><b>Farahani 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD):</p> <p> <ul id="CD014963-list-0049"> <li> <p>Intervention group: 61.07 (12.83)</p> </li> <li> <p>Control group: 66.80  (14.03)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0050"> <li> <p>Intervention group: 4 (28.6%)</p> </li> <li> <p>Control group: 6 (40%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. "><b>Horby 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (UK)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD):</p> <p> <ul id="CD014963-list-0051"> <li> <p>Intervention group: 66.9 (15.4)</p> </li> <li> <p>Control group: 65.8 (15.8)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention group:</p> <p> <ul id="CD014963-list-0052"> <li> <p>White: 1550 (74%)</p> </li> <li> <p>Black, Asian or minority ethnic group: 364 (17%)</p> </li> <li> <p>Unknown: 190 (9%)</p> </li> </ul> </p> <p>Control group:</p> <p> <ul id="CD014963-list-0053"> <li> <p>White: 3139 (73%)</p> </li> <li> <p>Black, Asian or minority ethnic group: 783 (18%)</p> </li> <li> <p>Unknown: 399 (9%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0054"> <li> <p>Intervention group: 766 (36%)</p> </li> <li> <p>Control group: 1572 (36%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]"><b>Jamaati 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0055"> <li> <p>Intervention group survivor: 54 (37 to 63)</p> </li> <li> <p>Intervention group non‐survivor: 63 (55.5 to 72.5)</p> </li> <li> <p>Control group survivor: 61.5 (54 to 62)</p> </li> <li> <p>Control group non‐survivor: 67 (48 to 73)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0056"> <li> <p>Intervention group: 7 (28%)</p> </li> <li> <p>Control group: 7 (28%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]"><b>Jeronimo 2020</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Brazil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0057"> <li> <p>Intervention group: 54 (15)</p> </li> <li> <p>Control group: 57 (15)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention group:</p> <p> <ul id="CD014963-list-0058"> <li> <p>White: 30 (15.5%)</p> </li> <li> <p>Mixed: 147 (75.8%)</p> </li> <li> <p>Black: 6 (3.1%)</p> </li> <li> <p>Asian: 3 (1.5%)</p> </li> <li> <p>Amerindian: 8 (4.1%)</p> </li> </ul> </p> <p>Control group:</p> <p> <ul id="CD014963-list-0059"> <li> <p>White: 28 (14.1%)</p> </li> <li> <p>Mixed: 147 (73.9%)</p> </li> <li> <p>Black: 17 (8.5%)</p> </li> <li> <p>Asian: 3 (1.5%)</p> </li> <li> <p>Amerindian: 4 (2.0%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0060"> <li> <p>Intervention group: 68 (35.1%)</p> </li> <li> <p>Control group: 71 (35.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). "><b>Maskin 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Argentina)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0061"> <li> <p>Low‐dose group: 60.04 (13.08)</p> </li> <li> <p>High‐dose group: 63.57 (13.59)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0062"> <li> <p>Low‐dose dexamethasone: 16 (33%)</p> </li> <li> <p>High‐dose dexamethasone: 13 (26%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]"><b>Munch 2021a</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Denmark)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0063"> <li> <p>Intervention group: 59 (52 to 74)</p> </li> <li> <p>Control group: 62 (55 to 71)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0064"> <li> <p>Intervention group: 2 (12%)</p> </li> <li> <p>Control group: 4 (29%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]"><b>Munch 2021b</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Denmark, India, Sweden, Switzerland)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0065"> <li> <p>Low‐dose group: 64 (54 to 72)</p> </li> <li> <p>High‐dose group: 65 (56 to 74)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0066"> <li> <p>Low‐dose dexamethasone: 154 (32%)</p> </li> <li> <p>High‐dose dexamethasone: 151 (30%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]"><b>Ranjbar 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0067"> <li> <p>Methylprednisolone group: 56.2 (17.5)</p> </li> <li> <p>Dexamethasone group: 61.3 (17.3)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0068"> <li> <p>Methylprednisolone group: 17 (38.6%)</p> </li> <li> <p>Dexamethasone group: 20 (47.6%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]"><b>Taboada 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0069"> <li> <p>Low‐dose group: 64.8 (14.1)</p> </li> <li> <p>High‐dose group: 63.9 (14.5)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0070"> <li> <p>Low‐dose dexamethasone: 41 (39.6%)</p> </li> <li> <p>High‐dose dexamethasone: 36 (36.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]"><b>Tang 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (China)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0071"> <li> <p>Intervention group: 57 (49 to 67)</p> </li> <li> <p>Control group: 55 (38 to 65)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0072"> <li> <p>Intervention group: 22 (51.2%)</p> </li> <li> <p>Control group: 23 (53.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]"><b>Tomazini 2020</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Brazil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0073"> <li> <p>Intervention group: 60.1 (15.8)</p> </li> <li> <p>Control group: 62.7 (13.1)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0074"> <li> <p>Intervention group: 61 (40.4%)</p> </li> <li> <p>Control group: 51 (34.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]"><b>Toroghi 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0075"> <li> <p>Low‐dose group (8 mg once a day): 59 (14)</p> </li> <li> <p>Intermediate‐dose group (8 mg twice a day): 59 (17)</p> </li> <li> <p>High‐dose group (8 mg 3 times a day): 56 (16)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0076"> <li> <p>Low‐dose dexamethasone: 19 (40.4%)</p> </li> <li> <p>High‐dose dexamethasone: 34 (39.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>NR:</b> not reported; <b>SD</b> : standard deviation; <b>IQR</b>: interquartile range </p> </div> </div> </section> <section id="CD014963-sec-0061"> <h6 class="title">Included studies for comparison of systemic corticosteroids plus standard care to standard care (plus/minus placebo) </h6> <p>We included 11 studies describing 8019 participants in this comparison, of whom 3002 were randomised to corticosteroids and 5017 to standard care (plus/minus placebo). Daily hydrocortisone equivalents of the initial doses ranged from 150 mg to 5000 mg and durations of treatment ranged from zero to approximately 20 days. The majority of participants (n = 2577; 86%) randomised to corticosteroids received equivalents of 200 mg/day or less, 463 (15%) received 201 mg/day to 500 mg/day, and 48 (2%) received 501 mg/day to 5000 mg/day. Please see <a href="#CD014963-tbl-0005">Table 2</a> for details, but note that no outcome data from <a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a> (29 participants) were applicable for further analysis, resulting in quantitative analysis of 10 trials only in this comparison. </p> <div class="table" id="CD014963-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of the included studies for the comparison: systemic corticosteroids versus placebo or standard care for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention and regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydrocortisone equivalent of initial dose: for 80 kg bodyweight if applicable (</b><a href="./references#CD014963-bbs2-0187" title="StoeltingRK , Hiller SC (editors). Pharmacology. In: Pharmacology &amp; Physiology in Anesthetic Practice. 4 edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006:462."><b>Stoelting 2006</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]">World Bank 2021</a><b>) and recruitment period</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sex (% female)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity at randomisation on WHO Clinical Progression Scale (</b><a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7."><b>Marshall 2020</b> </a><b>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydrocortisone, IV, 150 mg daily for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 (fixed‐dose) and 152 (shock‐dependent dose)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0077"> <li> <p>Platform</p> </li> <li> <p>Open‐label</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Australia, Canada, France, Ireland, the Netherlands, New Zealand, United Kingdom, USA) </p> <p>between March and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0078"> <li> <p>Fixed‐dose intervention group: 60.4 (11.6)</p> </li> <li> <p>Shock‐dependent intervention group: 59.5 (12.7)</p> </li> <li> <p>Control group: 59.9 (14.6)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0079"> <li> <p>Fixed‐dose intervention group: 39 (28.5%)</p> </li> <li> <p>Shock‐dependent intervention group: 43 (29.5%)</p> </li> <li> <p>Control group: 29 (28.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe ≥ 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, IV 80 mg for 3 days + 40 mg for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0080"> <li> <p>Open‐label</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> <p>between April and May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0081"> <li> <p>Intervention group: 73 (11)</p> </li> <li> <p>Control group: 66 (12)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0082"> <li> <p>Intervention group: 11 (32%)</p> </li> <li> <p>Control group: 13 (45%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe 5 to 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydrocortisone, IV 200 mg for 7 days, 100 mg for 4 days + 50 mg for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0083"> <li> <p>Double‐blind</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> <p>between March and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0084"> <li> <p>Intervention group: 63.1 (51.5 to 70.8)</p> </li> <li> <p>Control group: 66.3 (53.5 to 72.7)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0085"> <li> <p>Intervention group: 22 (28.9%)</p> </li> <li> <p>Control group: 23 (31.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe ≥ 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, IV, 250 mg for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> <ul id="CD014963-list-0086"> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> <p>between March and May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0087"> <li> <p>Intervention group: 55.8 (16.35)</p> </li> <li> <p>Control group: 61.7 (16.62)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0088"> <li> <p>Intervention group: 10 (29.4%)</p> </li> <li> <p>Control group: 13 (46.4%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe 5 to 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, IV 1000 mg/d for 3 days + tapering with 1 mg/kg prednisolone for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5000 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0089"> <li> <p>Open‐label</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> <p>between March and May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD):</p> <p> <ul id="CD014963-list-0090"> <li> <p>Intervention group: 61.07 (12.83)</p> </li> <li> <p>Control group: 66.80  (14.03)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0091"> <li> <p>Intervention group: 4 (28.6%)</p> </li> <li> <p>Control group: 6 (40%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe 5 to 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV or oral 6 mg daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0092"> <li> <p>Platform</p> </li> <li> <p>Open‐label</p> </li> <li> <p>Multi‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(United Kingdom)</p> <p>between May and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD):</p> <p> <ul id="CD014963-list-0093"> <li> <p>Intervention group: 66.9 (15.4)</p> </li> <li> <p>Control group: 65.8 (15.8)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0094"> <li> <p>Intervention group: 766 (36%)</p> </li> <li> <p>Control group: 1572 (36%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe 4 to 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 20 mg for 5 days + 10 mg for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0095"> <li> <p>Open‐label</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> <p>in March 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0096"> <li> <p>Intervention group survivor: 54 (37 to 63)</p> </li> <li> <p>Intervention group non‐survivor: 63 (55.5 to 72.5)</p> </li> <li> <p>Control group survivor: 61.5 (54 to 62)</p> </li> <li> <p>Control group non‐survivor: 67 (48 to 73)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0097"> <li> <p>Intervention group: 7 (28%)</p> </li> <li> <p>Control group: 7 (28%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most likely moderate 5; no IMV at randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone (as sodium succinate), IV 1 mg/kg for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0098"> <li> <p>Double‐blind</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Brazil)</p> <p>between April and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0099"> <li> <p>Intervention group: 54 (15)</p> </li> <li> <p>Control group: 57 (15)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0100"> <li> <p>Intervention group: 68 (35.1%)</p> </li> <li> <p>Control group: 71 (35.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe 5 to 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydrocortisone, IV, 200 mg per day, for 7 days or until hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0101"> <li> <p>Triple‐blind</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Denmark)</p> <p>between April and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0102"> <li> <p>Intervention group: 59 (52 to 74)</p> </li> <li> <p>Control group: 62 (55 to 71)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0103"> <li> <p>Intervention group: 2 (12%)</p> </li> <li> <p>Control group: 4 (29%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe ≥ 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, IV, 1 mg/kg for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0104"> <li> <p>Single‐blind</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(China)</p> <p>between February and March 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0105"> <li> <p>Intervention group: 57 (49 to 67)</p> </li> <li> <p>Control group: 55 (38 to 65)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0106"> <li> <p>Intervention group: 22 (51.2%)</p> </li> <li> <p>Control group: 23 (53.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate 4 to 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 20 mg for 5 days + 10 mg for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0107"> <li> <p>Open‐label</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Brazil)</p> <p>between April and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0108"> <li> <p>Intervention group: 60.1 (15.8)</p> </li> <li> <p>Control group: 62.7 (13.1)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0109"> <li> <p>Intervention group: 61 (40.4%)</p> </li> <li> <p>Control group: 51 (34.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe 7 to 9<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>d:</b> day;<b>IMV:</b> invasive mechanical ventilation; <b>IV:</b> intravenous; <b>SD:</b> standard deviation; <b>IQR:</b> interquartile range </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup> Shock‐dependent dose: shock‐dependent dosing strategy was that restricting hydrocortisone to the period when the patient had overt shock would maximise the risk‐benefit ratio. Shock was defined as the requirement for intravenous vasopressor infusion for the treatment of shock presumed due to COVID‐19. Hydrocortisone was discontinued in the shock‐dependent group once shock was considered to have resolved or vasopressors had been discontinued for 24 hours. </p> </div> </div> </section> <section id="CD014963-sec-0062"> <h6 class="title">Included studies for comparison of different types of systemic corticosteroids</h6> <p>We included <a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a> describing 86 participants in this comparison, of whom 44 were randomised to methylprednisolone and 42 to dexamethasone. For details please see <a href="#CD014963-tbl-0006">Table 3</a>. </p> <div class="table" id="CD014963-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of the included studies for the comparison: methylprednisolone versus dexamethasone for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention A</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydrocortisone equivalent of initial dose (for 80 kg bodyweight if applicable)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention B</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to intervention A<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to Intervention B</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]">World Bank 2021</a>) and recruitment period </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sex (% female)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity at randomisation on WHO Clinical Progression Scale (</b><a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7."><b>Marshall 2020</b> </a><b>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone 2 mg/kg, i.e. for an 80 kg participant: IV 160 mg for 5 days + 80 mg for 5 days + 40 mg for 5 days + 20 mg for 5 days (approximation of tapering scheme) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 mg/d in the methylprednisolone arm for an 80 kg participant</p> <p> </p> <p>1000 mg/d in the dexamethasone arm fixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 6 mg for 10 days<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0110"> <li> <p>Triple‐blind</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> <p>between August and November 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0111"> <li> <p>Methylprednisolone group: 56.2 (17.5)</p> </li> <li> <p>Dexamethasone group: 61.3 (17.3)</p> </li> </ul> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0112"> <li> <p>Intervention A group: 17 (38.6%)</p> </li> <li> <p>Intervention B group: 20 (47.6%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate 4 to 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>IV:</b> intravenous, <b>d:</b> day, <b>SD:</b> standard deviation </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD014963-sec-0063"> <h6 class="title">Included studies for comparison of high‐dose dexamethasone to low‐dose dexamethasone</h6> <p>We included <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>, <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>, <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>, and <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a> describing 1444 participants in this comparison, of whom 746 were randomised to high‐dose (12 mg/day or higher) dexamethasone and 698 to low‐dose (6 mg to 8 mg/day) dexamethasone. For details please see <a href="#CD014963-tbl-0007">Table 4</a>. </p> <div class="table" id="CD014963-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Characteristics of the included studies for the comparison: high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8 mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention dose and regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydrocortisone equivalent of initial dose: for 80 kg bodyweight if applicable (</b><a href="./references#CD014963-bbs2-0187" title="StoeltingRK , Hiller SC (editors). Pharmacology. In: Pharmacology &amp; Physiology in Anesthetic Practice. 4 edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006:462."><b>Stoelting 2006</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to high‐dose dexamethasone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to low‐dose dexamethasone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]"><b>World Bank 2021</b> </a><b>) and recruitment date</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sex (% female)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity at randomisation on WHO Clinical Progression Scale (</b><a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7."><b>Marshall 2020</b> </a><b>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 12 mg/day for up to 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg/d vs 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 6 mg/day for up to 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0113"> <li> <p>Multicentre</p> </li> <li> <p>Triple‐blind</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mainly high‐income countries</p> <p>(Denmark, India, Sweden, Switzerland)</p> <p>between August 2020 and May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median age (years, IQR)</p> <p> <ul id="CD014963-list-0114"> <li> <p>Low‐dose group: 64 (54 to 72)</p> </li> <li> <p>High‐dose group: 65 (56 to 74)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0115"> <li> <p>Low‐dose dexamethasone: 154 (32%)</p> </li> <li> <p>High‐dose dexamethasone: 151 (30%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe ≥5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone + standard care, IV, 16 mg once daily for 5 days, followed by 8 mg administered once daily for additional 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg/d vs 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone + standard care, IV, 6 mg per day for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0116"> <li> <p>Multicentre</p> </li> <li> <p>Open‐label</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Argentina)</p> <p>between June 2020 and March 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0117"> <li> <p>Low‐dose group: 60.04 (13.08)</p> </li> <li> <p>High‐dose group: 63.57 (13.59)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0118"> <li> <p>Low‐dose dexamethasone: 16 (33%)</p> </li> <li> <p>High‐dose dexamethasone: 13 (26%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe ≥ 7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm 2: Dexamethasone, IV, 8 mg twice a day for up to 10 days or until hospital discharge</p> <p>Arm 3: 8 mg 3 times a day for up to 10 days or until hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm 2: 400 mg/d or Arm 3: 600 mg/d vs 200 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 8 mg once a day for up to 10 days or until hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0119"> <li> <p>Open‐label</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> <p>between October 2020 and January 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0120"> <li> <p>Low‐dose group (8 mg once a day): 59 (14)</p> </li> <li> <p>Intermediate‐dose group (8 mg twice a day): 59 (17)</p> </li> <li> <p>High‐dose group (8 mg 3 times a day): 56 (16)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0121"> <li> <p>Low‐dose dexamethasone: 19 (40.4%)</p> </li> <li> <p>High‐dose dexamethasone: 34 (39.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe ≥ 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 20 mg once daily for 5 days, followed by 10 mg once daily for additional 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg/d vs 150  mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 6 mg once daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0122"> <li> <p>Open‐label</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> <p>between January and May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0123"> <li> <p>Low‐dose group: 64.8 (14.1)</p> </li> <li> <p>High‐dose group: 63.9 (14.5)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0124"> <li> <p>Low‐dose dexamethasone: 41 (39.6%)</p> </li> <li> <p>High‐dose dexamethasone: 36 (36.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe ≥ 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>IV:</b> intravenous; <b>d:</b> day; <b>SD:</b> standard deviation; <b>IQR:</b> interquartile range </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD014963-sec-0064"> <h6 class="title">Outcome summary</h6> <p>All studies except <a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a> reported utilisable dichotomous mortality data: for 7898 participants with follow‐up of up to 30 days and 485 participants with follow‐up between 31 and 120 days in the comparison of corticosteroids versus standard care (plus/minus placebo), 86 participants in the direct comparison of methylprednisolone and dexamethasone, and 1269 participants with follow‐up up to 30 days and 1399 participants with follow‐up between 31 and 120 days in the comparison of different corticosteroid doses. In the setting of acute COVID‐19 with immediate risk of death, we assumed in‐hospital mortality and all‐cause mortality with follow‐up of 14 to 30 days similar enough for meta‐analysis. For intermediate‐term survival we considered observation periods of 31 to 120 days equivalent and ready for meta‐analysis. </p> <p>Other efficacy outcomes were reported heterogeneously.</p> <p>The reporting of safety data was heterogeneous both in terms of whether reported at all (missing outcome data) and the underlying definitions. Including recent data requests for all studies, only four studies explicitly reported adverse events regardless of their nature and suspected relation to the intervention (<a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>; <a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>; <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>). Another eight studies reported specific serious adverse events and adverse events related to the expected side effects of corticosteroids in both arms (<a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>; <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>; <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>; <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>; <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>). </p> <p>Apart from that, by far the largest study with 6425 participants reported safety outcomes only for the intervention arm as suspected drug reactions (<a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>), and three studies with 165 participants did not report safety outcomes at all (<a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a>; <a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a>; <a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a>). </p> <p>Beware that only dichotomous safety data (participants with at least one event/participants at risk) is presented narratively in the summary of findings tables, while additional discrete continuous data (number of events/participants at risk) is presented in an overview of safety data reporting with additional information (<a href="#CD014963-tbl-0008">Table 5</a>). </p> <div class="table" id="CD014963-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Reporting of safety data</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition as published</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Way of counting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any SAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Shock‐dependent hydrocortisone: SAE: 5/141</p> <p> </p> <p>Fixed‐dose hydrocortisone: SAE: 4/137</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 0/52</p> <p> </p> <p> </p> <p>SAE: 1/49</p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microbiology‐proven infection and hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE, HAI: events/participants at risk</p> <p> </p> <p>HAI, FI: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 14/35</p> <p>HAI: 5/35 (events and participants)</p> <p>FI: 1/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 1/29</p> <p>HAI: 1/29 (events and participants)</p> <p>FI: 0/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nosocomial infections until day 28 defined by need for antibiotics. No other SAEs/AEs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE, HAI: events/participants at risk</p> <p> </p> <p>HAI: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 40/76</p> <p>HAI: 40/76 (events), 28/76 (participants)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 50/73</p> <p>HAI: 50/73 (events), 30/73 (participants)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All undesirable effects (adverse events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HAI: events/participants at risk</p> <p> </p> <p>AE: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 2/34</p> <p>HAI: 1/34</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 2/28</p> <p>HAI: 0/28</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐blind<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected drug reactions reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE/SAE not explicitly reported</p> <p>Positive blood culture, need for insulin therapy, sepsis reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse reaction reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triple‐blind</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperglycaemia, ventilator‐associated pneumonia, stress ulcer, gastrointestinal haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE, HAI: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 5/43</p> <p>HAI: 2/43</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 8/43</p> <p>HAI: 1/43</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐blind</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycaemic control, nosocomial infection, other AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE, AE, HAI: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 5/151</p> <p>AE: 122/151</p> <p>HAI: 30/151</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 9/148</p> <p>AE: 121/148</p> <p>HAI: 39/148</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison 2: Methylprednisolone versus dexamethasone</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition as published</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Way of counting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Methylprednisolone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Dexamethasone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triple‐blind</p> </td> </tr> <tr> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison 3: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition as published</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Way of counting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>High‐dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Low‐dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: effects causing disability (defined as muscular weakness with a MRC scale &lt; 48) or death </p> <p> </p> <p>AE: hyperglycaemia (≥ 200 mg/dL), delirium (positive CAM‐ICU or requirement of neuroleptic drugs), hospital‐acquired infections (according to investigator judgement) </p> <p> </p> <p>HAI: as defined by the attending physician</p> <p> </p> <p>FI: candidemia (documented as <i>Candida sp.</i> in blood cultures), aspergillosis (documented as <i>Aspergillus sp.</i> in cultures) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE, FI, AE, HAI: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 42/49</p> <p>AE: 49/49</p> <p>HAI: 34/49</p> <p>FI: 3/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 40/49</p> <p>AE: 48/49</p> <p>HAI: 38/49</p> <p>FI: 3/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse reaction (i.e. new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal bleeding, or anaphylactic reaction to dexamethasone) </p> <p> </p> <p>HAI: either new episode of septic shock OR invasive fungal infection, as per the elements of the composite outcome of ≥ 1 serious adverse reaction at day 28 </p> <p> </p> <p>FI: not further defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE, FI, HAI: participants with at least one event/participants at risk</p> <p> </p> <p>HAI, FI: events/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 70/497</p> <p>HAI: 27/497 (events), 50/497 (participants)</p> <p>FI: 15/497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 85/485</p> <p>HAI: 35/485 (events), 61/485 (participants)</p> <p>FI: 21/485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triple‐blind</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: nosocomial infection, insuline use for hyperglycaemia, thrombosis, death at day 28 and death at day 60 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE, HAI: events/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 58/98</p> <p>HAI: 10/98</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 65/102</p> <p>HAI: 10/102</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: not further defined</p> <p>HAI: secondary infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE, HAI: events/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 252/86</p> <p>HAI: 5/86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 122/47</p> <p>HAI: 1/47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>AE:</b> adverse event; <b>ICU:</b> intensive care unit; <b>FI:</b> fungal infection; <b>SAE:</b> serious adverse event; <b>HAI:</b> hospital‐acquired infection; <b>SAP</b>: statistical analysis plan </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD014963-sec-0065"> <h5 class="title">Ongoing studies</h5> <p>We identified 42 ongoing RCTs with systemic application of steroids for acute COVID‐19 (details listed in <a href="#CD014963-tbl-0009">Table 6</a>), of which 25 were classified as 'recruiting' or 'ongoing' according to the study registrations. One was classified as 'active, not recruiting', for one study recruitment was completed, and one was 'temporarily halted'. Thirteen were classified as 'not yet recruiting' and one as 'not recruiting'. The majority of studies were conducted in high‐income countries (about 62%). For further characteristics of ongoing studies please see <a href="#CD014963-tbl-0009">Table 6</a>. </p> <div class="table" id="CD014963-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Characteristics of ongoing studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sponsor/developer</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]"><b>World Bank 2021</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Route of administration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0068" title="ACTRN12621001200875. A randomised controlled trial of dexamethasone for emergency and life-threatening admissions due to COVID-19 in virtual care: the DELTA study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12621001200875 (first received 8 September 2021). ">ACTRN12621001200875</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Royal Prince Alfred Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Australia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exhibiting mild/moderate COVID‐19 symptoms (fever, respiratory tract symptoms, dyspnoea, headache, gastrointestinal symptoms), with no requirement for oxygen or hospitalisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0069" title="ACTRN12621001603808. The effect of prednisolone vs dexamethasone on Covid-19 in pregnancy: an open labelled randomised control trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12621001603808 (first received 24 November 2021). ">ACTRN12621001603808</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monash Health Hospital Victoria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Australia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women pregnant &gt; 16 weeks with COVID‐19 hospitalised with an oxygen requirement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone, dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0070" title="QinYY , ZhouYH , LuYQ , SunF , YangS , HarypursatV , et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomised controlled trial. Chinese Medical Journal2020;133(9):1080-6. [DOI: 10.1097/CM9.0000000000000791] [ChiCTR2000029386]">ChiCTR2000029386</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chongqing Public Health Medical Center</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(China)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0071" title="ChiCTR2000029656. A randomised, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalised patients with novel coronavirus pneumonia (COVID-19). www.chictr.org.cn/showprojen.aspx?proj=49086 (first received 9 February 2020). ">ChiCTR2000029656</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wuhan Pulmonary Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(China)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0072" title="ChiCTR2000030481. The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomised controlled trial. www.chictr.org.cn/showprojen.aspx?proj=50453 (first received 3 March 2020). ">ChiCTR2000030481</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zhongnan Hospital of Wuhan University</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(China)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosed COVID‐19 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early corticosteroid intervention, middle‐late corticosteroid intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0073" title="CTRI/2020/07/026608. A clinical trial to study the effects of two drugs methylprednisolone and dexamethasone in patients with severe COVID-19. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45638 (first received 15 July 2020). ">CTRI/2020/07/026608</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dr Ananthakumar PK, Chettinad Hospital and Research Institute Kelambakkam Kancheepuram Dist Pin 603103 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosed COVID‐infection + ARDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0074" title="Comparing the effectiveness of dexamethasone versus methylprednisolone in patients with moderate COVID 19 - a randomised controlled trial. ctri.nic.in/Clinicaltrials/showallp.php?mid1=49273&amp;EncHid=&amp;userName=029894 (first received 18 December 2020). CTRI/2020/12/029894. A study to compare the effectiveness of two drugs, dexamethasone versus methylprednisolone in the treatment of moderate Covid 19 patients. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/12/029894. ">CTRI/2020/12/029894</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SRM Medical College Hospital and Research Centre <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SpO<sub>2</sub> &lt; 94% under room air and requiring supplemental oxygen for hypoxaemia, respiratory rate 24 to 30/min<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0075" title="CTRI/2020/12/030143. Comparison of different steroid regimes in critically ill adult patients of COVID-19. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/12/030143. CTRI/2020/12/030143. Evaluation of different steroid regimes in critically ill adult patients of COVID-19 admitted to intensive care units. ctri.nic.in/Clinicaltrials/showallp.php?mid1=50886&amp;EncHid=&amp;userName=30143 (first received 31 December 2020). ">CTRI/2020/12/030143</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maulana Azad Medical College and associated Lok Nayak Hospital<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted to ICU within 14 days of onset of symptoms; receiving invasive or non‐invasive positive pressure ventilation or respiratory support through HFNC <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0076" title="CTRI/2021/05/033873. Pre-emptive steroids to alter the disease course in COVID-19 patients. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2021/05/033873 (first received: 31 May 2021). ">CTRI/2021/05/033873</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JK Hospital and LN Medical College</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: moderate to severe type of disease; eligible for home isolation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0077" title="CTRI/2021/08/035822. Assessment of doubling dose of dexamethasone in progressively worsening severe COVID-19 pneumonia - a randomised controlled trial. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=57048 (first received 19 August 2021). ">CTRI/2021/08/035822</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Animesh Ray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe COVID‐19 pneumonia (SpO2 &lt; 94%; PaO2/FiO2 &lt; 300 mm Hg or respiratory rate (RR) &gt; 30 breaths/min) with lack of response to dexamethasone 6 mg after 48 hours (defined as similar or worsening oxygen requirement (margin of error is 5% Fio2 for high‐flow nasal cannula, 2 L/min for NRBM, and 1 L/min for low flow oxygen devices) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone high‐dose, dexamethasone low‐dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV or oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0078" title="EUCTR2020-001413-20-ES. Efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID-19 pneumonia. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001413-20 (first received 7 April 2020). ">EUCTR2020‐001413‐20‐ES</a> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundació Clínic per a la Recerca Biomèdica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐critical patient with pneumonia in radiological progression and/or patient with progressive respiratory failure in the last 24 to 48 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporarily halted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0079" title="EUCTR2020-001457-43-FR. Dexamethasone and oxygen support strategies in ICU patients with COVID-19 pneumonia. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001457-43 (first received 10 April 2020). ">EUCTR2020‐001457‐43‐FR</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>APHP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted to ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0080" title="EUCTR2020-001622-64-ES. Outpatient treatment of COVID-19 with early pulmonary corticosteroids as an opportunity to modify the course of the disease. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001622-64 (first received 19 April 2020). Saiz-RodríguezM , PeñaT , LázaroL , GonzálezA , MartínezA , CorderoJA , et al. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: a structured summary of a randomised controlled trial. Trials2020;21(632):1-3. [DOI: 10.1186/s13063-020-04575-w]">EUCTR2020‐001622‐64‐ES</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dra Ana Pueyo Bastida</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis of pulmonary involvement (respiratory symptoms ± pathological auscultation ± O<sub>2</sub> desaturation) + chest X‐ray with mild‐moderate or normal alterations </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0081" title="EUCTR2020-001707-16-ES. Phase III randomised, unicentric open, controlled clinical trial to demonstrate the effectiveness of tocilizumab against systemic corticotherapy in patients entered by COVID-19 with bilateral pneumonia and bad evolution. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001707-16/ES (first received 25 June 2020). ">EUCTR2020‐001707‐16‐ES</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iis Biodonostia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bilateral pneumonia caused by SARS‐CoV‐2 without response to the treatment: defined as persistence of fever (above 37.5 ºC without other focus) and respiratory worsening (more dyspnoea, more cough, oxygen therapy at increasing doses, worsening of the degree of respiratory distress according to the PaO<sub>2</sub>/FiO<sub>2</sub> ratio in categories 'mild, moderate or serious') or absence of improvement with respect to the previous state </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0082" title="BusaniS , TosiM , MighaliP , VandelliP , D'AmicoR , MariettaM , et al. Multi-centre, three arm, randomised controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):724. [DOI: 10.1186/s13063-020-04645-z]EUCTR2020-001921-30. Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomised, three arms study design. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001921-30 (first received 26 June 2020). ">EUCTR2020‐001921‐30</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azienda Ospedaliero‐Universitaria Policlinico di Modena</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive pressure ventilation (either non‐invasive or invasive) from &gt; 24 h, IMV from &lt; 96 h, PaO<sub>2</sub>/FiO<sub>2</sub> ratio &lt; 150 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0083" title="EUCTR2020-003363-25-DK. Higher vs. lower doses of dexamethasone in patients with COVID-19 and severe oxygen deficiency: the COVID STEROID 2 trial. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003363-25 (first received 18 August 2020). ">EUCTR2020‐003363‐25‐DK</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Department of Intensive Care, Rigshospitalet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Denmark)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe, IMV/NIV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (high dose and low dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0084" title="EUCTR2020-006054-43-IT. Randomised controlled trial to evaluate the efficacy of per-protocol administration of methylprednisolone compared to dexamethasone in SARS-CoV-2 infections requiring respiratory support. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-006054-43-IT (first received 22 March 2021). ">EUCTR2020‐006054‐43‐IT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Università degli Studi di Trieste</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PaO2 ≤ 60 mmHg or SpO2 ≤ 90% or on HFNC, CPAP or NPPV at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0085" title="EUCTR2021-001416-29-ES. High-dose dexamethasone treatment for SARS-COV-2. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2021-001416-29-ES (first received 26 May 2021). ">EUCTR2021‐001416‐29‐ES</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Unive </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With need for oxygen therapy in NG = 1 lpm to maintain saturation = 94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone high‐dose, dexamethasone low‐dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0086" title="EUCTR2021-004021-71. Corticosteroids for loss of smell by COVID-19 infection – COCOS trial. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-004021-71 (first received 12 October 2021). ">EUCTR2021‐004021‐71</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University Medical Center Utrecht</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Netherlands)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recent COVID‐19 infection (&lt; 3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0087" title="IRCT20190606043826N2. Comparison of the effectiveness and complication of dexamethasone at doses of 8 and 24 mg in the treatment of in hospitalised patients with Covid-19. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190606043826N2 (first received 1 July 2021). ">IRCT20190606043826N2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Esfahan University of Medical Sciences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised patients with COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone high‐dose, dexamethasone low‐dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruitment completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0088" title="NCT04329650. Efficacy and safety of siltuximab vs. corticosteroids in hospitalised patients with COVID19 pneumonia. clinicaltrials.gov/show/NCT04329650 (first received 1 April 2020). ">NCT04329650</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Judit Pich Martínez, Fundacion Clinic per a la Recerca Biomédica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐critical patient with pneumonia in radiological progression and/or patient with progressive respiratory failure in the last 24 to 48 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0089" title="NCT04344730. Dexamethasone and oxygen support strategies in ICU patients with COVID-19 pneumonia. clinicaltrials.gov/show/NCT04344730 (first received 14 April 2020). ">NCT04344730</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assistance Publique ‐ Hôpitaux de Paris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted to ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Actual enrolment 550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0090" title="NCT04345445. Study to evaluate the efficacy and safety of tocilizumab versus corticosteroids in hospitalised COVID-19 patients with high risk of progression. clinicaltrials.gov/show/NCT04345445 (first received 14 April 2020). ">NCT04345445</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Malaya</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Malaysia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: receipt of mechanical ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0091" title="NCT04377503. Tocilizumab versus methylprednisolone in the cytokine release syndrome of patients with COVID-19. clinicaltrials.gov/show/NCT04377503 (first received 6 May 2020). ">NCT04377503</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital Sao Domingos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Brazil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COVID diagnosis confirmed by real time PCR, PaO<sub>2</sub>/FIO<sub>2</sub> &lt; 200, laboratory: high sensitivity CRP &gt; 5 mg/L; LDH &gt; 245 U/L; ferritin &gt; 300; D‐dimer &gt; 1500; interleukin‐6 &gt; 7.0 pg/mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0092" title="NCT04452565. NA-831, atazanavir and dexamethasone in the treatment of SARSCov-2 infection (NATADEX). clinicaltrials.gov/show/NCT04452565 (first received 30 June 2020). ">NCT04452565</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NeuroActiva, Inc.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(USA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: IMV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0093" title="NCT04499313. Dexamethasone versus methylprednisolone for the treatment of patients with ARDS caused by COVID-19. clinicaltrials.gov/show/NCT04499313 (first received 5 August 2020). ">NCT04499313</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chattogram General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Bangladesh)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe COVID‐19 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0094" title="MunchMW , GranholmA , MyatraSN , VijayaraghavanBK , CronhjortM , WahlinRR , et al. Higher vs. lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2021;00:1-12. [DOI: 10.1111/aas.13795]NCT04509973. Higher vs. lower doses of dexamethasone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04509973 (first received 12 August 2020). ">NCT04509973</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scandinavian Critical Care Trials Group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Denmark)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMV OR NIV or continuous use of CPAP for hypoxia OR oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active, not recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0095" title="NCT04513184. Randomised clinical trial of nasal dexamethasone as an adjuvant in patients with COVID-19. clinicaltrials.gov/show/NCT04513184 (first received 14 August 2020). ">NCT04513184</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Edda Sciutto Conde</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Mexico)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised patients with moderate to severe respiratory complications that have not received mechanical ventilation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV vs nasal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0096" title="NCT04528329. Anosmia and / or ageusia and early corticosteroid use. clinicaltrials.gov/show/NCT04528329 (first received 27 August 2020). ">NCT04528329</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ClinAmygate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Egypt)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0097" title="NCT04528888. Steroids and unfractionated heparin in critically ill patients with pneumonia from COVID-19 infection. clinicaltrials.gov/show/NCT04528888 (first received 27 August 2020). [EUDRA-CT: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001921-30/IT] [NCT: https://clinicaltrials.gov/ct2/show/study/NCT04528888]">NCT04528888</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Massimo Girardis, University of Modena and Reggio Emilia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included: positive pressure ventilation (IMV/NIV) for &gt; 24 h, IMV from &lt; 96 h, PaO2/FiO2 ratio &lt; 150 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0098" title="NCT04545242. Efficacy of dexamethasone in patients with acute hypoxemic respiratory failure caused by infections. clinicaltrials.gov/show/NCT04545242 (first received 10 September 2020). ">NCT04545242</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dr. Negrin University Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intubated and mechanically ventilated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0099" title="NCT04636671. Methylprednisolone vs. dexamethasone in COVID-19 pneumonia (MEDEAS RCT). clinicaltrials.gov/show/NCT04636671 (first received 19 November 2020). ">NCT04636671</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Trieste</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: on IMV</p> <p>Included: PaO<sub>2</sub> ≤ 60 mmHg or SpO<sub>2</sub> ≤ 90% or on HFNC, CPAP or NPPV at randomisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0100" title="NCT04663555. Effect of two different doses of dexamethasone in patients with ARDS and COVID-19. clinicaltrials.gov/show/NCT04663555 (first received 11 December 2020). ">NCT04663555</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brno University Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Czech Republic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intubation/mechanical ventilation or ongoing HFNC oxygen therapy; admission to ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0101" title="NCT04673162. Evaluation of the efficacy of high doses of methylprednisolone in SARS-CoV2 (COVID-19) pneumonia patients. clinicaltrials.gov/show/NCT04673162 (first received 17 December 2020). ">NCT04673162</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azienda Unità Sanitaria Locale Reggio Emilia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for supplemental oxygen in any delivery mode with the exception of IMV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0102" title="NCT04707534. Dexamethasone for COVID-19. clinicaltrials.gov/show/NCT04707534 (first received 13 January 2021). ">NCT04707534</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Oklahoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(USA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive pressure ventilation (non‐invasive or invasive) or HFNC or need supplemental oxygen with oxygen mask or nasal cannula </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0103" title="NCT04765371. Comparison between prednisolone and dexamethasone on mortality in patients on oxygen therapy, with COVID-19. clinicaltrials.gov/ct2/show/NCT04765371 (first received 21 February 2021). ">NCT04765371</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Centre Hospitalier René Dubos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient with SpaO<sub>2</sub> ≤ 94 % in room air (90% for patient with respiratory failure) and requiring an oxygen therapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0104" title="NCT04780581. Glucocorticoid therapy in coronavirus disease COVID-19 patients. clinicaltrials.gov/show/NCT04780581 (first received 3 March 2021). ">NCT04780581</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requires supplementary oxygen due to basal saturation ≤ 93% (with ambient O<sub>2</sub>, 21%), excluded if IMV, NIV, HFNC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0105" title="NCT04795583. Corticosteroids for COVID-19. clinicaltrials.gov/show/NCT04795583 (first received 12 March 2021). ">NCT04795583</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Alberta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Colombia, Mexico)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ambulatory, confirmed SARS‐CoV‐2. Clinical symptoms compatible with COVID‐19 for ≤ 14 days before randomisation. Oxygen saturation ≥ 95% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0106" title="NCT04834375. Randomised open investigation determining steroid dose. clinicaltrials.gov/show/NCT04834375 (first received 8 April 2021). ">NCT04834375</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Northwell Health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (USA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypoxaemia defined by an oxygen saturation &lt; 94% or the need for supplemental oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0107" title="NCT04836780. Dexamethasone early administration in hospitalised patients with COVID-19 pneumonia. clinicaltrials.gov/show/NCT04836780 (first received 8 April 2021). ">NCT04836780</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital Universitario Infanta Leonor<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peripheral capillary oxygen saturation (SpO<sub>2</sub>) ≥ 94% and &lt; 22 breaths per minute (bpm) breathing room air. High risk of developing ARDS<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0108" title="NCT04860518. Human intravenous interferon beta-Ia safety and preliminary efficacy in hospitalised subjects with coronavirus (HIBISCUS). https://clinicaltrials.gov/ct2/show/NCT04860518 (first received 22 April 2021). ">NCT04860518</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faron Pharmaceuticals Ltd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (USA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted to hospital with respiratory symptoms of COVID‐19 requiring hospital care and oxygen supplementation (≤ 8L/min) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone and human intravenous interferon beta‐Ia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0109" title="TCTR20211017001. A comparative study of the effectiveness between pulse regimen methylprednisolone versus high dose dexamethasone as the initial treatment of moderate Covid-19 pneumonia: an open-label randomised controlled trial. http://www.thaiclinicaltrials.org/show/TCTR20211017001 (first received 17 October 2021). ">TCTR20211017001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faculty of Medicine Ramathibodi Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Thailand)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resting oxygen saturation between 90% and 94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>ARDS:</b> acute respiratory distress syndrome; <b>CPAP:</b> continuous positive airway pressure; <b>CRP:</b> c‐reactive protein; <b>FiO2:</b> fraction of inspired oxygen; <b>HFNC:</b> high‐flow nasal cannula; <b>ICU:</b> intensive care unit; <b>IMV:</b> invasive mechanical ventilation; <b>IV:</b> intravenous; <b>LDH:</b> lactic dehydrogenase; <b>NIV:</b> non‐invasive ventilation; <b>NPPV:</b> non‐invasive positive pressure ventilation; <b>PaO2:</b> partial pressure oxygen; <b>PCR:</b> polymerase chain reaction <b>RCT:</b> randomised; controlled trial; <b>RT‐PCR:</b> reverse transcription polymerase chain reaction; <b>SpO2:</b> blood oxygen saturation </p> </td> </tr> </tbody> </table> </div> <p>On excluding the studies that were 'not recruiting', 'not yet recruiting', and 'active, not recruiting' the 27 studies that were recruiting, ongoing, temporarily halted and that completed recruitment comprised a total of 7617 expected participants. Most of the potentially eligible ongoing studies identified intend to recruit people who are admitted to hospital and require varying levels of respiratory support. Of the 42 ongoing studies, 15 planned to test dexamethasone, 11 methylprednisolone, and three prednisolone or prednisone. Four studies planned to compare different dexamethasone dosing regimens. Eight studies planned to compare dexamethasone to methylprednisolone, and one study dexamethasone to prednisolone, another dexamethasone to human intravenous interferon beta‐Ia. One study planned to compare corticosteroids at different time points. </p> </section> <section id="CD014963-sec-0066"> <h5 class="title">Studies awaiting classification</h5> <p>We identified 23 RCTs with systemic application of steroids for acute COVID‐19 (details listed in <a href="#CD014963-tbl-0010">Table 7</a>). Of the 23 studies comprising 5608 expected participants, 15 were classified as ‘completed’, four as ‘prematurely ended’, and four as 'terminated' (due to lack of enrolment, too few participants, local recommendations or corticosteroid use approval), according to the study registrations. For four studies, the full‐text publications are available, but the methodology is unclear. For one study only the abstract is available, which does not provide any information on the randomisation process. The majority of studies were conducted in low‐ and middle‐income countries (about 56%; for details see <a href="#CD014963-tbl-0010">Table 7</a>). </p> <div class="table" id="CD014963-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Characteristics of studies awaiting classification</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sponsor/developer</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]"><b>World Bank 2021</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Route of administration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0046" title="EUCTR2020-001333-13-FR. Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19: a randomised controlled trial. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001333-13 (first received 9 April 2020). ">EUCTR2020‐001333‐13‐FR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Groupe Hospitalier Paris Saint‐Joseph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included: patient diagnosed COVID positive by RT‐PCR and/or scanner (patients admitted with already mechanical ventilation and sedation, or with acute respiratory failure evolving very quickly) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prematurely ended<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0045" title="EUCTR2020-001307-16-ES. Efficacy and safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to coronavirus infection. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001307-16 (first received 1 April 2020). ">EUCTR2020‐001307‐16‐ES</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundación para la Investigación Biomédica Hospital Ramón y Cajal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prematurely ended</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0047" title="EUCTR2020-001553-48-FR. Corticoids in COVID-19 viral pneumonia in infection with SARS-CoV-2 (translation by the review authors) [Corticoides au cours de la pneumonie virale COVID-19 liee a linfection par le SARS-CoV-2]. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001553-48 (first received 13 April 2020). ">EUCTR2020‐001553‐48‐FR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospices Civils de Lyon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peripheral saturation by pulse oximeter SpO<sub>2</sub> ≤ 94% in ambient air measured twice at 5‐ to 15‐min intervals, or PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prematurely ended</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0052" title="IRCT20081027001411N3. Effect of prednisolone on treatment of COVID-19. irct.ir/trial/46975 (first received 6 January 2020). ">IRCT20081027001411N3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Teheran University of Medical Sciences<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood oxygen saturation &lt; 93%; with ARDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0053" title="IRCT20120215009014N354. Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19. irct.ir/trial/48043 (first received 12 May 2020). ">IRCT20120215009014N354</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hamedan University of Medical Sciences<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised in ICU, bilateral pulmonary infiltration in chest X‐ray or CT‐scan; respiratory distress with &gt; 24 breaths per minute<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydrocortisone, methylprednisolone, dexamethasone<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0054" title="IRCT20160118026097N4. The effect of dexamethasone in the treatment of high-risk COVID-19 patients. irct.ir/trial/48310 (first received 13 September 2020). ">IRCT20160118026097N4</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ghoum University of Medical Sciences<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypoxia requires supplemental oxygen to maintain oxygen saturation &gt; 90%<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0055" title="IRCT20200611047727N3. Evaluation of efficacy and safety of low dose corticosteroid with severe pneumonia COVID-19. irct.ir/trial/49116 (first received 3 January 2021). ">IRCT20200611047727N3</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Shahid Beheshti University of Medical Sciences<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen saturation level &lt; 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0056" title="IRCT20201015049030N1. Effect of dexamethasone on treatment of COVID-19. www.irct.ir/trial/51736 (first received 7 November 2020). ">IRCT20201015049030N1</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Teheran University of Medical Sciences<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood oxygen saturation between 90% and 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0057" title="ISRCTN33037282. Comparing two medications (dexamethasone and methylprednisolone high dose) for the treatment of pneumonia in patients with COVID-19. www.isrctn.com/ISRCTN33037282 (first received 26 November 2020). ">ISRCTN33037282</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clínica Medellín ‐ Grupo Quirónsalud</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Colombia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PaO<sub>2</sub> ≤ 60 mmHg or SpO<sub>2</sub> ≤ 90% or on HFNC, CPAP or NPPV at randomisation </p> <p>Excluded: on IMV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0059" title="NCT04244591. Glucocorticoid therapy for novel coronavirus critically ill patients with severe acute respiratory failure. www.clinicaltrials.gov/ct2/show/NCT04244591 (first received 28 January 2020). ">NCT04244591</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peking Union Medical College Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (China)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 200 mmHg; positive pressure ventilation (non‐invasive or invasive) or HFNC &gt; 45 L/min for &lt; 48 h; requiring ICU admission </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0060" title="NCT04325061. Efficacy of dexamethasone treatment for patients with ARDS caused by COVID-19. clinicaltrials.gov/ct2/show/NCT04325061 (first received 27 March 2020). ">NCT04325061</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dr. Negrin University Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intubated and mechanically ventilated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (lack of enrolment)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0064" title="NCT04530409. Timing of corticosteroids in COVID-19. clinicaltrials.gov/show/NCT04530409 (first received 28 August 2020). ">NCT04530409</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ClinAmygate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Egypt)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild and moderate severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0065" title="NCT04746430. COVID-19 primary care platform for early treatment and recovery (COPPER) study. clinicaltrials.gov/show/NCT04746430 (first received 9 February 2021). ">NCT04746430</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General Practitioners Research Institute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Netherlands)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exercise‐induced desaturation, defined as SpO<sub>2</sub> &lt; 92% (&lt; 90% for COPD patients) and/or an absolute drop of ≥ 4% in SpO<sub>2</sub> after a 1‐min sit‐to‐stand test or SpO<sub>2</sub> &lt; 92% (&lt; 90% for COPD patients) at rest with GP's and patient's shared decision to keep patient at home despite this in itself being an indication for referral to hospital </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (too few patients)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0048" title="EUCTR2020-002186-34-ES. Efficacy of the early use of corticotherapy in CoV-2 infection to prevent the progression of acute respiratory distress syndrome (ARDS). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002186-34 (first received 22 July 2020). ">EUCTR2020‐002186‐34‐ES</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundació Hospital Universitari Vall d'Hebron ‐ Institut de Recerca (VHIR)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Air oxygen saturation &gt; 90 and &lt; 94%; PaO<sub>2</sub>/FiO<sub>2</sub> &gt; 200 and ≤ 300 mmHg; Sa:FiO<sub>2</sub> (O<sub>2</sub> saturation measured with pulse oximeter/inspired O<sub>2</sub> fraction) ≤ 350<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prematurely ended</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0049" title="EUCTR2020-004323-16. Evaluation of the efficacy of high doses of methylprednisolone in SARS-CoV2 pneumonia patients. www.clinicaltrialsregister.eu/ctr-search/trial/2020-004323-16/IT (first received 23 November 2020). ">EUCTR2020‐004323‐16</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azienda Ospedaliera Arcispedale Santa Maria Nuova/IRCCS di Reggio Emilia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for supplemental oxygen in any delivery mode with the exception of IMV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0061" title="NCT04347980. Dexamethasone treatment for severe acute respiratory distress syndrome. clinicaltrials.gov/show/NCT04347980 (first received 15 April 2020). ">NCT04347980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Centre Chirurgical Marie Lannelongue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted to ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (ANSM (Agence nationale de sécurité du médicament et des produits de santé) Recommendation) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0062" title="Les BujandaI , Loureiro-AmigoJ , Capdevila BastonsF , Elejalde GuerraI , Anniccherico SánchezJ , Murgadella-SanchoA , et al. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial. Trials2021;22(1):43. [DOI: 10.1186/s13063-020-04999-4]NCT04438980. Glucocorticoids in COVID-19 (CORTIVID). clinicaltrials.gov/show/NCT04438980 (first received 19 June 2020). ">NCT04438980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundacion Miguel Servet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised</p> <p>Excluded: SpO<sub>2</sub> &lt; 90% (in air ambient) or PaO<sub>2</sub> &lt; 60 mmHg (in ambient air) or PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0063" title="NCT04451174. Early use of corticosteroids in hospitalised patients with moderate COVID19 pneumonia. clinicaltrials.gov/show/NCT04451174 (first received 30 June 2020). SalinasM , AndinoP , PalmaL , ValenciaJ , FigueroaE , OrtegaJ . Early use of corticosteroids in non-critical patients with COVID-19 pneumonia (PREDCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2021;22(1):92. [DOI: 10.1186/s13063-021-05046-6.]">NCT04451174</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Chile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Chile)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: requirements of mechanical ventilation (IMV/NIV)</p> <p>Included: oxygen requirements until 35 % by Venturi mask or 5 L/min by nasal cannula</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (corticosteroid use approval)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0067" title="SalukhovVV , KryukovEV , ChugunovAA , KharitonovMA , RudakovYV , LakhinRE , et al. The role and place of glucocorticosteroids in treatment of COVID-19 pneumonia without hypoxemia [Роль и место глюкокортикостероидов в терапии пневмоний, вызванных COVID-19, без гипоксемии]. Meditsinskiy Sovet = Medical Council2021;16(60):162-72. [DOI: 10.21518/2079- 701X-2021-12-162-172]">Salukhov 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT (unclear randomisation process)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Russia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe course with process prevalence according to computed tomography without hypoxaemia (saturation SpO2 &gt; 93%) with a duration of hyperthermia &gt; 38 °C for 3 days or more and C‐reactive protein levels of 15 to 50 mg/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed and published (but unclear randomisation process)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0051" title="GhaneiM , Solaymani‑DodaranM , QazviniA , Ghazale AH, SetarehdanSA , SaadatSH , et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respiratory Research2021;22(245):1-14. [DOI: 10.1186/s12931-021-01833-6]">Ghanei 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen saturation (Spo2) less than 94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed and published (not pre‐registered, no ethics vote named, no patient informed consent) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0050" title="GautamPB , KumarA , KannojiaBL , ChaudharyR . A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease. Asian Journal of Medical Sciences2021;12(12):17-22. [DOI: 10.3126/ajms.v12i12.39294]">Gautam 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe COVID‐19, oxygen saturation &lt; 93% on room air</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed and published (not pre‐registered, no ethics vote named, no patient informed consent, no information about randomisation) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0058" title="MontalvanE , CarcamoB , PalacionD , RiveraS , EstevezR , NorwoodD , et al. High-dose vs low-dose dexamethasone in patients with COVID-19 in a tertiary hospital in Western Honduras. Chest2021;160(4):A1117-8. [DOI: 10.1016/j.chest.2021.07.1027]">Montalvan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT (unclear randomisation process)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Honduras)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed and abstract published (no registration number, no information about randomisation process), only abstract available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0066" title="NCT04519385. Tocilizumab versus dexamethasone in severe COVID19 cases. clinicaltrials.gov/show/NCT04519385 (first received 19 August 2020). RashadA , MousaS , Nafady‑HegoH , NafadyA , ElgendyH . Short term survival of critically ill COVID‑19 Egyptian patients on assisted ventilation treated by either dexamethasone or tocilizumab. Scientific Reports2021;11(8816):1-7. [DOI: 10.1038/s41598-021-88086-x]">Rashad 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Valley University</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT (unclear randomisation process)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Egypt)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe ≥ 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed and published (no pre‐registration, unclear randomisation process)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>ARDS:</b> acute respiratory distress syndrome; <b>COPD:</b> chronic obstructive pulmonary disease; <b>CT:</b> computed tomography; <b>HFNC:</b> high‐flow nasal cannula;<b>ICU:</b> intensive care unit; <b>RCT:</b> randomised controlled trial; <b>RT‐PCR:</b> reverse transcription polymerase chain reaction. </p> </td> </tr> </tbody> </table> </div> <p>Only one of the studies awaiting classification was placebo‐controlled and compared methylprednisolone in addition to standard care to standard care plus placebo. Four studies planned to compare dexamethasone, four methylprednisolone, and three prednisolone or prednisone (each in addition to standard care) to standard care only. One open‐label study planned to compare methylprednisolone without specification of the control. Two studies planned to compare dexamethasone to methylprednisolone, one study methylprednisolone to prednisolone, and one study hydrocortisone to methylprednisolone to dexamethasone. Two other studies planned to compare dexamethasone plus hydroxychloroquine to hydroxychloroquine only and one prednisolone plus hydroxychloroquine plus azithromycin plus naproxen to hydroxychloroquine plus azithromycin plus naproxen. One study planned to compare two different treatment regimes: an early versus a late treatment with dexamethasone. One study planned to compare different doses of dexamethasone. Another study compared dexamethasone to tocilizumab. </p> </section> </section> <section id="CD014963-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded 28 studies (31 references) that did not meet our inclusion criteria.</p> <p> <ul id="CD014963-list-0125"> <li> <p>Nine studies investigated corticosteroids plus other active substances versus standard care (<a href="./references#CD014963-bbs2-0017" title="EUCTR2020-001445-39-ES. Clinical trial to evaluate methylprednisolone pulses and tacrolimus in hospitalized patients with severe pneumonia secondary to COVID-19 (tacrovid). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001445-39 (first received 31 March 2020). ">EUCTR2020‐001445‐39‐ES</a>; <a href="./references#CD014963-bbs2-0020" title="IRCT20120225009124N4. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):549. [DOI: 10.1186/s13063-020-04499-5]">IRCT20120225009124N4</a>; <a href="./references#CD014963-bbs2-0021" title="IRCT20190312043030N2. The effect of selenium, vitamin C and methylprednisolone combination on mortality and morbidity of COVID-19 patients. en.irct.ir/trial/49508 (first received 19 August 2020). ">IRCT20190312043030N2</a>; <a href="./references#CD014963-bbs2-0026" title="NCT04341038. Clinical trial to evaluate methylprednisolone pulses and tacrolimus in patients with COVID-19 lung injury. clinicaltrials.gov/show/NCT04341038 (first received 10 April 2020). NCT04341038. Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol. medRxiv [Preprint]2021;21(100716):1-8. [DOI: 10.1016/j.conctc.2021.100716]">NCT04341038</a>; <a href="./references#CD014963-bbs2-0031" title="SakoulasG , GeriakM , KullarR , GreenwoodKL , HabibM , VyasA , et al. Intravenous immunoglobulin plus methylprednisolone mitigate respiratory morbidity in coronavirus disease 2019. Critical Care Explorations2020;2(11):e0280. [DOI: 10.1097/CCE.0000000000000280]">NCT04411667</a>; <a href="./references#CD014963-bbs2-0033" title="RiffatM , FridoonA , AhadQ , MuhammadAR , SyedAG , MuhammadAT , et al. Aprepitant as a combinant with dexamethasone reduces the inflammation via neurokinin 1 receptor antagonism in severe to critical COVID-19 patients and potentiates respiratory recovery: a novel therapeutic approach. medRxiv [Preprint]. [DOI: https://doi.org/10.1101/2020.08.01.20166678]">NCT04468646</a>; <a href="./references#CD014963-bbs2-0038" title="NCT04561180. Study to evaluate the efficacy and safety of EG-HPCP-03a compared to DEX in patients with COVID-19 pneumonia. clinicaltrials.gov/show/NCT04561180 (first received 23 September 2020). ">NCT04561180</a>; <a href="./references#CD014963-bbs2-0040" title="NCT04640168. Adaptive COVID-19 treatment trial 4 (ACTT-4). clinicaltrials.gov/show/NCT04640168 (first received 23 November 2020). ">NCT04640168</a>; <a href="./references#CD014963-bbs2-0042" title="NCT04826822. Spironolactone and dexamethasone in patients hospitalised with COVID-19 (SPIDEX-II). clinicaltrials.gov/show/NCT04826822 (first received 1 April 2021). ">NCT04826822</a>). </p> </li> <li> <p>Six studies examined inhaled corticosteroids (<a href="./references#CD014963-bbs2-0018" title="TACTIC-COVID. www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001616-18. Treatment with inhaled corticoids in patients with COVID-19 and pneumonia. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001616-18-ES. ">EUCTR2020‐001616‐18‐ES</a>; <a href="./references#CD014963-bbs2-0019" title="EUCTR2020-001889-10. Use of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001889-10/GB (first received 15 May 2020). ">EUCTR2020‐001889‐10</a>; <a href="./references#CD014963-bbs2-0023" title="ISRCTN86534580. PRINCIPLE: a trial evaluating treatments for suspected COVID-19 in people aged 50 years and above with pre-existing conditions and those aged 65 years and above. www.isrctn.com/ISRCTN86534580 (first received 20 March 2020). ">ISRCTN86534580</a>; <a href="./references#CD014963-bbs2-0027" title="NCT04355637. Inhaled corticosteroid treatment of COVID-19 patients with pneumonia. clinicaltrials.gov/show/NCT04355637 (first received 21 April 2020). ">NCT04355637</a>; <a href="./references#CD014963-bbs2-0030" title="NCT04381364. Inhalation of ciclesonide for patients with COVID-19: a randomised open treatment study (HALT COVID-19). clinicaltrials.gov/show/NCT04381364 (first received 8 May 2020). ">NCT04381364</a>; <a href="./references#CD014963-bbs2-0032" title="RamakrishnanS , Nicolau DV Jr, LangfordB , MahdiM , JeffersH , MwasukuC , et al. Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. medRxiv [Preprint]. [DOI: https://doi.org/10.1101/2021.02.04.21251134]">NCT04416399</a>). </p> </li> <li> <p>Four studies investigated topical corticosteroids (<a href="./references#CD014963-bbs2-0022" title="IRCT20200522047542N1. Effect of corton on olfactory dysfunction in COVID-19 patients. en.irct.ir/trial/48379 (first received 4 August 2020). ">IRCT20200522047542N1</a>; <a href="./references#CD014963-bbs2-0029" title="DavalM , CorreA , PalpacuerC , HoussetteJ , PoillonG , EliezerM , et al. Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(666):1-3. [DOI: https://doi.org/10.1186/s13063-020-04585-8]NCT04361474. Trial evaluating the efficacy of local budesonide therapy in the management of hyposmia in COVID-19 patients without signs of severity. clinicaltrials.gov/show/NCT04361474 (first received 24 April 2020). ">NCT04361474</a>; <a href="./references#CD014963-bbs2-0034" title="AbdelalimAA , MohamadyAA , ElsayedRA , ElawadyMA , GhallabAF . Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: a randomised controlled trial. American Journal of Otolaryngology2021;42(2):1-6. [PMID: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836546/pdf/main.pdf]">NCT04484493</a>; <a href="./references#CD014963-bbs2-0039" title="NCT04569825. Effect of nasal steroid in the treatment of anosmia due to COVID-19 disease. clinicaltrials.gov/ct2/show/NCT04569825 (first received 30 September 2020). ">NCT04569825</a>). </p> </li> <li> <p>Three studies considered corticosteroids for long‐COVID treatment (<a href="./references#CD014963-bbs2-0037" title="NCT04551781. Short term low dose corticosteroids for management of post COVID19 pulmonary fibrosis. clinicaltrials.gov/show/NCT04551781 (first received 16 September 2020). ">NCT04551781</a>; <a href="./references#CD014963-bbs2-0036" title="NCT04534478. Oral prednisone regimens to optimise the therapeutic strategy in patients with organising pneumonia post-COVID-19. clinicaltrials.gov/show/NCT04534478 (first received 1 September 2020). ">NCT04534478</a>; <a href="./references#CD014963-bbs2-0041" title="NCT04657484. Comparison of two corticosteroid regimens for post-COVID diffuse lung disease. clinicaltrials.gov/show/NCT04657484 (first received 8 December 2020). ">NCT04657484</a>). </p> </li> <li> <p>One study stopped early before enrolling its first participant (<a href="./references#CD014963-bbs2-0028" title="NCT04359511. Efficacy and safety of corticosteroids in oxygen-dependent patients with COVID-19 pneumonia. clinicaltrials.gov/show/NCT04359511 (first received 24 April 2020). ">NCT04359511</a>). </p> </li> <li> <p>One study was withdrawn due to a recent study suggesting a new corticosteroid regime for intensive care unit patients, so that no participants were recruited (<a href="./references#CD014963-bbs2-0043" title="NCT05133635. High-dose corticosteroid or tocilizumab for clinical worsening of COVID-19. https://clinicaltrials.gov/show/NCT05133635 (first received 11 January 2021). ">NCT05133635</a>). </p> </li> <li> <p>In one study the administered antibody (foralumab) was not standard care (<a href="./references#CD014963-bbs2-0024" title="MoreiraTG , MatosKTF , De PaulaGS , SantanaTMM , Da MataRG , PanseraFC , et al. Nasal administration of anti-CD3 monoclonal antibody (foralumab) reduces lung inflammation and blood inflammatory biomarkers in mild to moderate COVID-19 patients: a pilot study. Frontiers in Immunology2021;12:3255. [DOI: 10.3389/fimmu.2021.709861]">Moreira 2021</a>). </p> </li> <li> <p>In one study the participants received low‐dose dexamethasone in addition to standard care (<a href="./references#CD014963-bbs2-0025" title="NaikNB , PuriGD , KajalK , MahajanV , BhallaA , KatariaS , et al. High-dose dexamethasone versus tocilizumab in moderate to severe COVID-19 pneumonia: a randomised controlled trial. Cureus2021;13(12):e20353. [DOI: 10.7759/cureus.20353]">Naik 2021</a>). </p> </li> <li> <p>One study compared bio‐marker adjusted corticosteroid dosing with usual care (corticosteroid use and dosing determined by the physician) (<a href="./references#CD014963-bbs2-0044" title="OdeyemiYE , ChalmersSJ , BarretoEF , JentzerJC , GajicO , YadavH . Early, biomarker-guided steroid dosing in COVID-19 pneumonia: a pilot randomised controlled trial. Critical Care2022;26(9):1-3. [DOI: 10.1186/s13054-021-03873-2]">Odeyemi 2021</a>). </p> </li> <li> <p>For one study it was not possible to perform the trial due to the availability and logistics of porcine heparin (<a href="./references#CD014963-bbs2-0035" title="NCT04485429. Efficacy assessment of methylprednisolone and heparin in patients with COVID-19 pneumonia. clinicaltrials.gov/show/NCT04485429 (first received 24 July 2020). ">NCT04485429</a>). </p> </li> </ul> </p> </section> </section> <section id="CD014963-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias of results from 15 RCTs that contributed to our analyses (<a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>; <a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>; <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>; <a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a>; <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>; <a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a>; <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>; <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a>;<a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>; <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>; <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>), using the RoB 2 tool (version 22 August 2019) recommended in Chapter 8 of the C<i>ochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014963-bbs2-0142" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022b</a>). We made no assessment of bias for <a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a> as it did not report any outcomes relevant to this review. </p> <p>The 15 studies contributed 47 study results to eight outcomes in the respective summary of findings tables and three more in additional analyses for inpatient individuals. The completed RoB 2 tool with responses to all assessed signalling questions is available online at: <a href="https://zenodo.org/record/6500842" target="_blank">https://zenodo.org/record/6500842</a>. </p> <section id="CD014963-sec-0069"> <h4 class="title">Overall judgements for studies that included individuals with a confirmed diagnosis of moderate to severe COVID‐19 </h4> <section id="CD014963-sec-0070"> <h5 class="title">Overall risk of bias by study</h5> <p>From 47 study results, we rated 5 (11%) at low risk of bias, noted some concerns in 20 (43%) study results, and rated 22 (47%) at high risk of bias. Regarding the respective studies we included the following: </p> <p> <ul id="CD014963-list-0126"> <li> <p><a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a> ‐ two study results with some concerns and one with high risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a> ‐ one study result with some concerns and two with high risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a> ‐ one study result with some concerns and one with high risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a> ‐ two study results with some concerns and one with high risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> ‐ three study results with some concerns and one with high risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a> ‐ one study result with some concerns. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a> ‐ two study results with some concerns and three with high risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a> ‐ two study results with some concerns and four with high risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a> ‐ two study results with low risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a> ‐ two study results with low risk and three with high risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a> ‐ one study result with some concerns. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a> ‐ three study results with some concerns. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a> ‐ one study result with low risk and two with high risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a> ‐ two study results with some concerns and three with high risk. </p> </li> <li> <p><a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a> ‐ one study result with high risk. </p> </li> </ul> </p> </section> <section id="CD014963-sec-0071"> <h5 class="title">Overall risk of bias by outcome</h5> <section id="CD014963-sec-0072"> <h6 class="title">Systemic corticosteroids (plus standard care) versus standard care (plus/minus placebo)</h6> <p>We had some concerns about all‐cause‐mortality up to 30 days (<a href="./references#CD014963-tblf-0084" title="">Risk of bias table for Analysis 1.1</a>) and all‐cause‐mortality up to 120 days (<a href="./references#CD014963-tblf-0085" title="">Risk of bias table for Analysis 1.2</a>) because of issues with randomisation, deviations from intended interventions, and pre‐specification of the outcomes. We also applied the respective risk of bias assessments to the six subgroup analyses (<a href="./references#CD014963-tblf-0095" title="">Risk of bias table for Analysis 2.1</a>; <a href="./references#CD014963-tblf-0096" title="">Risk of bias table for Analysis 3.1</a>; <a href="./references#CD014963-tblf-0097" title="">Risk of bias table for Analysis 3.2</a>; <a href="./references#CD014963-tblf-0098" title="">Risk of bias table for Analysis 3.3</a>; <a href="./references#CD014963-tblf-0099" title="">Risk of bias table for Analysis 4.1</a>; <a href="./references#CD014963-tblf-0100" title="">Risk of bias table for Analysis 5.1</a>; <a href="./references#CD014963-tblf-0101" title="">Risk of bias table for Analysis 6.1</a>; <a href="./references#CD014963-tblf-0102" title="">Risk of bias table for Analysis 7.1</a>). We also had some concerns about clinical improvement (discharged alive) because of issues with randomisation, deviations from intended intervention, assessment, and pre‐specification of the outcome (<a href="./references#CD014963-tblf-0086" title="">Risk of bias table for Analysis 1.3</a>). There were some concerns about clinical worsening (new need for invasive mechanical ventilation (IMV) or death) because of deviations from intended interventions and assessment of the outcome only (<a href="./references#CD014963-tblf-0087" title="">Risk of bias table for Analysis 1.4</a>). We judged all safety outcomes (serious adverse events, adverse events, hospital‐acquired infections, and invasive fungal infections), need for dialysis, and viral clearance to be at high risk of bias mainly due to missing adjustment for competing risk of death (<a href="./references#CD014963-tblf-0088" title="">Risk of bias table for Analysis 1.5</a>; <a href="./references#CD014963-tblf-0089" title="">Risk of bias table for Analysis 1.6</a>; <a href="./references#CD014963-tblf-0090" title="">Risk of bias table for Analysis 1.7</a>; <a href="./references#CD014963-tblf-0091" title="">Risk of bias table for Analysis 1.8</a>; <a href="./references#CD014963-tblf-0093" title="">Risk of bias table for Analysis 1.10</a>; <a href="./references#CD014963-tblf-0094" title="">Risk of bias table for Analysis 1.11</a>). </p> </section> <section id="CD014963-sec-0073"> <h6 class="title">Methylprednisolone versus dexamethasone</h6> <p>We had some concerns about all‐cause‐mortality up to 30 days because of questionable pre‐specification, the only outcome included in this version of the review (<a href="./references#CD014963-tblf-0105" title="">Risk of bias table for Analysis 8.1</a>). </p> </section> <section id="CD014963-sec-0074"> <h6 class="title">High‐dose dexamethasone versus low‐dose dexamethasone</h6> <p>We had some concerns about all‐cause‐mortality up to 30 days because of issues with randomisation and deviations from intended interventions (<a href="./references#CD014963-tblf-0106" title="">Risk of bias table for Analysis 9.1</a>). We judged all‐cause mortality up to 120 days to be at high risk of bias mainly because of deviations from intended interventions (<a href="./references#CD014963-tblf-0107" title="">Risk of bias table for Analysis 9.2</a>). We also applied the respective risk of bias assessments to the four subgroup analyses, although it has to be noted that thereby the age‐stratified analysis could be assessed to be at low risk of bias (<a href="./references#CD014963-tblf-0113" title="">Risk of bias table for Analysis 10.1</a>; <a href="./references#CD014963-tblf-0114" title="">Risk of bias table for Analysis 10.2</a>; <a href="./references#CD014963-tblf-0115" title="">Risk of bias table for Analysis 11.1</a>; <a href="./references#CD014963-tblf-0116" title="">Risk of bias table for Analysis 11.2</a>; <a href="./references#CD014963-tblf-0117" title="">Risk of bias table for Analysis 12.1</a>; <a href="./references#CD014963-tblf-0118" title="">Risk of bias table for Analysis 12.2</a>). We had some concerns about clinical improvement (discharged alive) because of issues with randomisation (<a href="./references#CD014963-tblf-0108" title="">Risk of bias table for Analysis 9.3</a>). We judged all safety outcomes (serious adverse events, adverse events, hospital‐acquired infections, and invasive fungal infections) to be at high risk of bias due to missing adjustment for competing risk of death (<a href="./references#CD014963-tblf-0109" title="">Risk of bias table for Analysis 9.4</a>; <a href="./references#CD014963-tblf-0110" title="">Risk of bias table for Analysis 9.5</a>; <a href="./references#CD014963-tblf-0111" title="">Risk of bias table for Analysis 9.6</a>; <a href="./references#CD014963-tblf-0112" title="">Risk of bias table for Analysis 9.7</a>). </p> </section> </section> </section> </section> <section id="CD014963-sec-0075"> <h3 class="title" id="CD014963-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD014963-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ Corticosteroids plus standard care compared to standard care (plus/minus placebo) for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</a>; <a href="./full#CD014963-tbl-0002"><b>Summary of findings 2</b> Summary of findings table ‐ Methylprednisolone compared to dexamethasone for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</a>; <a href="./full#CD014963-tbl-0003"><b>Summary of findings 3</b> Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) compared to low‐dose dexamethasone (6 mg to 8 mg) for hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19</a> </p> <section id="CD014963-sec-0076"> <h4 class="title">Hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</h4> <p>From 16 RCTs in this population (<a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>; <a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>; <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>; <a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a>; <a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a>; <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>; <a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a>; <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>; <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a>; <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>; <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>; <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>), the study of <a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a> did not report any of the prioritised outcomes of interest. </p> <p>We received data for serious adverse events, adverse events, hospital‐acquired infections, invasive fungal infections, age‐stratified, sex‐stratified and ethnicity‐stratified mortality from four studies upon request (<a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>; <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>). </p> <section id="CD014963-sec-0077"> <h5 class="title">Systemic corticosteroids plus standard care versus standard care (plus/minus placebo)</h5> <p>The evidence profile is presented in <a href="./full#CD014963-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD014963-sec-0078"> <h6 class="title">All‐cause mortality up to 30 days</h6> <p>Data on all‐cause mortality up to 30 days were available from nine studies with a total of 7898 participants (<a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>; <a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>; <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>; <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>; <a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a>; <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>; <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>; <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>). The observation periods ranged from 21 to 28 days. Overall, 764 of 2937 participants in the intervention groups died compared with 1357 of 4961 participants in the control groups. The risk ratio (RR) of this dichotomous outcome of death was 0.90 (95% confidence interval (CI) 0.84 to 0.97; I² = 0%; random‐effects model; <a href="./references#CD014963-fig-0003" title="">Analysis 1.1</a>). We downgraded the certainty of the evidence for this outcome from high to moderate due to serious risk of bias. </p> <section id="CD014963-sec-0079"> <p><b>Subgroup analyses: clinical relevance</b></p> <p> <ul id="CD014963-list-0127"> <li> <p><b>Respiratory support at randomisation:</b> the test for subgroup differences indicated no difference (P = 0.11) (<a href="./references#CD014963-fig-0014" title="">Analysis 2.1</a>). In contrast with the beneficial effect on mortality in all those subgroups needing respiratory support, a higher risk of death with systemic corticosteroids was seen among symptomatic COVID‐19 participants who did not need any respiratory support (RR 1.27, 95% CI 1.00 to 1.61). A single large study contributed data for participants without the need for respiratory support (<a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>). </p> </li> <li> <p><b>Dexamethasone versus methylprednisolone versus hydrocortisone indirectly compared for their effects relative to placebo/standard care:</b> the test for subgroup differences indicated no difference (P = 0.71) (<a href="./references#CD014963-fig-0015" title="">Analysis 3.1</a>). However, the effect estimates for each subgroup were in favour of corticosteroid use. </p> </li> </ul> </p> </section> <section id="CD014963-sec-0080"> <p><b>Subgroup analyses: equity‐related aspects</b></p> <p> <ul id="CD014963-list-0128"> <li> <p><b>Sex ‐ female versus male:</b> the test for subgroup differences indicated no difference (P = 0.44) (<a href="./references#CD014963-fig-0018" title="">Analysis 4.1</a>). However, the effect estimates for each subgroup were in favour of corticosteroid use. </p> </li> <li> <p><b>Age ‐ &lt; 70 years versus ≥ 70 years:</b> the test for subgroup differences indicated differences (P = &lt; 0.0001) (<a href="./references#CD014963-fig-0019" title="">Analysis 5.1</a>). Participants younger than 70 years seem to benefit from corticosteroids in contrast to participants who were aged 70 years and older. Furthermore, the degree of heterogeneity in each of the subgroups is much lower (&lt; 10 %) than in the set of the combined subgroups (77%). This might be a sign for identifying one of the causes of overall heterogeneity. </p> </li> <li> <p><b>Ethnicity ‐ White versus Black, Asian or minority ethnic group versus unknown:</b> the test for subgroup differences indicated differences (P = 0.01) (<a href="./references#CD014963-fig-0020" title="">Analysis 6.1</a>). The few participants from a Black, Asian, or minority ethnic group had a larger estimated effect than the many White participants. </p> </li> <li> <p><b>Place of residence ‐ high‐income versus low‐ and middle‐income countries:</b> the test for subgroup differences indicated no difference (P = 0.42) (<a href="./references#CD014963-fig-0021" title="">Analysis 7.1</a>). However, the effect estimates for both subgroups were in favour of corticosteroid use. </p> </li> </ul> </p> </section> <section id="CD014963-sec-0081"> <p><b>Sensitivity analyses</b></p> <p>We summarised the effects of sensitivity analyses in <a href="#CD014963-tbl-0011">Table 8</a>. Reported effects in our main analysis were robust when removing platform trials and using the fixed‐effect model. As we found only a low risk of bias or some concerns in our included RCTs for this outcome, there was no opportunity to exclude studies at high risk of bias for sensitivity analysis. Furthermore, none of the included studies for this comparison were preprints. </p> <div class="table" id="CD014963-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Sensitivity analyses for the comparison: systemic corticosteroids plus standard care versus standard care (plus/minus placebo)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analyses</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of bias (excluding studies at high risk of bias)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fixed‐effect model or random‐effects model</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Preprint (excluding preprints)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platform trial (excluding platform trials<sup>a</sup>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90, 95% CI 0.84 to 0.97; 9 studies, 7898 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs with high risk of bias concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90, 95% CI 0.83 to 0.97; 9 studies, 7898 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs as a preprint concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94, 95% CI 0.82 to 1.08; 7 studies, 1094 participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 120 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.74, 95% CI 0.23 to 2.34; 3 studies, 485 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs with high risk of bias concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92, 95% CI 0.73 to 1.15; 3 studies, 485 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs as a preprint concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no platform trials concerning this outcome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: discharged alive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07, 95% CI 1.03 to 1.11; 3 studies, 6786 participants<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs with high risk of bias concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.36, 95% CI 0.95 to 1.96; 3 studies, 6786 participants<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs as a preprint concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.65, 95% CI 1.23 to 2.21; 2 studies, 361 participants</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Excluding platform trials: <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>; <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>. </p> <p><sup>b</sup>Using the fixed‐effect model. </p> <p><sup>c</sup> Using the random‐effects model. </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </div> </div> </section> </section> <section id="CD014963-sec-0082"> <h6 class="title">All‐cause mortality up to 120 days</h6> <p>Data on all‐cause mortality up to 120 days were available from three studies with a total of 485 participants (<a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a>; <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a> (matched with long‐term data from <a href="./references#CD014963-bbs2-0119" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]">Barros 2021</a>); <a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>). Overall, 89 of 244 participants in the intervention groups died compared with 97 of 241 participants in the control groups. The RR of death was 0.74 (95% CI 0.23 to 2.34; I² = 79%; random‐effects model; <a href="./references#CD014963-fig-0004" title="">Analysis 1.2</a>). We downgraded the certainty of the evidence for this outcome from high to very low due to serious risk of bias, serious inconsistency, and serious imprecision. </p> <section id="CD014963-sec-0083"> <p><b>Subgroup analyses: clinical relevance</b></p> <p> <ul id="CD014963-list-0129"> <li> <p><b>Respiratory support at randomisation:</b> We refrained from performing this analysis because only a single study would have contributed 62 participants. </p> </li> <li> <p><b>Methylprednisolone versus hydrocortisone indirectly compared for their effect relative to placebo/standard care:</b> the test for subgroup differences indicated no difference (P = 0.17) (<a href="./references#CD014963-fig-0016" title="">Analysis 3.2</a>) and description of different directions of effects appears misleading, taking into account the small sample size. </p> </li> </ul> </p> </section> <section id="CD014963-sec-0084"> <p><b>Subgroup analyses: equity‐related aspects</b></p> <p> <ul id="CD014963-list-0130"> <li> <p><b>High‐income versus low‐ and middle‐income countries:</b> the test for subgroup differences indicated no difference (P = 0.14) (<a href="./references#CD014963-fig-0022" title="">Analysis 7.2</a>) and the description of different directions of effects appears misleading, taking into account the small sample size. </p> </li> </ul> </p> <p>We could not perform the subgroup analyses for sex, age, and ethnicity due to missing data. </p> </section> <section id="CD014963-sec-0085"> <p><b>Sensitivity analyses</b></p> <p>We summarised the effects of the two sensitivity analyses in <a href="#CD014963-tbl-0011">Table 8</a>. When using the random‐effects and fixed‐effect model, we found different effects with broad confidence intervals pointing in the same direction (random‐effects model: RR 0.74, 95% CI 0.23 to 2.34; fixed‐effect model: RR 0.92, 95% CI 0.73 to 1.15). There were no study results with high risk of bias and none of the included RCTs were published as preprints for this comparison. Hence, we did not perform the further two planned analyses. </p> </section> </section> <section id="CD014963-sec-0086"> <h6 class="title">Clinical improvement: discharged alive (at 28 days)</h6> <p>Data on clinical improvement were available from three studies with a total of 6786 participants (<a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a>; <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>). Overall, 1490 of 2289 participants in the intervention groups were discharged alive compared with 2789 of 4497 participants in the control groups. The RR of being discharged alive was 1.07 (95% CI 1.03 to 1.11; I² = 81%; fixed‐effect model; <a href="./references#CD014963-fig-0005" title="">Analysis 1.3</a>). We downgraded the certainty of the evidence for this outcome from high to low due to serious risk of bias, serious inconsistency, and serious imprecision. Although this is not a critical outcome, because of the high statistical heterogeneity we performed subgroup and sensitivity analyses as pre‐specified: </p> <section id="CD014963-sec-0087"> <p><b>Subgroup analyses: clinical relevance</b></p> <p> <ul id="CD014963-list-0131"> <li> <p><b>Methylprednisolone versus hydrocortisone indirectly compared for their effect relative to placebo/standard care:</b> the test for subgroup differences indicated a difference (P = 0.01) (<a href="./references#CD014963-fig-0017" title="">Analysis 3.3</a>), but large heterogeneity (I<sup>2</sup> = 85%). In both groups, the risk ratio favoured treatment with glucocorticoids, while the effect estimate in the trial evaluating methylprednisolone was stronger, but the number of the included participants very low. </p> </li> </ul> </p> </section> <section id="CD014963-sec-0088"> <p><b>Subgroup analyses: equity‐related aspects</b></p> <p> <ul id="CD014963-list-0132"> <li> <p><b>High‐income versus low‐ and middle‐income countries:</b> the test for subgroup differences indicated a difference (P = 0.003) (<a href="./references#CD014963-fig-0023" title="">Analysis 7.3</a>), but large heterogeneity (I<sup>2</sup> = 88%). In both groups, the risk ratio favoured treatment with glucocorticoids, while the effect estimate in the trial evaluating low‐ and middle‐income countries was stronger, but the number of the included participants very low. </p> </li> </ul> </p> <p>We could not perform the subgroup analyses for sex, age, and ethnicity because of missing data. </p> </section> <section id="CD014963-sec-0089"> <p><b>Sensitivity analyses</b></p> <p>We summarised the effects of the sensitivity analyses in <a href="#CD014963-tbl-0011">Table 8</a>. When using the random‐effects and fixed‐effect model, we found different effects with broad confidence intervals pointing in the same direction (random‐effects model: RR 1.36, 95% CI 0.95 to 1.96; fixed‐effect model: RR 1.07, 95% CI 1.03 to 1.11). When removing the platform trial we found a different effect with a broader confidence interval pointing in the same direction as the main analysis (main analysis: RR 1.07, 95% CI 1.03 to 1.11; excluding <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>: RR 1.65, 95% CI 1.23 to 2.21). As we found only a risk of bias of 'some concerns' in our included RCTs for this outcome, there was no opportunity to exclude studies at high risk of bias for sensitivity analysis. Furthermore, all included RCTs were published in full in peer‐reviewed journals for this comparison. </p> </section> </section> <section id="CD014963-sec-0090"> <h6 class="title">Clinical worsening: new need for invasive mechanical ventilation or death</h6> <p>Data on clinical worsening were available from two studies with a total of 5586 participants (<a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>; <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>). Overall, 527 of 1900 participants in the intervention groups needed invasive mechanical ventilation or died compared with 1040 of 3686 participants in the control groups. The RR of needing invasive mechanical ventilation or death was 0.92 (95% CI 0.84 to 1.01; I² = 72%; fixed‐effect model; <a href="./references#CD014963-fig-0006" title="">Analysis 1.4</a>). We downgraded the certainty of the evidence for this outcome from high to low due to serious risk of bias and serious inconsistency. </p> </section> <section id="CD014963-sec-0091"> <h6 class="title">Serious adverse events</h6> <p>Two studies reported serious adverse events for 678 participants (<a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>). In <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a> (shock‐dependent hydrocortisone group) 5 of 141 participants in the intervention group and 0 of 52 participants in the control group developed a serious adverse event (RR 4.11, 95% CI 0.23 to 72.98). In <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a> (fixed‐dose hydrocortisone group), 4 of 137 participants in the intervention group and 1 of 49 participants in the control group developed a serious adverse event (RR 1.43, 95% CI 0.16 to 12.49). In <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>, 5 of 151 participants in the intervention group and 9 of 148 participants in the control group developed a serious adverse event (RR 0.54, 95% CI 0.19 to 1.59). Data on serious adverse events can be taken from <a href="./references#CD014963-fig-0007" title="">Analysis 1.5</a> and additional information from <a href="#CD014963-tbl-0008">Table 5</a>. We decided not to carry out a meta‐analysis because we are highly uncertain about the size and direction of the effects not adjusted for competing risk of death. However, a cautious analysis of the descriptive statistics suggested little to no difference between the groups. We downgraded the certainty of the evidence for this outcome from high to very low due to very serious risk of bias and serious imprecision. </p> </section> <section id="CD014963-sec-0092"> <h6 class="title">Adverse events (any grade)</h6> <p>Three studies reported adverse events amongst 447 participants (<a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a>; <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>). In <a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a>, 2 of 34 participants in the intervention group and 2 of 28 participants in the control group developed an adverse event (RR 0.82, 95% CI 0.12 to 5.48). In <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>, 5 of 43 participants in the intervention group and 8 of 43 participants in the control group developed an adverse event (RR 0.63, 95% CI 0.22 to 1.76). In <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>, 122 of 151 participants in the intervention group and 121 of 148 participants in the control group developed an adverse event (RR 0.99, 95% CI 0.89 to 1.10). Data on adverse events are presented in <a href="./references#CD014963-fig-0008" title="">Analysis 1.6</a> and <a href="#CD014963-tbl-0008">Table 5</a>. We decided not to carry out meta‐analysis because we are highly uncertain about size and the direction of the effects not adjusted for competing risk of death. However, a cautious analysis of the descriptive statistics suggested little to no difference between the groups. We downgraded the certainty of the evidence for this outcome from high to very low due to very serious risk of bias and serious imprecision. </p> </section> <section id="CD014963-sec-0093"> <h6 class="title">Hospital‐acquired infections</h6> <p>Four studies involving 598 participants reported hospital‐acquired infections (<a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>; <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>; <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>; <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>). In <a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>, 5 of 35 participants in the intervention group and 1 of 29 participants in the control group developed a hospital‐acquired infection (RR 4.14, 95% CI 0.51 to 33.49). In <a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a>, 28 of 76 participants in the intervention group and 30 of 73 participants in the control group developed a hospital‐acquired infection (RR 0.90, 95% CI 0.60 to 1.34). In <a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a>, 2 of 43 participants in the intervention group and 1 of 43 participants in the control group developed a hospital‐acquired infection (RR 2.00, 95% CI 0.19 to 21.24). In <a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a>, 30 of 151 participants in the intervention group and 39 of 148 participants in the control group developed a hospital‐acquired infection (RR 0.75, 95% CI 0.50 to 1.15). Data on hospital‐acquired infections can be taken from <a href="./references#CD014963-fig-0009" title="">Analysis 1.7</a> and additional information from <a href="#CD014963-tbl-0008">Table 5</a>. We decided not to carry out meta‐analysis because we are highly uncertain about size and the direction of the effects not adjusted for competing risk of death. However, a cautious analysis of the descriptive statistics suggested little to no difference between the groups. We downgraded the certainty of the evidence for this outcome from high to very low due to very serious risk of bias and serious imprecision. </p> </section> <section id="CD014963-sec-0094"> <h6 class="title">Invasive fungal infections</h6> <p>One study reported this outcome for 64 participants (<a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a>), where 1 of 35 participants in the intervention group and 0 of 29 participants in the control group developed an invasive fungal infection (RR 2.50, 95% CI 0.11 to 59.15). Data on invasive fungal infections can be taken from <a href="./references#CD014963-fig-0010" title="">Analysis 1.8</a> and additional information from <a href="#CD014963-tbl-0008">Table 5</a>. We are highly uncertain about size and the direction of the effects not adjusted for competing risk of death. We downgraded the certainty of the evidence for this outcome from high to very low due to very serious risk of bias and serious imprecision. </p> </section> <section id="CD014963-sec-0095"> <h6 class="title">Quality of life (up to 120 days)</h6> <p>One study reported quality of life for 118 participants with the Duke activity status index (DASI) (<a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>). The score ranged from 0 to 58.2, with higher scores indicating greater levels of fitness. Participants in the intervention group reached a mean score of 43.3 (SD 14.2) and participants in the control group reached a mean score of 40.6 (SD 13.9). The mean difference was 2.70 (95% CI ‐2.38 to 7.78). Data on quality of life can be taken from <a href="./references#CD014963-fig-0011" title="">Analysis 1.9</a>. However, a cautious analysis of the descriptive statistics suggested little to no difference between the groups. We would downgrade the certainty of the evidence from high to very low due to serious risk of bias and very serious imprecision. </p> </section> <section id="CD014963-sec-0096"> <h6 class="title">New need for dialysis</h6> <p>Two studies reported data on new need for dialysis for 6613 participants (<a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>; <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>). In <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>, 89 of 2034 participants in the intervention group and 314 of 4194 participants in the control group needed dialysis (RR 0.58, 95% CI 0.46 to 0.74). In <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>, 29 of 191 participants in the intervention group and 33 of 194 participants in the control group needed dialysis (RR 0.89, 95% CI 0.57 to 1.41). Data on the new need for dialysis can be taken from <a href="./references#CD014963-fig-0012" title="">Analysis 1.10</a>. We decided not to carry out a meta‐analysis because we are highly uncertain about the size and direction of the unadjusted effects. We would downgrade the certainty of the evidence from high to very low due to serious risk of bias and very serious imprecision. </p> </section> <section id="CD014963-sec-0097"> <h6 class="title">Viral clearance</h6> <p>One study reported data on viral clearance (<a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>). Viral clearance was defined as the presence of viral RNA detected through RT‐PCR in the naso‐/oropharyngeal swab on day seven. In <a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a>, no viral load was detected in 61 of 117 participants in the intervention group and in 50 of 95 in the control group (RR 0.99, 95% CI 0.77 to 1.28). Data on viral clearance can be taken from <a href="./references#CD014963-fig-0013" title="">Analysis 1.11</a>. We would downgrade the certainty of the evidence from high to very low due to serious risk of bias and very serious imprecision. </p> </section> </section> <section id="CD014963-sec-0098"> <h5 class="title">Different types of systemic corticosteroids: methylprednisolone versus dexamethasone</h5> <p>The evidence profile is presented in <a href="./full#CD014963-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD014963-sec-0099"> <h6 class="title">All‐cause mortality up to 30 days</h6> <p>Data on all‐cause mortality up to 30 days were available from one trial with 86 participants (<a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a>), where 8 of 44 participants in the intervention group died compared with 15 of 42 participants in the control group. The RR of death was 0.51 (95% CI 0.24 to 1.07; <a href="./references#CD014963-fig-0024" title="">Analysis 8.1</a>), favouring methylprednisolone. We downgraded the certainty of the evidence for this outcome to very low due to serious risk of bias and very serious imprecision. </p> <section id="CD014963-sec-0100"> <p><b>Subgroup and sensitivity analyses</b></p> <p>We could not perform any of our planned subgroup and sensitivity analyses for the comparison of methylprednisolone versus dexamethasone and the outcome of all‐cause mortality up to 30 days. </p> </section> </section> <section id="CD014963-sec-0101"> <h6 class="title">Other outcomes</h6> <p>No further outcome of interest was available from <a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a> nor could we identify any other study for this comparison. </p> </section> </section> <section id="CD014963-sec-0102"> <h5 class="title">High‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8 mg) </h5> <p>The evidence profile is presented in <a href="./full#CD014963-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD014963-sec-0103"> <h6 class="title">All‐cause mortality up to 30 days</h6> <p>Data on all‐cause mortality up to 30 days were available from three studies involving a total of 1269 participants (<a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>). The observation period in the studies was 28 days. Overall, 159 of 638 participants in the intervention group died compared with 180 of 631 participants in the control group. The RR of death was 0.87 (95% CI 0.73 to 1.04; I² = 0%; random‐effects model; <a href="./references#CD014963-fig-0025" title="">Analysis 9.1</a>). We downgraded the certainty of the evidence for this outcome from high to low due to serious risk of bias and serious imprecision. </p> <section id="CD014963-sec-0104"> <p><b>Subgroup analyses: equity‐related aspects</b></p> <p> <ul id="CD014963-list-0133"> <li> <p><b>Female versus male:</b> the test for subgroup differences indicated no difference (P = 0.92) between subgroups stratified by the sex of the participants (<a href="./references#CD014963-fig-0032" title="">Analysis 10.1</a>). However, the effect estimates for each subgroup were in favour of high‐dose dexamethasone. </p> </li> <li> <p><b>&lt; 70 years versus ≥ 70 years:</b> the test for subgroup differences indicated no difference (P = 0.55) between subgroups stratified by the age of the participants (<a href="./references#CD014963-fig-0034" title="">Analysis 11.1</a>). However, the effect estimates for each subgroup were in favour of high‐dose dexamethasone. </p> </li> <li> <p><b>High‐income versus low‐ and middle‐income countries:</b> the test for subgroup differences indicated no difference (P = 0.41) between subgroups stratified by income of the country (<a href="./references#CD014963-fig-0036" title="">Analysis 12.1</a>). </p> </li> </ul> </p> <p>We could not perform the subgroup analyses for respiratory support at randomisation and ethnicity due to insufficient data. </p> </section> <section id="CD014963-sec-0105"> <p><b>Sensitivity analyses</b></p> <p>We summarised the effects of sensitivity analyses in <a href="#CD014963-tbl-0012">Table 9</a>. Reported effects of our main analysis were robust when using the fixed‐effect model. We found no preprints, platform trials, or trials with high risk of bias concerning this outcome, so we could not exclude them. </p> <div class="table" id="CD014963-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Sensitivity analyses for the comparison: high‐dose dexamethasone versus low‐dose dexamethasone</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analyses</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of bias (excluding studies at high risk of bias)<sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fixed‐effect model or random‐effects model</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Preprint (excluding preprints)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platform trials (excluding platform trials)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87, 95% CI 0.73 to 1.04; 3 studies, 1269 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs with high risk of bias concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87, 95% CI 0.73 to 1.04; 3 studies, 1269 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs as a preprint concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no platform trials concerning this outcome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 120 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05, 95% CI 0.74 to 1.48; 4 studies, 1399 participants<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87, 95% CI 0.74 to 1.02; 3 studies, 1266 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.93, 95% CI 0.79 to 1.08; 4 studies, 1399 participants<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs as a preprint concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no platform trials concerning this outcome</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Using the fixed‐effect model. </p> <p><sup>b</sup>Excluded studies with high risk of bias: <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>. </p> <p><sup>c</sup>Using the random‐effects model. </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </div> </div> </section> </section> <section id="CD014963-sec-0106"> <h6 class="title">All‐cause mortality up to 120 days</h6> <p>Data on all‐cause mortality up to 120 days were available from four studies with a total of 1383 participants (<a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>; <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>). The observation periods ranged from 60 to 90 days. Overall, 218 of 717 participants in the intervention group died compared with 219 of 666 participants in the control group. The RR of death was 0.93 (95% CI 0.79 to 1.08; I² = 54%; fixed‐effect model; <a href="./references#CD014963-fig-0026" title="">Analysis 9.2</a>). We downgraded the certainty of the evidence for this outcome from high to very low due to serious risk of bias, serious inconsistency, and serious imprecision. </p> <section id="CD014963-sec-0107"> <p><b>Subgroup analyses: equity‐related aspects</b></p> <p> <ul id="CD014963-list-0134"> <li> <p><b>Female versus male:</b> the test for subgroup differences indicated no difference (P = 0.59) between subgroups stratified by the sex of the participants (<a href="./references#CD014963-fig-0033" title="">Analysis 10.2</a>). However, the effect estimates for each subgroup were in favour of high‐dose dexamethasone. </p> </li> <li> <p><b>&lt; 70 years versus ≥ 70 years:</b> the test for subgroup differences indicated no difference (P = 0.30) between subgroups stratified by the age of the participants (<a href="./references#CD014963-fig-0035" title="">Analysis 11.2</a>). However, the effect estimates for each subgroup were in favour of high‐dose dexamethasone. </p> </li> <li> <p><b>High‐income versus low‐ and middle‐income countries:</b> the test for subgroup differences indicated differences (P = 0.03) between subgroups stratified by income of the country (<a href="./references#CD014963-fig-0037" title="">Analysis 12.2</a>) favouring high‐dose dexamethasone in high‐income countries, while the effect estimate in low‐income countries favoured low‐dose dexamethasone. However, the estimated effect for <b>low‐ and middle‐income countries</b> was fully carried by <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>, the only study result at high risk of bias in this analysis. </p> </li> </ul> </p> <p>We could not perform the subgroup analyses for respiratory support at randomisation and ethnicity due to insufficient data. </p> </section> <section id="CD014963-sec-0108"> <p><b>Sensitivity analyses</b></p> <p>We summarised the effects of sensitivity analyses in <a href="#CD014963-tbl-0012">Table 9</a>. When using the random‐effects and fixed‐effect models, we found different effects with broad confidence intervals pointing in opposite directions (random‐effects model: RR 0.93, 95% CI 0.79 to 1.08; fixed‐effect model: RR 1.05, 95% CI 0.74 to 1.48). When excluding the study with high risk of bias (<a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>), we found effects with broad confidence intervals also pointing in different directions (main analysis: RR 1.05, 95% CI 0.74 to 1.48; excluding study at high risk of bias: RR 0.87, 95% CI 0.74 to 1.02). No preprints nor platform trials contributed to this outcome for this comparison, and thus we did not pursue the respective sensitivity analyses. </p> </section> </section> <section id="CD014963-sec-0109"> <h6 class="title">Clinical improvement: discharged alive</h6> <p>Data on clinical improvement were available from one study with a total of 200 participants (<a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>). Overall, 85 of 98 participants in the intervention group were discharged alive compared with 90 of 102 participants in the control group. The RR of being discharged alive was 0.98 (95% CI 0.89 to 1.09; I² = not applicable; random‐effects model; <a href="./references#CD014963-fig-0027" title="">Analysis 9.3</a>). We downgraded the certainty of the evidence for this outcome from high to low due to serious risk of bias and serious imprecision. </p> </section> <section id="CD014963-sec-0110"> <h6 class="title">Clinical worsening: new need for invasive mechanical ventilation or death</h6> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD014963-sec-0111"> <h6 class="title">Serious adverse events</h6> <p>Two studies reported serious adverse events for 1080 participants (<a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>; <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>). In <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>, 42 of 49 participants in the high‐dose group and 40 of 49 participants in the low‐dose group developed a serious adverse event (RR 1.05, 95% CI 0.88 to 1.25). In <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>, 70 of 497 participants in the high‐dose group and 85 of 485 participants in the low‐dose group developed a serious adverse event (RR 0.80, 95% CI 0.60 to 1.07). Data on serious adverse events can be taken from <a href="./references#CD014963-fig-0028" title="">Analysis 9.4</a> and additional information from <a href="#CD014963-tbl-0008">Table 5</a>. We decided not to carry out a meta‐analysis because we are highly uncertain about the size and direction of the effects not adjusted for competing risk of death. However, a cautious analysis of the descriptive statistics suggested little to no difference between the groups. We downgraded the certainty of the evidence for this outcome from high to very low due to serious risk of bias and very serious imprecision. </p> </section> <section id="CD014963-sec-0112"> <h6 class="title">Adverse events (any grade)</h6> <p>One study reported data for 98 participants for this outcome (<a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>), where all 49 participants in the high‐dose group and 48 of 49 participants in the low‐dose group developed an adverse event (RR 1.02, 95% CI 0.96 to 1.08). Data on adverse events can be taken from <a href="./references#CD014963-fig-0029" title="">Analysis 9.5</a> and <a href="#CD014963-tbl-0008">Table 5</a>. Without adjustment for competing risk of death, a cautious analysis of the descriptive statistics nonetheless suggested little to no difference between the groups. We downgraded the certainty of the evidence for this outcome from high to very low due to serious risk of bias and very serious imprecision. </p> </section> <section id="CD014963-sec-0113"> <h6 class="title">Hospital‐acquired infections</h6> <p>Two studies reported this outcome for 1080 participants (<a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>). In <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>, 34 of 49 participants in the high‐dose group and 38 of 49 participants in the low‐dose group developed a hospital‐acquired infection (RR 0.89, 95% CI 0.70 to 1.14). In <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>, 50 of 497 participants in the high‐dose group and 61 of 485 participants in the low‐dose group developed a hospital‐acquired infection (RR 0.80, 95% CI 0.56 to 1.14). Data on hospital‐acquired infections can be taken from <a href="./references#CD014963-fig-0030" title="">Analysis 9.6</a> and additional information from <a href="#CD014963-tbl-0008">Table 5</a>. We decided not to carry out a meta‐analysis because we are highly uncertain about the size and direction of the effects not adjusted for competing risk of death. However, a cautious analysis of the descriptive statistics suggested little to no difference between the groups. We downgraded the certainty of the evidence for this outcome from high to very low due to serious risk of bias and very serious imprecision. </p> </section> <section id="CD014963-sec-0114"> <h6 class="title">Invasive fungal infections</h6> <p>Two studies reported this outcome for 1080 participants (<a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>; <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>). In <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>, 3 of 49 participants in the high‐dose group and 3 of 49 participants in the low‐dose group developed an invasive fungal infection (RR 1.00, 95% CI 0.21 to 4.71). In <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>, 15 of 497 participants in the high‐dose group and 21 of 485 participants in the low‐dose group developed an invasive fungal infection (RR 0.70, 95% CI 0.36 to 1.34). Data on invasive fungal infections can be taken from <a href="./references#CD014963-fig-0031" title="">Analysis 9.7</a> and <a href="#CD014963-tbl-0008">Table 5</a>. We decided not to carry out a meta‐analysis because we are highly uncertain about the size and direction of the effects not adjusted for competing risk of death. However, a cautious analysis of the descriptive statistics suggested little to no difference between the groups. We downgraded the certainty of the evidence for this outcome from high to very low due to serious risk of bias and very serious imprecision. </p> </section> <section id="CD014963-sec-0115"> <h6 class="title">Other outcomes</h6> <p>No further outcome of interest was available from <a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a>, <a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a>, <a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a>, and <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>. </p> </section> </section> <section id="CD014963-sec-0116"> <h5 class="title">Timing comparisons (early versus late)</h5> <p>No studies provided data for this comparison.</p> </section> <section id="CD014963-sec-0117"> <h5 class="title">Systemic corticosteroids versus other active substances</h5> <p>No studies provided data for this comparison.</p> </section> </section> <section id="CD014963-sec-0118"> <h4 class="title">Outpatients with asymptomatic or mild disease</h4> <p>We did not identify any study that investigated the effects of systemic corticosteroids in people with asymptomatic infection or mild disease (i.e. non‐hospitalised individuals). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014963-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014963-sec-0119"></div> <section id="CD014963-sec-0120"> <h3 class="title" id="CD014963-sec-0120">Summary of main results</h3> <p>This review aimed to assess the efficacy and safety of systemic corticosteroids for the treatment of COVID‐19, as well as equity‐related aspects quantitatively in subgroup analyses where possible. We found no studies for people with asymptomatic infection or mild COVID‐19 disease. </p> <p>For hospitalised people with a confirmed or suspected diagnosis of symptomatic COVID‐19, we identified 16 RCTs (9549 participants). Eleven trials (8019 participants) evaluated systemic corticosteroids plus standard care compared to standard care (with or without placebo), one trial compared different types of corticosteroids (86 participants), and four studies compared different doses of dexamethasone (1444 participants). We identified 42 ongoing studies evaluating systemic corticosteroids and 23 completed studies lacking published results or relevant information on the study design, which we categorised as 'studies awaiting classification'. We checked the proportion of PCR‐positive tests in each study, as some studies included confirmed or suspected COVID‐19 infections, or both. The study with the lowest PCR‐positive rate of approximately 80% was <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>. </p> <section id="CD014963-sec-0121"> <h4 class="title">Effects of interventions</h4> <section id="CD014963-sec-0122"> <h5 class="title">Hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</h5> <section id="CD014963-sec-0123"> <h6 class="title">Systemic corticosteroids plus standard care versus standard care (plus/minus placebo)</h6> <p> <ul id="CD014963-list-0135"> <li> <p>Systemic corticosteroids probably slightly reduce all‐cause mortality up to 30 days (moderate‐certainty evidence). </p> </li> <li> <p>The evidence is very uncertain about the effect of systemic corticosteroids on all‐cause mortality up to 120 days (very low‐certainty evidence). </p> </li> <li> <p>Systemic corticosteroids may slightly increase the chance of clinical improvement (discharged alive) and may slightly decrease the risk of clinical worsening (new need for invasive mechanical ventilation or death) (both low‐certainty evidence). </p> </li> <li> <p>We are uncertain of the effects of systemic corticosteroids on serious adverse events, adverse events, hospital‐acquired infections, and invasive fungal infections (very low‐certainty evidence). </p> </li> </ul> </p> </section> <section id="CD014963-sec-0124"> <h6 class="title">Direct comparisons of different types and different dosages</h6> <p>The evidence is of low and mostly very low certainty.</p> </section> </section> </section> </section> <section id="CD014963-sec-0125"> <h3 class="title" id="CD014963-sec-0125">Overall completeness and applicability of evidence</h3> <p>Diagnosis of COVID‐19 was confirmed by positive SARS‐CoV‐2 PCR testing in 93.8% of the participants. Regarding virological aspects, all participants included in this review were enrolled up to 26 May 2021 and none of the studies reported information on vaccination status. Thus, it is important to consider that the findings of this review might no longer be directly applicable to the current (i.e. late 2022) treatment situation of patients who are infected with later variants of SARS‐CoV‐2 including Delta and Omicron, and, at the same time, with an increasing proportion being vaccinated with different types and dosage regimens of SARS‐CoV‐2 vaccines or having recovered from prior infections. Specifically, these limitations regarding variants and vaccination apply most importantly to data comparison 1 (Systemic corticosteroids plus standard care versus standard care (plus/minus placebo)) for which recruitment of the majority of patients had ended in mid 2020 (<a href="#CD014963-tbl-0005">Table 2</a>). </p> <p> In addition, a considerable share of participants also received various COVID‐19 treatment options such as antibiotics with potential antiviral and anti‐inflammatory properties (i.e. azithromycin), established antiviral drugs (e.g. remdesivir, lopinavir/ritonavir), hydroxychloroquine, convalescent plasma, or combinations of these drugs, mostly balanced between the arms. None of the trials evaluated participants with asymptomatic infections or mild disease (non‐hospitalised participants, WHO clinical progression scale 0 to 3); at this point we would like to refer the reader to the Cochrane Review <a href="./references#CD014963-bbs2-0137" title="GrieselM , WagnerC , MikolajewskaA , StegemannM , FichtnerF , MetzendorfMI , et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Griesel 2022</a>, addressing the use of inhaled corticosteroids against COVID‐19, which were mostly studied in outpatient participants with mild disease. </p> <p>Considering the severity of COVID‐19 at the beginning of corticosteroid treatment, the difficult issue remains of the different scales of severity and progression used across studies and in the different guidelines and consensus statements (<a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>; <a href="./references#CD014963-bbs2-0205" title="World Health Organization. Therapeutics and COVID-19: living guideline. 6 July 2021. 6. Who do the recommendations apply to?www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.">WHO 2021b</a>). Similar to the first version of this review (<a href="./references#CD014963-bbs2-0214" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 16 August 2021, Issue 8. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Wagner 2021a</a>), we used the need for respiratory support (no oxygen, low‐flow oxygen support, non‐invasive ventilation/high‐flow nasal cannula, and invasive ventilation) at randomisation and its changes as a surrogate for COVID‐19 disease severity. Among the 9314 of 9549 participants from all three comparisons for whom we could extract respiratory support information at randomisation, 16% did not receive any additional oxygen, 61% received any non‐invasive respiratory support, and 22% received invasive ventilation. </p> <p>Regarding our equity‐related analyses, firstly we would like to highlight the fact that study participants in this version of the review mainly originated from high‐income countries. The share of participants from middle‐income countries has sunk from 13% in the first version of this review (<a href="./references#CD014963-bbs2-0214" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 16 August 2021, Issue 8. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Wagner 2021a</a>) to 12% in this version, and again none came from low‐income countries although about 80% of the world's population lives in a low‐ or middle‐income country (<a href="./references#CD014963-bbs2-0114" title="AllenL , CobiacL , TownsendN . Quantifying the global distribution of premature mortality from non-communicable diseases. Journal of Public Health December 2017;49(4):698–703. [DOI: https://doi.org/10.1093/pubmed/fdx008]">Allen 2017</a>). These numbers are quite similar to the findings of a systematic review on representation of low‐ and middle‐income countries in all COVID‐19‐related RCTs in high‐ranking journals, so the inequality extends beyond corticosteroids to the structural level (<a href="./references#CD014963-bbs2-0175" title="RamananM , TongSYC , KumarA , VenkateshB . Geographical representation of low- and middle-income countries in randomized clinical trials for COVID-19. JAMA Network Open2022;5(2):e220444. [PMID: 10.1001/jamanetworkopen.2022.0444]">Ramanan 2022</a>). Regarding the applicability of the evidence in this version of the review, unfortunately we must reiterate that it might only partially apply to people with COVID‐19 who are treated under different circumstances to those of most studies included in our review: there might be a more severe shortage of hospital beds in both ordinary wards and intensive care units, shortage of oxygen, and other resource constraints on the delivery of respiratory support, and other aspects of care labelled as standard care in this review. </p> <section id="CD014963-sec-0126"> <h4 class="title">Benefits </h4> <section id="CD014963-sec-0127"> <h5 class="title">Effects on all‐cause mortality</h5> <p>As the main result of our analysis, we found that systemic corticosteroid treatment probably reduces all‐cause mortality (up to 30 days) in hospitalised patients with moderate to severe COVID‐19 from estimated absolute mortality of 27.4 % (standard of care, plus/minus placebo) to 24.6% (95% CI 23% to 26.5%). Considering this small effect size on all‐cause mortality (absolute mortality reduction 2.8%, RR 0.90), we aimed by additional subgroup analyses to identify subsets of patients potentially benefiting most and, further, to ascertain the types and doses of steroids that are more or less beneficial in treating COVID‐19 patients. </p> <section id="CD014963-sec-0128"> <h6 class="title">Disease severity by level of respiratory support</h6> <p>Since none of the newly included studies contained corresponding data subsets, the result of the subgroup analysis regarding respiratory support as an indicator for disease severity at baseline did not change: subgroup analysis did not reveal a significant difference in all‐cause mortality up to 30 days between the different levels of respiratory support. Despite missing statistical significance for a subgroup difference on 5% alpha error level, we observed a gradient of harm to benefit as the level of respiratory support increased at randomisation, which could be plausible from a biological perspective and might indicate harm in COVID‐19 patients without clinical signs of COVID‐19‐associated pulmonary gas exchange impairment, i.e. no oxygen at baseline. Nonetheless, for scientific rigour we kept our approach to subgroup analysis as per the first version of this review (<a href="./references#CD014963-bbs2-0214" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 16 August 2021, Issue 8. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Wagner 2021a</a>), i.e. with the highest possible level of respiratory support (reported in each trial or through data request) at randomisation and refrained from a posteriori data‐driven pooling of all participants with any need for respiratory support. We acknowledge that this approach may lead to some overlap of subgroups and reduce statistical power; however, we would like to point out again that the observed consistent trend along with the increasing need for respiratory support and the negative effect among those without respiratory support is of informative value, too. However, there is a widely read pre‐planned analysis of combined respiratory support subgroups of the many participants of <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> in their referenced publication showing a clearer subgroup difference. </p> </section> <section id="CD014963-sec-0129"> <h6 class="title">Comparison of different types of corticosteroids</h6> <p>Compared to the first version of this review (<a href="./references#CD014963-bbs2-0214" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 16 August 2021, Issue 8. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Wagner 2021a</a>), our subgroup analysis of different types of corticosteroids included only one additional study with a very low number of participants treated with hydrocortisone (<a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a>). Hence, the majority of the participants (about 86%) included in this analysis were treated with dexamethasone. Again, we did not detect any significant differences between the estimated effects of dexamethasone, methylprednisolone, or hydrocortisone on all‐cause mortality in COVID‐19. We did an additional subgroup analysis regarding the different types of corticosteroids for the newly included outcomes all‐cause mortality up to 120 days and clinical improvement (discharged alive), but the certainty of the evidence was low to very low. Furthermore, equivalence of dosages could not be ensured. Hence, we refrain from further interpretation of those analyses. Further, unchanged from the first version of this review, in the direct comparison of two different types of corticosteroids the certainty of the evidence remains very low and interpretation of data unwarranted. </p> </section> <section id="CD014963-sec-0130"> <h6 class="title">Dose escalation</h6> <p>Most participants in the RCTs included for the comparison of systemic corticosteroids versus standard care received daily doses of corticosteroids of hydrocortisone equivalent ≤ 200 mg/day, and we again refrained from subgroup analyses stratified by dosing because data for the high‐dose pulse regimens were very few. However, in this version of the review we were able to include a new comparison encompassing 1444 participants from four RCTs, in which different doses of dexamethasone were directly compared ‐ this had been identified as a research gap in the first version of this review (<a href="./references#CD014963-bbs2-0214" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 16 August 2021, Issue 8. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Wagner 2021a</a>). Low‐certainty evidence showed that dexamethasone dosed at least twice as high (12 mg/day and higher, 300 mg hydrocortisone equivalent) as in <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> (6 mg/day, 150 mg hydrocortisone equivalent) may add to the probable slight reduction in <i>All‐cause mortality up to 30 days</i> from <a href="./references#CD014963-fig-0003" title="">Analysis 1.1</a> when compared to low‐dose hydrocortisone equivalents (6 mg to 8 mg dexamethasone/day). Still, the decision for dose escalation based on our evidence should be critically scrutinised, taking into account the low‐certainty evidence basis for the cited result and that safety data on dose escalation are even more scarce in this comparison and of very low certainty. Moreover, large patient groups and settings peculiar to constrained resources and climate are again underrepresented, and harm through fungal secondary infections as discussed below can increase. Finally, the benefits and harms of corticosteroids do not only depend on dose but on treatment duration and regimens; the included studies only examined pulse dose and short‐term regimens of up to 10 days (or up to 14 days when dose tapering was part of the regimen). </p> </section> <section id="CD014963-sec-0131"> <h6 class="title">Equity‐related subgroup analyses</h6> <p>Here we discuss the equity‐related subgroup analyses of the only moderate‐certainty outcome, <i>All‐cause mortality up to 30 days</i> in the comparison of systemic corticosteroids plus standard care versus standard care (plus/minus placebo). </p> <p>It should be noted that all the subgroup analyses are only useful for generation of hypotheses, are not adjusted for multiple testing, suffer heavily from missing outcome data, and most likely lack statistical power. </p> <p><b>Sex </b> </p> <p>In the analyses of sex, estimated effects of both groups were in favour of corticosteroid use without a large difference (<a href="./references#CD014963-fig-0018" title="">Analysis 4.1</a>). </p> <p><b>Age</b> </p> <p>Participants younger than 70 years seem to benefit from corticosteroids in contrast to participants who are aged 70 years and older (<a href="./references#CD014963-fig-0019" title="">Analysis 5.1</a>), which might be attributable to the fact that the immune system's activity generally declines with entering the senium (<a href="./references#CD014963-bbs2-0116" title="Aw, D, SilvaAB , PalmerDB . Immunosenescence: emerging challenges for an ageing population. Immunology2007;120(4):435-46. [DOI: 10.1111/j.1365-2567.2007.02555.x]">Aw 2007</a>). Consequently, targetting hyper‐inflammation in COVID‐19 in this older population with systemic corticosteroids could be less effective but more harmful due to known adverse effects of corticosteroids, including hyperglycaemia, further immunosuppression, and consequent vulnerability to secondary infection, which might outweigh the modest benefits as seen in our meta‐analysis (<a href="./references#CD014963-fig-0003" title="">Analysis 1.1</a>). Moreover, the degree of heterogeneity in each of the subgroups is much lower (below 10%) than in the analysis of the two subgroups combined (77%), which could be a hint for identifying one of the causes of overall heterogeneity. </p> <p><b>Ethnicity</b> </p> <p>Black, Asian or minority ethnic group participants seem to benefit from corticosteroids in contrast to White participants, which we struggle to explain based on our own data without the possibility of multiple regression analysis (<a href="./references#CD014963-fig-0020" title="">Analysis 6.1</a>). However, these subgroup data were mainly from <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> and it is known from a pre‐COVID‐19, large prospective cohort study in the UK that first emergency hospital admissions in patients of Black and Asian ethnicity took place at a significantly earlier age than in Whites (<a href="./references#CD014963-bbs2-0196" title="WanYI , RobbinsAJ , ApeaVJ , OrkinCM , PearseRM , PuthuchearyZA , et al. Ethnicity and acute hospital admissions: multi-center analysis of routine hospital data. EClinicalMedicine2021;39:101077. [DOI: 10.1016/j.eclinm.2021.101077]">Wan 2021</a>), which might link this finding with the above discussed age‐stratified analysis. It is unclear why details on ethnicity were unavailable for some study participants, or whether they were missing at random or because of specific ethnicity.  </p> <p><b>Place of residence </b> </p> <p>In our own subgroup analysis, estimated effects were slightly in favour of corticosteroid use without a large difference (<a href="./references#CD014963-fig-0021" title="">Analysis 7.1</a>), but there are compelling signs from non‐RCT studies that widespread corticosteroid use in COVID‐19 might do substantial harm. Data from low‐ and middle‐income countries were relatively scarce, but we felt it was important to explore geographical and economical inequities and hence hypothesised beyond our approach that systemic corticosteroids might have a different impact on outcomes amongst people with COVID‐19 in low‐ and middle‐income countries. Related factors such as ethnicity and climatic zone have been shown to influence COVID‐19 outcomes (<a href="./references#CD014963-bbs2-0154" title="LiuZ , ZhuL , WangX , ZhouZ , GuoY . The correlation between COVID-19 activities and climate factors in different climate types areas. Journal of Occupational and Environmental Medicine2021;63(8):e-533-41. [DOI: DOI: 10.1097/JOM.0000000000002274]">Liu 2021</a>). Studies from the UK have consistently shown that ethnic minorities have a higher chance of having poorer COVID‐19 outcomes ‐ including hospitalisation and mortality (<a href="./references#CD014963-bbs2-0112" title="AldridgeRW , LewerD , KatikireddiSV , MathurR , PathakN , BurnsR , et al. Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. Wellcome Open Research2020;5(88):1-20. [DOI: 10.12688/wellcomeopenres.15922.2]">Aldridge 2020</a>; <a href="./references#CD014963-bbs2-0157" title="MathurR , RentschCT , MortonCE , HulmeWJ , SchultzeA , MacKennaB , et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet2021;397(10286):1711-24. [DOI: 10.1016/S0140-6736(21)00634-6]">Mathur 2021</a>). Similar findings were made in Brazil where the Pardo and Preto ethnicities had a higher risk of COVID‐19‐related mortality (<a href="./references#CD014963-bbs2-0117" title="BaquiP , BicaI , MarraV , ErcoleA , van derSchaarM . Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study. Lancet Global Health2020;8(8):e1018-e26. [DOI: 10.1016/S2214-109X(20)30285-0]">Baqui 2020</a>). There were possible confounding factors such as larger family size, poor access to quality health care, and higher prevalence of co‐morbidities, which could have played a role in the association between ethnicity and COVID‐19 outcomes (<a href="./references#CD014963-bbs2-0161" title="MoralesD , AliSN . COVID-19 and disparities affecting ethnic minorities. Lancet2021;397(10286):1684-5. [DOI: 10.1016/S0140-6736(21)00949-1]">Morales 2021</a>). Regarding co‐morbidities, type 2 diabetes mellitus is of high importance: the prevalence varies significantly among various ethnicities and is exceptionally high among Asians and middle‐eastern countries (<a href="./references#CD014963-bbs2-0131" title="El-KebbiIM , BidikianNH , HneinyL , NasrallahMP . Epidemiology of type 2 diabetes in the Middle East and North Africa: challenges and call for action. World Journal of Diabetes2021;12(9):1401-25. [DOI: 10.4239/wjd.v12.i9.1401]">El‐Kebbi 2021</a>; <a href="./references#CD014963-bbs2-0174" title="RamachandranA , SnehalathaC , ShettyAS , NandithaA . Trends in prevalence of diabetes in Asian countries. World Journal of Diabetes2012;3(6):110-7. [DOI: 10.4239/wjd.v3.i6.110]">Ramachandran 2012</a>). Hence, administration of systemic (gluco‐)corticosteroids like the one under study in this review could be associated with higher diabetes‐related adverse effects in populations with a higher prevalence of diabetes and less resources to diagnose and control the condition both acutely and chronically (<a href="./references#CD014963-bbs2-0113" title="AlessiJ , deOliveiraGB , SchaanBD , TeloGH . Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetology and Metabolic Syndrome2020;12(80):1-11. [DOI: 10.1186/s13098-020-00583-7]">Alessi 2020</a>; <a href="./references#CD014963-bbs2-0125" title="CaugheyGE , PreissAK , VitryAI , GilbertAL , RougheadEE . Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care2013;36(10):3009-14. [DOI: 10.2337/dc12-2197]">Caughey 2013</a>). Before the second wave of COVID‐19 began globally in March 2021 (<a href="./references#CD014963-bbs2-0207" title="World Health Organization. WHO coronavirus disease (COVID-19) dashboard. covid19.who.int (accessed 31 March 2022).">WHO 2022a</a>), it was hypothesised that countries with higher temperatures, relative humidity, and those closer to the equator would have fewer daily cases of COVID‐19, possibly due to unfavourable aerosol transmission, particularly in summer (<a href="./references#CD014963-bbs2-0127" title="ChenS , PrettnerK , KuhnM , GeldsetzerP , WangC , BärnighausenT , et al. Climate and the spread of COVID-19. Scientific Reports2021;11(1):9042. [DOI: 10.1038/s41598-021-87692-z]">Chen 2021</a>). However, at the end of the second wave (July 2021), no such apparent dissimilarities across countries were noted in COVID‐19 prevalence. Despite the climatic factors, the implementation of public health policies such as social distancing and vaccination programmes could have played a part in the prevention of SARS‐CoV‐2 infections. This argument continues in the following discussion of the potential harms of systemic corticosteroid use. </p> </section> </section> </section> <section id="CD014963-sec-0132"> <h4 class="title">Potential harms</h4> <p>In general, there is still a relevant underreporting of safety data (serious adverse events, adverse events, hospital‐acquired infections and fungal infections) from the included studies: only two evaluated serious adverse events for 678 participants, five reported partly selected adverse events for 660 participants, five studies provided information on hospital‐acquired infections for 660 participants, and only one study including 64 participants reported data on invasive fungal infections. Unfortunately, the largest included study did not report any adverse event data, but only four suspected drug reactions from the 1996 participants that received at least one dose of dexamethasone. Hence, the certainty of the evidence about potential harmful effects of corticosteroid treatment remains low and the few results from individual trials regarding safety outcomes should not be readily applied to the current clinical treatment situation of COVID‐19 patients. </p> <section id="CD014963-sec-0133"> <h5 class="title">Invasive fungal infections</h5> <p>As mentioned above, the certainty of the evidence about the safety outcome fungal infections and hospital‐acquired infections is very low. Nevertheless, specific difficult to treat fungal infections like mucormycosis and invasive aspergillosis increasingly draw attention in the context of widespread usage of corticosteroids in critical ill COVID‐19 patients. Even before the onset of COVID‐19, the prevalence of mucormycosis was high in Asian countries, particularly India (<a href="./references#CD014963-bbs2-0173" title="PrakashH , ChakrabartiA . Global epidemiology of mucormycosis. Journal of Fungi2019;5(1):26. [DOI: 10.3390/jof5010026]">Prakash 2019</a>). However, mucormycosis cases were on an unprecedented rapid rise in India during the second wave of COVID in April 2021. It throttled the already struggling health care machinery as the disease was invariably fatal either due to morbid surgery or highly nephrotoxic antifungal therapy. After COVID‐19, there was a sudden increase in the prevalence of mucormycosis. A single‐centre study from South India reported that poorly controlled diabetes (odds ratio of 4.6), previously undiagnosed diabetes (odds ratio of 3.3), and unwarranted steroid use (odds ratio of 28.4) were the three main risk factors that were associated with increased risk of mucormycosis in COVID‐19. The authors have highlighted that almost all the patients who had mucormycosis only had mild COVID‐19, which did not warrant corticosteroids in the management of COVID‐19 (<a href="./references#CD014963-bbs2-0120" title="BhanuprasadK , ManeshA , DevasagayamE , VargheseL , CherianLM , KurienR , et al. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. International Journal of Infectious Diseases2021;111:267-70. [DOI: 10.1016/j.ijid.2021.08.037]">Bhanuprasad 2021</a>). From a global perspective, mucormycosis cases have been reported in various countries, including Europe. The high prevalence of diabetes among mucormycosis patients was a common factor across all countries (<a href="./references#CD014963-bbs2-0145" title="HoeniglM , SeidelD , CarvalhoA , RudramurthySM , ArastehfarA , GangneuxJP , et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe2022;21:00237-8. [DOI: 10.1016/S2666-5247(21)00237-8]">Hoenigl 2022</a>). It is well known that corticosteroid therapy is associated with a higher risk of fungal infections. However, a retrospective study from Berlin, Germany reported more than twice the prevalence of aspergillosis in severe and critical COVID‐19 patients receiving corticosteroids compared to those who did not receive them. Diabetes, inappropriate use of steroids, oxygen, and antibiotics are all associated with mucormycosis in COVID‐19 patients (<a href="./references#CD014963-bbs2-0110" title="AranjaniJM , ManuelA , Abdul RazackHI , MathewST . COVID-19–associated mucormycosis: evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India. PLOS Neglected Tropical Diseases2021;15(11):e0009921. [DOI: 10.1371/journal.pntd.0009921]">Aaranjani 2021</a>). We tried to obtain these data for our review, particularly from <a href="./references#CD014963-bbs2-0050" title="GautamPB , KumarA , KannojiaBL , ChaudharyR . A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease. Asian Journal of Medical Sciences2021;12(12):17-22. [DOI: 10.3126/ajms.v12i12.39294]">Gautam 2021</a>; however, the data were unavailable. In summary, while the certainty of the evidence about fungal and other secondary infections from prospective randomised trials remains very low, observational data from various countries indicate potential clinically relevant harmful effects of corticosteroid therapy in COVID‐19 patients. </p> </section> </section> <section id="CD014963-sec-0134"> <h4 class="title">Prospect of studies ongoing and awaiting classification</h4> <p>With regard to additional evidence from future publications, we identified 42 ongoing, recruiting, or temporarily halted studies (compared to 31 as identified in the first version of the review) (<a href="./references#CD014963-bbs2-0214" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 16 August 2021, Issue 8. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Wagner 2021a</a>), encompassing approximately 13,500 participants. The number of studies described as completed, prematurely ended, or terminated grew from 16 to 23, encompassing approximately 5500 participants. Most of the studies intend to recruit people treated with different levels of respiratory support and a growing number seek to investigate different dexamethasone doses or different types of steroids. With the publication of even parts of these data, possible publication bias would be countered and changes to the precision and effect estimates themselves are not unlikely, although we do not expect a relevant difference or even a change of direction in the effect of mortality in the first comparison but rather more precise estimates for subgroup analyses, subordinate and safety outcomes, regarding dosing, and for outpatients. At this point we would like to emphasise that there are five completed and partially published studies from low‐ and middle‐income countries, for which we have so far unsuccessfully contacted the authors for full publication or additional information (<a href="./references#CD014963-bbs2-0050" title="GautamPB , KumarA , KannojiaBL , ChaudharyR . A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease. Asian Journal of Medical Sciences2021;12(12):17-22. [DOI: 10.3126/ajms.v12i12.39294]">Gautam 2021</a>; <a href="./references#CD014963-bbs2-0051" title="GhaneiM , Solaymani‑DodaranM , QazviniA , Ghazale AH, SetarehdanSA , SaadatSH , et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respiratory Research2021;22(245):1-14. [DOI: 10.1186/s12931-021-01833-6]">Ghanei 2021</a>; <a href="./references#CD014963-bbs2-0058" title="MontalvanE , CarcamoB , PalacionD , RiveraS , EstevezR , NorwoodD , et al. High-dose vs low-dose dexamethasone in patients with COVID-19 in a tertiary hospital in Western Honduras. Chest2021;160(4):A1117-8. [DOI: 10.1016/j.chest.2021.07.1027]">Montalvan 2021</a>; <a href="./references#CD014963-bbs2-0066" title="NCT04519385. Tocilizumab versus dexamethasone in severe COVID19 cases. clinicaltrials.gov/show/NCT04519385 (first received 19 August 2020). RashadA , MousaS , Nafady‑HegoH , NafadyA , ElgendyH . Short term survival of critically ill COVID‑19 Egyptian patients on assisted ventilation treated by either dexamethasone or tocilizumab. Scientific Reports2021;11(8816):1-7. [DOI: 10.1038/s41598-021-88086-x]">Rashad 2021</a>). </p> </section> </section> <section id="CD014963-sec-0135"> <h3 class="title" id="CD014963-sec-0135">Quality of the evidence</h3> <section id="CD014963-sec-0136"> <h4 class="title">Systemic corticosteroids plus standard care versus standard care (plus/minus placebo)</h4> <p>We included data from 10 RCTs in the analysis of the efficacy and safety of systemic corticosteroids. The population of interest was hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 when compared to treatment with standard care (plus/minus placebo). </p> <p>We rated the certainty of the evidence as moderate to very low (see <a href="./full#CD014963-tbl-0001">summary of findings Table 1</a>). We downgraded the certainty of the evidence due to risk of bias arising from deviations from the intended intervention for all outcomes, missing adjustment for competing risk of death for all safety outcomes, selection of the reported results (all‐cause mortality up to 30 and 120 days and clinical improvement: discharged alive), missing information about allocation concealment (all‐cause mortality up to 30 and 120 days, clinical improvement: discharged alive, adverse events, hospital‐acquired infections, invasive fungal infections), baseline differences (all‐cause mortality up to 30 days), measurement of the outcome (new need for invasive mechanical ventilation or death), and reporting bias (serious adverse events, adverse events, hospital‐acquired infections, invasive fungal infections). Moreover, we downgraded for inconsistency for the following outcomes: all‐cause mortality up to 120 days, clinical improvement (discharged alive), and new need for invasive mechanical ventilation or death. Low numbers of events/imprecision affected all‐cause mortality up to 120 days and all safety outcomes. </p> </section> <section id="CD014963-sec-0137"> <h4 class="title">Comparison of different types of corticosteroids</h4> <section id="CD014963-sec-0138"> <h5 class="title">Methylprednisolone versus dexamethasone</h5> <p>We included data from one RCT assessing the efficacy and safety of methylprednisolone for individuals with a confirmed diagnosis of COVID‐19 when compared to treatment with dexamethasone. </p> <p>We rated the certainty of the evidence as very low (see <a href="./full#CD014963-tbl-0002">summary of findings Table 2</a>). We downgraded the certainty of the evidence due to risk of bias arising from the missing pre‐specification of the outcome and the missing protocol, and due to very serious imprecision. </p> </section> </section> <section id="CD014963-sec-0139"> <h4 class="title">High‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8 mg) </h4> <p>We included data from four RCTs assessing the efficacy and safety of different doses of dexamethasone for individuals with a confirmed diagnosis of COVID‐19. </p> <p>We rated the certainty of the evidence as low to very low (see <a href="./full#CD014963-tbl-0003">summary of findings Table 3</a>). We downgraded the certainty of the evidence due to risk of bias arising from deviations from the intended intervention (<i>All‐cause mortality up to 30 and 120 days, Adverse events, Hospital‐acquired infections, Invasive fungal infections</i> ), missing information about the allocation concealment (<i>All‐cause mortality up to 30 and 120 days, Clinical improvement: Discharged alive, Hospital‐acquired infections, Invasive fungal infections),</i> missing adjustment for competing risk of death (all safety outcomes) and measurement of the outcome (<i>Hospital‐acquired infections, Invasive fungal infections)</i> . Furthermore, we downgraded for inconsistency for <i>All‐cause mortality up to 120 days</i> and <i>Hospital‐acquired infections</i>. Low numbers of events/imprecision affected all outcomes. </p> </section> <section id="CD014963-sec-0140"> <h4 class="title">Critical appraisal of selected outcome parameters</h4> <section id="CD014963-sec-0141"> <h5 class="title">Outcomes with death as competing risk</h5> <p>Death and our exploratory endpoints in the domain of clinical improvement and worsening, as well as safety data, have to be seen as semi‐competing risks for each other: death precludes the occurrence of non‐terminal outcomes if participants die early. We discussed the issue extensively in the first version of this review, and it still has an impact on the risk of bias assessment and decisions not to meta‐analyse non‐terminal endpoints that were not adjusted by design or modelling (<a href="./references#CD014963-bbs2-0123" title="BrockGN , BarnesC , RamirezJA , MyersJ . How to handle mortality when investigating length of hospital stay and time to clinical stability. BMC Medical Research Methodology2011;11:144. [DOI: https://doi.org/10.1186/1471-2288-11-144]">Brock 2011</a>; <a href="./references#CD014963-bbs2-0128" title="Competing Risk Analysis. Columbia University Mailman School of Public Health Website. Available from www.publichealth.columbia.edu/research/population-health-methods/competing-risk-analysis (accessed 13 July 2021). [ACCESSED JULY 13 2021: https://www.publichealth.columbia.edu/research/population-health-methods/competing-risk-analysis]">Columbia Public Health 2021</a>; <a href="./references#CD014963-bbs2-0212" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). </p> </section> <section id="CD014963-sec-0142"> <h5 class="title">Composite outcomes</h5> <p>Conceptual peculiarity of composite outcomes like <i>New need for invasive mechanical ventilation or death</i> and <i>Discharged alive</i> with inherent quasi‐adjustment for competing risk of death were discussed in the first version of this review. </p> </section> </section> <section id="CD014963-sec-0143"> <h4 class="title">Importance of platform trials and their specific sources of bias</h4> <p>Without a doubt, platform trials such as the included studies <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a> and <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> offered great chances for rapid and adaptive generation of evidence involving huge numbers of participants in the pandemic. A few platform trials have extraordinarily contributed to the evidence base of pharmacotherapy in COVID‐19, which can be illustrated by their weight in the main RCT‐only mortality analyses in selected Cochrane Reviews: 99.6% regarding colchicine (<a href="./references#CD014963-bbs2-0159" title="MikolajewskaA , FischerAL , PiechottaV , MuellerA , MetzendorfMI , BeckerM , et al. Colchicine for the treatment of COVID-19. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD015045. [DOI: 10.1002/14651858.CD015045]">Mikolajewska 2021</a>), 77% regarding remdesivir (<a href="./references#CD014963-bbs2-0115" title="AnsemsK , GrundeisF , DahmsK , MikolajewskaA , ThiemeV , PiechottaV , et al. Remdesivir for the treatment of COVID-19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014962. [DOI: 10.1002/14651858.CD014962]">Ansems 2021</a>), &gt; 90% overall regarding convalescent plasma (<a href="./references#CD014963-bbs2-0171" title="PiechottaV , IannizziC , ChaiKL , ValkSJ , KimberC , DorandoE , et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub4]">Piechotta 2021</a>), 100% regarding inhaled corticosteroids (<a href="./references#CD014963-bbs2-0137" title="GrieselM , WagnerC , MikolajewskaA , StegemannM , FichtnerF , MetzendorfMI , et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Griesel 2022</a>), and 51% regarding systemic corticosteroids in the first version of this review (<a href="./references#CD014963-bbs2-0214" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 16 August 2021, Issue 8. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Wagner 2021a</a>). Thus, by impacting evidence synthesis their results have significantly influenced treatment guideline recommendations on COVID‐19 treatment. Nevertheless, they inherently have specific sources of risk of bias through their adaptive, multi‐arm, and often pragmatic (e.g. missing source data verification in <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>) and open‐label designs, which are under‐ or unrepresented in the latest tools for risk of bias assessment in randomised trials, e.g. RoB 2 (<a href="./references#CD014963-bbs2-0185" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweN , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). In an attempt to address these issues and since there is not yet an established tool for critically appraising platform trials, we pioneered a checklist (<a href="./references#CD014963-bbs2-0168" title="ParkJJ , HarariO , DronL , LesterRT , ThorlundK , MillsEJ . An overview of platform trials with a checklist for clinical readers. Journal of Clinical Epidemiology2020;125:1-8. [DOI: 10.1016/j.jclinepi.2020.04.025]">Park 2020</a>), with results available at <a href="https://zenodo.org/record/7015269#.YwOn43HP2Ul" target="_blank">https://zenodo.org/record/7015269#.YwOn43HP2Ul</a>. In summary, easily detectable bias risk arose from the combination of open‐label and pragmatic design, leading to questionable allocation concealment. However, it was not feasible to sufficiently review and judge the different protocol versions and statistical architecture with its main pillars of multiple interim analyses, adaptive randomisation, and case‐count reducing compilation of control groups within factorial trial design from the outside without employing additional expert resources. The scientific community needs to build up expertise in reviewing platform trials and research groups conducting them should ensure high‐quality standards of data acquisition despite the pragmatic approaches and support the understanding of their architecture in comparison to traditionally performed RCTs in their respective fields of research. </p> </section> </section> <section id="CD014963-sec-0144"> <h3 class="title" id="CD014963-sec-0144">Potential biases in the review process</h3> <p>In addition to peer‐reviewed, full‐text articles, we also included preprints. We are aware of the potentially lower quality of preprint publications, and that the results could change once the peer‐reviewed journal publications are available. In cases of missing data, we contacted study authors for additional data or relevant details if we needed more information. We are confident that we identified all relevant studies and will monitor ongoing studies as well as full publications of preprints closely after the publication of this review.  </p> <p>We decided on definitions of subgroups before running the first analyses based on the availability of data and based on clinical considerations. Subgroup analyses are exploratory only and confounding variables may have impacted their influence through biology, equity, or both. Our equity‐related subgroup analyses, like the other meta‐analyses, were not adjusted for multiple testing. </p> </section> <section id="CD014963-sec-0145"> <h3 class="title" id="CD014963-sec-0145">Agreements and disagreements with other studies or reviews</h3> <p>In the first version of this review (<a href="./references#CD014963-bbs2-0214" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews 16 August 2021, Issue 8. Art. No: CD015125. [DOI: 10.1002/14651858.CD015125]">Wagner 2021a</a>), we compared our findings to the four RCT‐only reviews: <a href="./references#CD014963-bbs2-0126" title="ChaudhuriD , SasakiK , KarkarA , SharifS , LewisK , MammenMJ , et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Medicine2021;47:521–37. [DOI: https://doi.org/10.1007/s00134-021-06394-2]">Chaudhuri 2021</a>; <a href="./references#CD014963-bbs2-0170" title="PasinL , NavalesiP , ZangrilloA , KuzovlevA , LikhvantsevV , HajjarLA , et al. Corticosteroids for patients with coronavirus disease 2019 (COVID-19) with different disease severity: a meta-analysis of randomized clinical trials. Journal of Cardiothoracic and Vascular Anesthesia2021;35(2):578-84. [DOI: https://doi.org/10.1053/j.jvca.2020.11.057]">Pasin 2021</a>; <a href="./references#CD014963-bbs2-0183" title="SiemieniukRA , BartoszkoJJ , GeL , ZeraatkarD , IzcovichA , KumE , et al. Drug treatments for COVID-19: living systematic review and network meta-analysis. BMJ2020;370:m2980. [BMJ: https://www.bmj.com/content/370/bmj.m2980]">Siemieniuk 2020</a>; <a href="./references#CD014963-bbs2-0186" title="SterneJA . Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA2020;324(13):1330-41.">Sterne 2020</a>. Since then no updates on these nor other high‐quality, RCT‐only systematic reviews of compelling relevance for discussion in this field have been published. </p> <p>Once again, the open‐label adaptive and pragmatic platform study <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> must be discussed due to its huge impact. Not only was it the largest contributor to our review in terms of events and participants, but it also had an immense influence on treatment guidelines and ongoing studies in 2020 when its preliminary report became available (<a href="./references#CD014963-bbs2-0206" title="WHO. Therapeutics and COVID-19: living guideline. 6 July 2021. 7. Recommendations for therapeutics. 7.6 Systemic corticosteroids (published 2 September 2020). www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2.">WHO 2021c</a>). The direction and size of the effect on 30‐day mortality is congruent with our overall findings as well as the findings in the subgroup analysis stratified by respiratory support at randomisation. It is worth highlighting that this statement is based on analyses of unadjusted dichotomous 30‐day mortality data, including <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>, in this review, while the authors of <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> in their publication presented rate ratios of time‐to‐event data from age‐adjusted Cox regression. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014963-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-FIG-01" target="_blank"><b></b></a></p> </div><img alt="WHO Clinical Progression Scale (Marshall 2020). Copyright © 2020 Elsevier Ltd. All rights reserved: reproduced with permission.ECMO = extracorporeal membrane oxygenation; FiO2 = fraction of inspired oxygen; NIV = non‐invasive ventilation; pO2 = partial pressure of oxygen; RNA = ribonucleic acid; SpO2 = oxygen saturation.*If hospitalised for isolation only, record status for ambulatory patients." data-id="CD014963-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>WHO Clinical Progression Scale (<a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">Marshall 2020</a>). Copyright © 2020 Elsevier Ltd. All rights reserved: reproduced with permission. </p> <p>ECMO = extracorporeal membrane oxygenation; FiO<sub>2</sub> = fraction of inspired oxygen; NIV = non‐invasive ventilation; pO<sub>2</sub> = partial pressure of oxygen; RNA = ribonucleic acid; SpO<sub>2</sub> = oxygen saturation. </p> <p>*If hospitalised for isolation only, record status for ambulatory patients.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-FIG-02" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram illustrating our study selection process." data-id="CD014963-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>PRISMA flow diagram illustrating our study selection process.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days" data-id="CD014963-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 3: Clinical improvement: discharged alive" data-id="CD014963-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 3: Clinical improvement: discharged alive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 4: Clinical worsening: new need for IMV or death" data-id="CD014963-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 4: Clinical worsening: new need for IMV or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 5: Serious adverse events" data-id="CD014963-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 5: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 6: Adverse events" data-id="CD014963-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 6: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 7: Hospital‐acquired infections" data-id="CD014963-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 7: Hospital‐acquired infections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 8: Invasive fungal infections" data-id="CD014963-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 8: Invasive fungal infections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 9: Quality of life up to 120 days" data-id="CD014963-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 9: Quality of life up to 120 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 10: New need for dialysis" data-id="CD014963-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 10: New need for dialysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 11: Viral clearance" data-id="CD014963-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 11: Viral clearance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: respiratory support for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: respiratory support for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: dexamethasone versus methylprednisolone versus hydrocortisone for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: dexamethasone versus methylprednisolone versus hydrocortisone for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: dexamethasone versus methylprednisolone versus hydrocortisone for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days" data-id="CD014963-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: dexamethasone versus methylprednisolone versus hydrocortisone for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: dexamethasone versus methylprednisolone versus hydrocortisone for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 3: Clinical improvement: discharged alive" data-id="CD014963-fig-0017" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: dexamethasone versus methylprednisolone versus hydrocortisone for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 3: Clinical improvement: discharged alive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: female versus male for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0018" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: female versus male for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis: &lt; 70 years versus ≥ 70 years for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0019" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis: &lt; 70 years versus ≥ 70 years for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Subgroup analysis: White versus Black, Asian or minority ethnic group versus unknown for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0020" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Subgroup analysis: White versus Black, Asian or minority ethnic group versus unknown for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days" data-id="CD014963-fig-0022" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 3: Clinical improvement: discharged alive" data-id="CD014963-fig-0023" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 3: Clinical improvement: discharged alive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Methylprednisolone versus dexamethasone for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0024" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Methylprednisolone versus dexamethasone for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0025" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days" data-id="CD014963-fig-0026" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 3: Clinical improvement: discharged alive" data-id="CD014963-fig-0027" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 3: Clinical improvement: discharged alive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 4: Serious adverse events" data-id="CD014963-fig-0028" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 4: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 5: Adverse events" data-id="CD014963-fig-0029" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 5: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 6: Hospital‐acquired infections" data-id="CD014963-fig-0030" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 6: Hospital‐acquired infections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-009.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 7: Invasive fungal infections" data-id="CD014963-fig-0031" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-009.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 7: Invasive fungal infections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-009.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: female versus male for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0032" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: female versus male for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: female versus male for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days" data-id="CD014963-fig-0033" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: female versus male for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Subgroup analysis: &lt; 70 years versus ≥ 70 years for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0034" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Subgroup analysis: &lt; 70 years versus ≥ 70 years for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Subgroup analysis: &lt; 70 years versus ≥ 70 years for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days" data-id="CD014963-fig-0035" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Subgroup analysis: &lt; 70 years versus ≥ 70 years for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days" data-id="CD014963-fig-0036" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014963-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/urn:x-wiley:14651858:media:CD014963:CD014963-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days" data-id="CD014963-fig-0037" src="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_t/tCD014963-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19, Outcome 2: All‐cause mortality up to 120 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/media/CDSR/CD014963/image_n/nCD014963-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014963-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Corticosteroids plus standard care compared to standard care (plus/minus placebo) for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Corticosteroids plus standard care compared to standard care (plus/minus placebo) for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19<br/><b>Setting:</b> inpatient, ICU<br/><b>Intervention:</b> corticosteroids plus standard care<br/><b>Comparison:</b> standard care (plus/minus placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care (plus/minus placebo)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with corticosteroids plus standard care</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>274 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b><br/>(230 to 265) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b><br/>(0.84 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7898<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic corticosteroids probably reduce all‐cause mortality up to 30 days slightly.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 120 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>402 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>298 per 1000</b><br/>(93 to 942) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b><br/>(0.23 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of systemic corticosteroids on all‐cause mortality up to 120 days. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: discharged alive (follow‐up: 28 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>664 per 1000</b><br/>(639 to 688) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b><br/>(1.03 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6786<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic corticosteroids may slightly increase the chance of clinical improvement: discharged alive. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: new need for invasive mechanical ventilation or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>282 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b><br/>(237 to 285) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b><br/>(0.84 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5586<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systemic corticosteroids may slightly decrease the risk of clinical deterioration: new need for invasive mechanical ventilation or death. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias, heterogeneous definitions, and underreporting. Therefore, we only present descriptive statistics: Angus 2020 shock‐dependent hydrocortisone: RR 4.11 (95% CI 0.23 to 72.98); Angus 2020 fixed‐dose hydrocortisone: RR 1.43 (95% CI 0.16 to 12.49); Tomazini 2020: RR 0.54 (95% CI 0.19 to 1.59). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>678<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of systemic corticosteroids on serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any grade) (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias, heterogeneous definitions, and underreporting. We only present descriptive statistics: Edalatifard 2020: RR 0.82 (95% CI 0.12 to 5.48); Tang 2021: RR 0.63 (95% CI 0.22 to 1.76); Tomazini 2020: RR 0.99 (95% CI 0.89 to 1.10). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of systemic corticosteroids on adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐acquired infections (follow up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias, heterogeneous definitions, and underreporting. We present descriptive statistics only: Corral‐Gudino 2021: RR 4.14 (95% CI 0.51 to 33.49); Dequin 2020: RR 0.90 (95% CI 0.60 to 1.34); Tang 2021: RR 2.00 (95% CI 0.19 to 21.24); Tomazini 2020: RR 0.75 (95% CI 0.50 to 1.15). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>598<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of systemic corticosteroids on hospital‐acquired infections. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive fungal infections (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We present descriptive statistics only because of high risk of bias: Corral‐Gudino 2021: RR 2.50 (95% CI 0.11 to 59.15). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of systemic corticosteroids on invasive fungal infections. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424096272361428897" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424096272361428897</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> We downgraded one level for serious risk of bias (partly deviations from the intended intervention, selection of the reported results, missing information about the allocation concealment, baseline differences)<br/><sup>b</sup> We downgraded one level for serious risk of bias (partly deviations from the intended intervention, selection of the reported results, missing information about the allocation concealment), one level for serious inconsistency and one level for serious imprecision (wide confidence interval, low number of participants)<br/><sup>c</sup> We downgraded one level for serious risk of bias (partly deviations from the intended intervention, selection of the reported results, missing information about the allocation concealment) and one level for serious inconsistency.<br/><sup>d</sup> We downgraded one level for serious risk of bias (deviations from the intended intervention, measurement of the outcome) and one level for serious inconsistency.<br/><sup>e</sup> We downgraded two levels for very serious risk of bias (deviations from the intended intervention, missing adjustment for competing risk of death, reporting bias (the safety‐relevant outcome was not reported)) and one level for serious imprecision (fewer than 500 events).<br/><sup>f</sup> We downgraded two levels for very serious risk of bias (deviations from the intended intervention, missing adjustment for competing risk of death, missing information about the allocation concealment, reporting bias (the safety‐relevant outcome was not reported) and one level for serious imprecision (fewer than 500 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Corticosteroids plus standard care compared to standard care (plus/minus placebo) for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014963-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Methylprednisolone compared to dexamethasone for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Methylprednisolone compared to dexamethasone for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19<br/><b>Setting:</b> inpatient, ICU<br/><b>Intervention:</b> methylprednisolone<br/><b>Comparison:</b> dexamethasone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with dexamethasone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with methylprednisolone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>357 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b><br/>(86 to 382) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.51</b><br/>(0.24 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of methylprednisolone on all‐cause mortality up to 30 days. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 120 days ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: discharged alive ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: new need for invasive mechanical ventilation or death ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐acquired infections ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive fungal infections ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424391243004646489" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_424391243004646489</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> We downgraded one level for serious risk of bias for missing pre‐specification/protocol/statistical analysis plan and two levels for very serious imprecision (fewer than 50 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Methylprednisolone compared to dexamethasone for hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014963-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) compared to low‐dose dexamethasone (6 mg to 8 mg) for hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High‐dose dexamethasone (12 mg or higher) compared to low‐dose dexamethasone (6 mg to 8 mg) for hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19<br/><b>Setting:</b> inpatient<br/><b>Intervention:</b> high‐dose dexamethasone (12 mg or higher)<br/><b>Comparison:</b> low‐dose dexamethasone (6 mg to 8 mg) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with low‐dose dexamethasone (6 mg to 8 mg)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with high‐dose dexamethasone (12 mg or higher)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>285 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>248 per 1000</b><br/>(208 to 297) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b><br/>(0.73 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1269<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose dexamethasone may further reduce all‐cause mortality up to 30 days compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 120 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>329 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>306 per 1000</b><br/>(260 to 355) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b><br/>(0.79 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1383<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of high‐dose dexamethasone (12 mg or higher) on all‐cause mortality up to 120 days compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: discharged alive (follow‐up: 28 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>882 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>865 per 1000</b><br/>(785 to 962) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b><br/>(0.89 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose dexamethasone (12 mg or higher) may have little or no impact on the chance of clinical improvement: discharged alive compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: new need for invasive mechanical ventilation or death ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias arising from the missing adjustment for competing risk of death. We present descriptive data only: Munch 2021b: RR 0.80 (95% CI 0.60 to 1.07); Maskin 2021: RR 1.05 (95% CI 0.88 to 1.25). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1080<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of high‐dose dexamethasone (12 mg or higher) on serious adverse events compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any grade) (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias arising from the missing adjustment for competing risk of death. We present descriptive data only: Maskin 2021: RR 1.02 (95% CI 0.96 to 1.08). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of high‐dose dexamethasone (12 mg or higher) on adverse events compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐acquired infections (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias arising from the missing adjustment for competing risk of death. We present descriptive data only: Maskin 2021: RR 0.89 (95% CI 0.70 to 1.14); Munch 2021b: RR 0.80 (95% CI 0.56 to 1.14). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1080<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of high‐dose dexamethasone (12 mg or higher) on hospital‐acquired infections compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive fungal infections (follow‐up: during treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We did not perform meta‐analyses because of high risk of bias arising from the missing adjustment for competing risk of death. We present descriptive data only: Munch 2021b: RR 0.70 (95% CI 0.36 to 1.34); Maskin 2021: RR 1.00 (95% CI 0.21 to 4.71). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1080<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of high‐dose dexamethasone (12 mg or higher) on invasive fungal infections compared to low‐dose dexamethasone (6 mg to 8 mg). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431226044092715996" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431226044092715996</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> We downgraded one level for serious risk of bias (deviations from the intended intervention, no information about the allocation concealment) and one level for serious imprecision (wide confidence interval, low number of participants/events). <br/><sup>b</sup> We downgraded one level for serious risk of bias (no information about the allocation concealment; deviations from the protocol), one level for serious imprecision (wide confidence interval, low number of participants/events) and one level for serious inconsistency (Toroghi 2021 differs from the other studies). <br/><sup>c</sup> We downgraded one level for serious risk of bias (no information about the allocation concealment) and one level for serious imprecision (wide confidence interval, low number of participants/events). <br/><sup>d</sup> We downgraded one level for serious risk of bias (missing adjustment of competing risk of death) and two levels for very serious imprecision (very low number of events/participants).<br/><sup>e</sup> We downgraded one level for serious risk of bias (missing adjustment for competing risk of death, deviations from the intended intervention), two levels for very serious imprecision (very low number of events/participants).<br/><sup>f</sup> We downgraded one level for serious risk of bias (missing adjustment for competing risk of death, protocol deviations, measurement of the outcome, no information about the allocation concealment), two levels for very serious imprecision (very low number of events/participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) compared to low‐dose dexamethasone (6 mg to 8 mg) for hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014963-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Equity elements of the included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study/equity‐element</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]"><b>World Bank 2021</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ethnicity (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Occupation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sex (% female)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Religion</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Education</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Socioeconomic status</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Social capital</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]"><b>Angus 2020</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Australia, Canada, France, Ireland, the Netherlands, New Zealand, UK, USA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0038"> <li> <p>Fixed‐dose intervention group: 60.4 (11.6)</p> </li> <li> <p>Shock‐dependent intervention group: 59.5 (12.7)</p> </li> <li> <p>Control group: 59.9 (14.6)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fixed‐dose intervention group:</p> <p> <ul id="CD014963-list-0039"> <li> <p>White: 79 (72.2%)</p> </li> <li> <p>Asian: 18 (16.2%)</p> </li> <li> <p>Black: 4 (3.6%)</p> </li> <li> <p>Mixed: 4 (3.6%)</p> </li> <li> <p>Other: 6 (5.4%)</p> </li> </ul> </p> <p>Shock‐dependent intervention group:</p> <p> <ul id="CD014963-list-0040"> <li> <p>White: 80 (76.2%)</p> </li> <li> <p>Asian: 11 (10.5%)</p> </li> <li> <p>Black: 7 (6.7%)</p> </li> <li> <p>Mixed: 0</p> </li> <li> <p>Other: 7 (6.7%)</p> </li> </ul> </p> <p> </p> <p>Control group:</p> <p> <ul id="CD014963-list-0041"> <li> <p>White: 45 (57%)</p> </li> <li> <p>Asian: 22 (27.9%)</p> </li> <li> <p>Black: 4 (5.1%)</p> </li> <li> <p>Mixed: 2 (2.5%)</p> </li> <li> <p>Other: 6 (7.6%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0042"> <li> <p>Fixed‐dose intervention group: 39 (28.5%)</p> </li> <li> <p>Shock‐dependent intervention group: 43 (29.5%)</p> </li> <li> <p>Control group: 29 (28.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]"><b>Corral‐Gudino 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0043"> <li> <p>Intervention group: 73 (11)</p> </li> <li> <p>Control group: 66 (12)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0044"> <li> <p>Intervention group: 11 (32%)</p> </li> <li> <p>Control group: 13 (45%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]"><b>Dequin 2020</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0045"> <li> <p>Intervention group: 63.1 (51.5 to 70.8)</p> </li> <li> <p>Control group: 66.3 (53.5 to 72.7)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0046"> <li> <p>Intervention group: 22 (28.9%)</p> </li> <li> <p>Control group: 23 (31.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]"><b>Edalatifard 2020</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0047"> <li> <p>Intervention group: 55.8 (16.35)</p> </li> <li> <p>Control group: 61.7 (16.62)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0048"> <li> <p>Intervention group: 10 (29.4%)</p> </li> <li> <p>Control group: 13 (46.4%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]"><b>Farahani 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD):</p> <p> <ul id="CD014963-list-0049"> <li> <p>Intervention group: 61.07 (12.83)</p> </li> <li> <p>Control group: 66.80  (14.03)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0050"> <li> <p>Intervention group: 4 (28.6%)</p> </li> <li> <p>Control group: 6 (40%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. "><b>Horby 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (UK)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD):</p> <p> <ul id="CD014963-list-0051"> <li> <p>Intervention group: 66.9 (15.4)</p> </li> <li> <p>Control group: 65.8 (15.8)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention group:</p> <p> <ul id="CD014963-list-0052"> <li> <p>White: 1550 (74%)</p> </li> <li> <p>Black, Asian or minority ethnic group: 364 (17%)</p> </li> <li> <p>Unknown: 190 (9%)</p> </li> </ul> </p> <p>Control group:</p> <p> <ul id="CD014963-list-0053"> <li> <p>White: 3139 (73%)</p> </li> <li> <p>Black, Asian or minority ethnic group: 783 (18%)</p> </li> <li> <p>Unknown: 399 (9%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0054"> <li> <p>Intervention group: 766 (36%)</p> </li> <li> <p>Control group: 1572 (36%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]"><b>Jamaati 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0055"> <li> <p>Intervention group survivor: 54 (37 to 63)</p> </li> <li> <p>Intervention group non‐survivor: 63 (55.5 to 72.5)</p> </li> <li> <p>Control group survivor: 61.5 (54 to 62)</p> </li> <li> <p>Control group non‐survivor: 67 (48 to 73)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0056"> <li> <p>Intervention group: 7 (28%)</p> </li> <li> <p>Control group: 7 (28%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]"><b>Jeronimo 2020</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Brazil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0057"> <li> <p>Intervention group: 54 (15)</p> </li> <li> <p>Control group: 57 (15)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention group:</p> <p> <ul id="CD014963-list-0058"> <li> <p>White: 30 (15.5%)</p> </li> <li> <p>Mixed: 147 (75.8%)</p> </li> <li> <p>Black: 6 (3.1%)</p> </li> <li> <p>Asian: 3 (1.5%)</p> </li> <li> <p>Amerindian: 8 (4.1%)</p> </li> </ul> </p> <p>Control group:</p> <p> <ul id="CD014963-list-0059"> <li> <p>White: 28 (14.1%)</p> </li> <li> <p>Mixed: 147 (73.9%)</p> </li> <li> <p>Black: 17 (8.5%)</p> </li> <li> <p>Asian: 3 (1.5%)</p> </li> <li> <p>Amerindian: 4 (2.0%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0060"> <li> <p>Intervention group: 68 (35.1%)</p> </li> <li> <p>Control group: 71 (35.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). "><b>Maskin 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Argentina)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0061"> <li> <p>Low‐dose group: 60.04 (13.08)</p> </li> <li> <p>High‐dose group: 63.57 (13.59)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0062"> <li> <p>Low‐dose dexamethasone: 16 (33%)</p> </li> <li> <p>High‐dose dexamethasone: 13 (26%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]"><b>Munch 2021a</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Denmark)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0063"> <li> <p>Intervention group: 59 (52 to 74)</p> </li> <li> <p>Control group: 62 (55 to 71)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0064"> <li> <p>Intervention group: 2 (12%)</p> </li> <li> <p>Control group: 4 (29%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]"><b>Munch 2021b</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Denmark, India, Sweden, Switzerland)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0065"> <li> <p>Low‐dose group: 64 (54 to 72)</p> </li> <li> <p>High‐dose group: 65 (56 to 74)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0066"> <li> <p>Low‐dose dexamethasone: 154 (32%)</p> </li> <li> <p>High‐dose dexamethasone: 151 (30%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]"><b>Ranjbar 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0067"> <li> <p>Methylprednisolone group: 56.2 (17.5)</p> </li> <li> <p>Dexamethasone group: 61.3 (17.3)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0068"> <li> <p>Methylprednisolone group: 17 (38.6%)</p> </li> <li> <p>Dexamethasone group: 20 (47.6%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]"><b>Taboada 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0069"> <li> <p>Low‐dose group: 64.8 (14.1)</p> </li> <li> <p>High‐dose group: 63.9 (14.5)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0070"> <li> <p>Low‐dose dexamethasone: 41 (39.6%)</p> </li> <li> <p>High‐dose dexamethasone: 36 (36.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]"><b>Tang 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (China)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0071"> <li> <p>Intervention group: 57 (49 to 67)</p> </li> <li> <p>Control group: 55 (38 to 65)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0072"> <li> <p>Intervention group: 22 (51.2%)</p> </li> <li> <p>Control group: 23 (53.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]"><b>Tomazini 2020</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Brazil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0073"> <li> <p>Intervention group: 60.1 (15.8)</p> </li> <li> <p>Control group: 62.7 (13.1)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0074"> <li> <p>Intervention group: 61 (40.4%)</p> </li> <li> <p>Control group: 51 (34.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]"><b>Toroghi 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0075"> <li> <p>Low‐dose group (8 mg once a day): 59 (14)</p> </li> <li> <p>Intermediate‐dose group (8 mg twice a day): 59 (17)</p> </li> <li> <p>High‐dose group (8 mg 3 times a day): 56 (16)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0076"> <li> <p>Low‐dose dexamethasone: 19 (40.4%)</p> </li> <li> <p>High‐dose dexamethasone: 34 (39.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><b>NR:</b> not reported; <b>SD</b> : standard deviation; <b>IQR</b>: interquartile range </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Equity elements of the included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014963-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of the included studies for the comparison: systemic corticosteroids versus placebo or standard care for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention and regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydrocortisone equivalent of initial dose: for 80 kg bodyweight if applicable (</b><a href="./references#CD014963-bbs2-0187" title="StoeltingRK , Hiller SC (editors). Pharmacology. In: Pharmacology &amp; Physiology in Anesthetic Practice. 4 edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006:462."><b>Stoelting 2006</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to corticosteroids</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]">World Bank 2021</a><b>) and recruitment period</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sex (% female)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity at randomisation on WHO Clinical Progression Scale (</b><a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7."><b>Marshall 2020</b> </a><b>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydrocortisone, IV, 150 mg daily for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 (fixed‐dose) and 152 (shock‐dependent dose)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0077"> <li> <p>Platform</p> </li> <li> <p>Open‐label</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Australia, Canada, France, Ireland, the Netherlands, New Zealand, United Kingdom, USA) </p> <p>between March and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0078"> <li> <p>Fixed‐dose intervention group: 60.4 (11.6)</p> </li> <li> <p>Shock‐dependent intervention group: 59.5 (12.7)</p> </li> <li> <p>Control group: 59.9 (14.6)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0079"> <li> <p>Fixed‐dose intervention group: 39 (28.5%)</p> </li> <li> <p>Shock‐dependent intervention group: 43 (29.5%)</p> </li> <li> <p>Control group: 29 (28.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe ≥ 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, IV 80 mg for 3 days + 40 mg for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0080"> <li> <p>Open‐label</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> <p>between April and May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0081"> <li> <p>Intervention group: 73 (11)</p> </li> <li> <p>Control group: 66 (12)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0082"> <li> <p>Intervention group: 11 (32%)</p> </li> <li> <p>Control group: 13 (45%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe 5 to 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydrocortisone, IV 200 mg for 7 days, 100 mg for 4 days + 50 mg for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0083"> <li> <p>Double‐blind</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> <p>between March and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0084"> <li> <p>Intervention group: 63.1 (51.5 to 70.8)</p> </li> <li> <p>Control group: 66.3 (53.5 to 72.7)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0085"> <li> <p>Intervention group: 22 (28.9%)</p> </li> <li> <p>Control group: 23 (31.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe ≥ 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, IV, 250 mg for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> <ul id="CD014963-list-0086"> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> <p>between March and May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0087"> <li> <p>Intervention group: 55.8 (16.35)</p> </li> <li> <p>Control group: 61.7 (16.62)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0088"> <li> <p>Intervention group: 10 (29.4%)</p> </li> <li> <p>Control group: 13 (46.4%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe 5 to 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, IV 1000 mg/d for 3 days + tapering with 1 mg/kg prednisolone for 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5000 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0089"> <li> <p>Open‐label</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> <p>between March and May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD):</p> <p> <ul id="CD014963-list-0090"> <li> <p>Intervention group: 61.07 (12.83)</p> </li> <li> <p>Control group: 66.80  (14.03)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0091"> <li> <p>Intervention group: 4 (28.6%)</p> </li> <li> <p>Control group: 6 (40%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe 5 to 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV or oral 6 mg daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0092"> <li> <p>Platform</p> </li> <li> <p>Open‐label</p> </li> <li> <p>Multi‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(United Kingdom)</p> <p>between May and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD):</p> <p> <ul id="CD014963-list-0093"> <li> <p>Intervention group: 66.9 (15.4)</p> </li> <li> <p>Control group: 65.8 (15.8)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0094"> <li> <p>Intervention group: 766 (36%)</p> </li> <li> <p>Control group: 1572 (36%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe 4 to 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 20 mg for 5 days + 10 mg for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0095"> <li> <p>Open‐label</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> <p>in March 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0096"> <li> <p>Intervention group survivor: 54 (37 to 63)</p> </li> <li> <p>Intervention group non‐survivor: 63 (55.5 to 72.5)</p> </li> <li> <p>Control group survivor: 61.5 (54 to 62)</p> </li> <li> <p>Control group non‐survivor: 67 (48 to 73)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0097"> <li> <p>Intervention group: 7 (28%)</p> </li> <li> <p>Control group: 7 (28%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most likely moderate 5; no IMV at randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone (as sodium succinate), IV 1 mg/kg for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0098"> <li> <p>Double‐blind</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Brazil)</p> <p>between April and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0099"> <li> <p>Intervention group: 54 (15)</p> </li> <li> <p>Control group: 57 (15)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0100"> <li> <p>Intervention group: 68 (35.1%)</p> </li> <li> <p>Control group: 71 (35.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe 5 to 9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydrocortisone, IV, 200 mg per day, for 7 days or until hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0101"> <li> <p>Triple‐blind</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Denmark)</p> <p>between April and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0102"> <li> <p>Intervention group: 59 (52 to 74)</p> </li> <li> <p>Control group: 62 (55 to 71)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0103"> <li> <p>Intervention group: 2 (12%)</p> </li> <li> <p>Control group: 4 (29%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe ≥ 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, IV, 1 mg/kg for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0104"> <li> <p>Single‐blind</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(China)</p> <p>between February and March 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (years, IQR)</p> <p> <ul id="CD014963-list-0105"> <li> <p>Intervention group: 57 (49 to 67)</p> </li> <li> <p>Control group: 55 (38 to 65)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0106"> <li> <p>Intervention group: 22 (51.2%)</p> </li> <li> <p>Control group: 23 (53.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate 4 to 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 20 mg for 5 days + 10 mg for 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0107"> <li> <p>Open‐label</p> </li> <li> <p>Multicentre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Brazil)</p> <p>between April and June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0108"> <li> <p>Intervention group: 60.1 (15.8)</p> </li> <li> <p>Control group: 62.7 (13.1)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0109"> <li> <p>Intervention group: 61 (40.4%)</p> </li> <li> <p>Control group: 51 (34.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe 7 to 9<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>d:</b> day;<b>IMV:</b> invasive mechanical ventilation; <b>IV:</b> intravenous; <b>SD:</b> standard deviation; <b>IQR:</b> interquartile range </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p><sup>a</sup> Shock‐dependent dose: shock‐dependent dosing strategy was that restricting hydrocortisone to the period when the patient had overt shock would maximise the risk‐benefit ratio. Shock was defined as the requirement for intravenous vasopressor infusion for the treatment of shock presumed due to COVID‐19. Hydrocortisone was discontinued in the shock‐dependent group once shock was considered to have resolved or vasopressors had been discontinued for 24 hours. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of the included studies for the comparison: systemic corticosteroids versus placebo or standard care for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014963-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of the included studies for the comparison: methylprednisolone versus dexamethasone for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention A</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydrocortisone equivalent of initial dose (for 80 kg bodyweight if applicable)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention B</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to intervention A<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to Intervention B</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]">World Bank 2021</a>) and recruitment period </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sex (% female)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity at randomisation on WHO Clinical Progression Scale (</b><a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7."><b>Marshall 2020</b> </a><b>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone 2 mg/kg, i.e. for an 80 kg participant: IV 160 mg for 5 days + 80 mg for 5 days + 40 mg for 5 days + 20 mg for 5 days (approximation of tapering scheme) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 mg/d in the methylprednisolone arm for an 80 kg participant</p> <p> </p> <p>1000 mg/d in the dexamethasone arm fixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 6 mg for 10 days<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0110"> <li> <p>Triple‐blind</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> <p>between August and November 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (years, SD)</p> <p> <ul id="CD014963-list-0111"> <li> <p>Methylprednisolone group: 56.2 (17.5)</p> </li> <li> <p>Dexamethasone group: 61.3 (17.3)</p> </li> </ul> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0112"> <li> <p>Intervention A group: 17 (38.6%)</p> </li> <li> <p>Intervention B group: 20 (47.6%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate 4 to 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>IV:</b> intravenous, <b>d:</b> day, <b>SD:</b> standard deviation </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of the included studies for the comparison: methylprednisolone versus dexamethasone for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014963-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Characteristics of the included studies for the comparison: high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8 mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention dose and regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydrocortisone equivalent of initial dose: for 80 kg bodyweight if applicable (</b><a href="./references#CD014963-bbs2-0187" title="StoeltingRK , Hiller SC (editors). Pharmacology. In: Pharmacology &amp; Physiology in Anesthetic Practice. 4 edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006:462."><b>Stoelting 2006</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to high‐dose dexamethasone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised to low‐dose dexamethasone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]"><b>World Bank 2021</b> </a><b>) and recruitment date</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sex (% female)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity at randomisation on WHO Clinical Progression Scale (</b><a href="./references#CD014963-bbs2-0156" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7."><b>Marshall 2020</b> </a><b>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 12 mg/day for up to 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg/d vs 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 6 mg/day for up to 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0113"> <li> <p>Multicentre</p> </li> <li> <p>Triple‐blind</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mainly high‐income countries</p> <p>(Denmark, India, Sweden, Switzerland)</p> <p>between August 2020 and May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median age (years, IQR)</p> <p> <ul id="CD014963-list-0114"> <li> <p>Low‐dose group: 64 (54 to 72)</p> </li> <li> <p>High‐dose group: 65 (56 to 74)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0115"> <li> <p>Low‐dose dexamethasone: 154 (32%)</p> </li> <li> <p>High‐dose dexamethasone: 151 (30%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe ≥5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone + standard care, IV, 16 mg once daily for 5 days, followed by 8 mg administered once daily for additional 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 mg/d vs 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone + standard care, IV, 6 mg per day for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0116"> <li> <p>Multicentre</p> </li> <li> <p>Open‐label</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Argentina)</p> <p>between June 2020 and March 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0117"> <li> <p>Low‐dose group: 60.04 (13.08)</p> </li> <li> <p>High‐dose group: 63.57 (13.59)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0118"> <li> <p>Low‐dose dexamethasone: 16 (33%)</p> </li> <li> <p>High‐dose dexamethasone: 13 (26%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe ≥ 7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm 2: Dexamethasone, IV, 8 mg twice a day for up to 10 days or until hospital discharge</p> <p>Arm 3: 8 mg 3 times a day for up to 10 days or until hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm 2: 400 mg/d or Arm 3: 600 mg/d vs 200 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 8 mg once a day for up to 10 days or until hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0119"> <li> <p>Open‐label</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> <p>between October 2020 and January 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0120"> <li> <p>Low‐dose group (8 mg once a day): 59 (14)</p> </li> <li> <p>Intermediate‐dose group (8 mg twice a day): 59 (17)</p> </li> <li> <p>High‐dose group (8 mg 3 times a day): 56 (16)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0121"> <li> <p>Low‐dose dexamethasone: 19 (40.4%)</p> </li> <li> <p>High‐dose dexamethasone: 34 (39.5%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe ≥ 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 20 mg once daily for 5 days, followed by 10 mg once daily for additional 5 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg/d vs 150  mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, IV, 6 mg once daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0122"> <li> <p>Open‐label</p> </li> <li> <p>Single‐centre</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> <p>between January and May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years, SD)</p> <p> <ul id="CD014963-list-0123"> <li> <p>Low‐dose group: 64.8 (14.1)</p> </li> <li> <p>High‐dose group: 63.9 (14.5)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD014963-list-0124"> <li> <p>Low‐dose dexamethasone: 41 (39.6%)</p> </li> <li> <p>High‐dose dexamethasone: 36 (36.7%)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe ≥ 5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p><b>IV:</b> intravenous; <b>d:</b> day; <b>SD:</b> standard deviation; <b>IQR:</b> interquartile range </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Characteristics of the included studies for the comparison: high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8 mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014963-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Reporting of safety data</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison 1: Systemic corticosteroids plus standard care versus standard care (plus/minus placebo)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition as published</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Way of counting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any SAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Shock‐dependent hydrocortisone: SAE: 5/141</p> <p> </p> <p>Fixed‐dose hydrocortisone: SAE: 4/137</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 0/52</p> <p> </p> <p> </p> <p>SAE: 1/49</p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0002" title="Corral-GudinoL , BahamondeA , Arnaiz-RevillasF , Gómez-BarqueroJ , Abadía-OteroJ , García-IbarbiaC , et al. Methylprednisolone in adults hospitalised with COVID-19 pneumonia: an open-label randomised trial (GLUCOCOVID). Wiener Klinische Wochenschrift2021;133(7-8):303-11. [DOI: 10.1007/s00508-020-01805-8] [EUCTR2020-001934-37-ES]CorralL , BahamondeA , Arnaiz delas RevillasF , Gomez-BarqueroJ , Abadia-OteroJ , Garcia-IbarbiaC , et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia. medRxiv [Preprint]. [DOI: 10.1101/2020.06.17.20133579] [EUCTR2020-001934-37-ES]">Corral‐Gudino 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microbiology‐proven infection and hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE, HAI: events/participants at risk</p> <p> </p> <p>HAI, FI: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 14/35</p> <p>HAI: 5/35 (events and participants)</p> <p>FI: 1/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 1/29</p> <p>HAI: 1/29 (events and participants)</p> <p>FI: 0/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0003" title="DequinPF , GougeAL , TavernierE , GiraudeauB , ZoharS . Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research2020:1-5. [EMBASE: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005906375&amp;from=export]DequinPF , HemingN , MezianiF , PlantefèveG , VoiriotG , BadiéJ , et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomised clinical trial. JAMA2020;324(13):1298-306. [DOI: 10.1001/jama.2020.16761] [NCT02517489]">Dequin 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nosocomial infections until day 28 defined by need for antibiotics. No other SAEs/AEs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE, HAI: events/participants at risk</p> <p> </p> <p>HAI: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 40/76</p> <p>HAI: 40/76 (events), 28/76 (participants)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 50/73</p> <p>HAI: 50/73 (events), 30/73 (participants)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0004" title="EdalatifardM , AkhtariM , SalehiM , NaderiZ , JamshidiA , MostafaeiS , et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal2020;56(6):1-13. [DOI: 10.1183/13993003.02808-2020] [IRCT20200404046947N1]">Edalatifard 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All undesirable effects (adverse events)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HAI: events/participants at risk</p> <p> </p> <p>AE: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 2/34</p> <p>HAI: 1/34</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 2/28</p> <p>HAI: 0/28</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐blind<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0005" title="FarahaniRH , MosaedR , Nezami-AslA , ChamanaraM , Soleiman-MeigooniS , KalantarS , et al. Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of COVID-19 adult patients with severe respiratory failure: randomised, clinical trial. Research Square2021;Version 1:1-19. [DOI: 10.21203/rs.3.rs-66909/v1] [IRCT20200406046963N1]">Farahani 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suspected drug reactions reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0007" title="JamaatiH , HashemianSM , FarzaneganB , MalekmohammadM , TabarsiP , MarjaniM , et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomised clinical trial. European Journal of Pharmacology2021;897:173947. [DOI: 10.1016/j.ejphar.2021.173947] [IRCT20151227025726N17]">Jamaati 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0008" title="BarrosCMSS , FreireRS , FrotaE , SantosAGR , FariasMAL , RodriguesMGA , et al. Short-course of methylprednisolone improves respiratory functional parameters after 120 days in hospitalised COVID-19 patients (Metcovid Trial): a randomised clinical trial. Frontiers in Medicine2021;8(758405):1-9. [DOI: 10.3389/fmed.2021.758405]JeronimoCM , FariasME , ValFF , SampaioVS , AlexandreMA , MeloGC , et al. Methylprednisolone as adjunctive therapy for patients hospitalised with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clinical Infectious Diseases2020;72(9):e373–e81. [DOI: 10.1093/cid/ciaa1177] [NCT04343729]">Jeronimo 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE/SAE not explicitly reported</p> <p>Positive blood culture, need for insulin therapy, sepsis reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0010" title="MunchMW , MeyhoffTS , HellebergM , Kjær M-BN, GranholmA , HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiologica Scandinavica2021;65(10):1421-30. [DOI: 10.1111/aas.13941]NCT04348305. Hydrocortisone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04348305 (first received 16 April 2020). PetersenMW , MeyhoffTS , HellebergM , Nørregaard KjærMB , GranholmA , Steensen HjortsøCJ , et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2020;64(9):1365-75. [DOI: 10.1111/aas.13673]">Munch 2021a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse reaction reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triple‐blind</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0014" title="TangX , FengYM , NiJX , ZhangJY , LiuLM , HuK , et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomised control trial. Respiration2021;100(2):116-26. [DOI: 10.1159/000512063] [NCT04273321]">Tang 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperglycaemia, ventilator‐associated pneumonia, stress ulcer, gastrointestinal haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE, HAI: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 5/43</p> <p>HAI: 2/43</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 8/43</p> <p>HAI: 1/43</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐blind</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0015" title="TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomised trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.24.20139303]TomaziniBM , MaiaIS , BuenoFR , Silva Mvao BaldassareFP , CostaEL , MouraRA , et al. COVID-19-associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomised trial. Revista Brasileira de Terapia Intensiva2020;32(3):354-62. [DOI: 10.5935/0103-507X.20200063]TomaziniBM , MaiaIS , CavalcantiAB , BerwangerO , RosaRG , VeigaVC , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomised clinical trial. JAMA2020;324(13):1307-16. [DOI: 10.1001/jama.2020.17021] [NCT04327401]">Tomazini 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycaemic control, nosocomial infection, other AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE, AE, HAI: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 5/151</p> <p>AE: 122/151</p> <p>HAI: 30/151</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 9/148</p> <p>AE: 121/148</p> <p>HAI: 39/148</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison 2: Methylprednisolone versus dexamethasone</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition as published</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Way of counting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Methylprednisolone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Dexamethasone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0012" title="RanjbarK , ShahriariradR , ErfaniA , KhodamoradiZ , SaadiMHG , et al. Methylprednisolone or dexamethasone, which one is the superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. Research Square (Preprint). [DOI: https://doi.org/10.21203/rs.3.rs-148529/v1] [IRCT20200204046369N1]">Ranjbar 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triple‐blind</p> </td> </tr> <tr> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison 3: High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition as published</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Way of counting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>High‐dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Low‐dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0009" title="MaskinLP , BonelliI , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter and randomised open-label clinical trial. medRxiv2021;Version 1:1-21. [DOI: 10.1101/2021.09.15.21263597]MaskinLP , BonelliI , OlarteGL , Palizas Jr F, VeloAE , LurbetMF , et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomised open-label clinical trial. Journal of Intensive Care Medicine2021;Version 1:1-9. [DOI: 10.1177/08850666211066799]MaskinLP , OlarteGL , Palizas F Jr, VeloAE , LurbetMF , BonelliI , et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):743. [DOI: 10.1186/s13063-020-04646-y]NCT04395105. Dexamethasone for COVID-19 related ARDS: a multicenter, randomised clinical trial. clinicaltrials.gov/show/NCT04395105 (first received 20 May 2020). ">Maskin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: effects causing disability (defined as muscular weakness with a MRC scale &lt; 48) or death </p> <p> </p> <p>AE: hyperglycaemia (≥ 200 mg/dL), delirium (positive CAM‐ICU or requirement of neuroleptic drugs), hospital‐acquired infections (according to investigator judgement) </p> <p> </p> <p>HAI: as defined by the attending physician</p> <p> </p> <p>FI: candidemia (documented as <i>Candida sp.</i> in blood cultures), aspergillosis (documented as <i>Aspergillus sp.</i> in cultures) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE, FI, AE, HAI: participants with at least one event/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 42/49</p> <p>AE: 49/49</p> <p>HAI: 34/49</p> <p>FI: 3/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 40/49</p> <p>AE: 48/49</p> <p>HAI: 38/49</p> <p>FI: 3/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0011" title="GranholmA , MunchMW , MyatraSN , VijayaraghavanBKT , CronhjortM , WahlinRR , et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Medicine2022;48(1):45-55. [DOI: 10.1007/s00134-021-06573-1]The COVID STEROID 2 trial group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia The COVID STEROID 2 randomised trial. JAMA2021;326(18):1807–17. [DOI: 10.1001/jama.2021.18295]">Munch 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse reaction (i.e. new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal bleeding, or anaphylactic reaction to dexamethasone) </p> <p> </p> <p>HAI: either new episode of septic shock OR invasive fungal infection, as per the elements of the composite outcome of ≥ 1 serious adverse reaction at day 28 </p> <p> </p> <p>FI: not further defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE, FI, HAI: participants with at least one event/participants at risk</p> <p> </p> <p>HAI, FI: events/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 70/497</p> <p>HAI: 27/497 (events), 50/497 (participants)</p> <p>FI: 15/497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAE: 85/485</p> <p>HAI: 35/485 (events), 61/485 (participants)</p> <p>FI: 21/485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Triple‐blind</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0013" title="NCT04726098. Low or high dose of dexamethasone in patients with respiratory failure by COVID-19. clinicaltrials.gov/ct2/show/record/NCT04726098 (first received 27 January 2021). TaboadaM , RodríguezN , VarelaPM , RodríguezMT , AbelleiraR , GonzálezA , et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. European Respiratory Journal2021;59(1):1-43. [DOI: 10.1183/13993003.02518-2021]">Taboada 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: nosocomial infection, insuline use for hyperglycaemia, thrombosis, death at day 28 and death at day 60 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE, HAI: events/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 58/98</p> <p>HAI: 10/98</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 65/102</p> <p>HAI: 10/102</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: not further defined</p> <p>HAI: secondary infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE, HAI: events/participants at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 252/86</p> <p>HAI: 5/86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE: 122/47</p> <p>HAI: 1/47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open‐label</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>AE:</b> adverse event; <b>ICU:</b> intensive care unit; <b>FI:</b> fungal infection; <b>SAE:</b> serious adverse event; <b>HAI:</b> hospital‐acquired infection; <b>SAP</b>: statistical analysis plan </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Reporting of safety data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014963-tbl-0009"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Characteristics of ongoing studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sponsor/developer</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]"><b>World Bank 2021</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Route of administration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0068" title="ACTRN12621001200875. A randomised controlled trial of dexamethasone for emergency and life-threatening admissions due to COVID-19 in virtual care: the DELTA study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12621001200875 (first received 8 September 2021). ">ACTRN12621001200875</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Royal Prince Alfred Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Australia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exhibiting mild/moderate COVID‐19 symptoms (fever, respiratory tract symptoms, dyspnoea, headache, gastrointestinal symptoms), with no requirement for oxygen or hospitalisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0069" title="ACTRN12621001603808. The effect of prednisolone vs dexamethasone on Covid-19 in pregnancy: an open labelled randomised control trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12621001603808 (first received 24 November 2021). ">ACTRN12621001603808</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monash Health Hospital Victoria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Australia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women pregnant &gt; 16 weeks with COVID‐19 hospitalised with an oxygen requirement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone, dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0070" title="QinYY , ZhouYH , LuYQ , SunF , YangS , HarypursatV , et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomised controlled trial. Chinese Medical Journal2020;133(9):1080-6. [DOI: 10.1097/CM9.0000000000000791] [ChiCTR2000029386]">ChiCTR2000029386</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chongqing Public Health Medical Center</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(China)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0071" title="ChiCTR2000029656. A randomised, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalised patients with novel coronavirus pneumonia (COVID-19). www.chictr.org.cn/showprojen.aspx?proj=49086 (first received 9 February 2020). ">ChiCTR2000029656</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wuhan Pulmonary Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(China)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0072" title="ChiCTR2000030481. The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomised controlled trial. www.chictr.org.cn/showprojen.aspx?proj=50453 (first received 3 March 2020). ">ChiCTR2000030481</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zhongnan Hospital of Wuhan University</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(China)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosed COVID‐19 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early corticosteroid intervention, middle‐late corticosteroid intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0073" title="CTRI/2020/07/026608. A clinical trial to study the effects of two drugs methylprednisolone and dexamethasone in patients with severe COVID-19. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45638 (first received 15 July 2020). ">CTRI/2020/07/026608</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dr Ananthakumar PK, Chettinad Hospital and Research Institute Kelambakkam Kancheepuram Dist Pin 603103 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosed COVID‐infection + ARDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0074" title="Comparing the effectiveness of dexamethasone versus methylprednisolone in patients with moderate COVID 19 - a randomised controlled trial. ctri.nic.in/Clinicaltrials/showallp.php?mid1=49273&amp;EncHid=&amp;userName=029894 (first received 18 December 2020). CTRI/2020/12/029894. A study to compare the effectiveness of two drugs, dexamethasone versus methylprednisolone in the treatment of moderate Covid 19 patients. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/12/029894. ">CTRI/2020/12/029894</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SRM Medical College Hospital and Research Centre <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SpO<sub>2</sub> &lt; 94% under room air and requiring supplemental oxygen for hypoxaemia, respiratory rate 24 to 30/min<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0075" title="CTRI/2020/12/030143. Comparison of different steroid regimes in critically ill adult patients of COVID-19. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/12/030143. CTRI/2020/12/030143. Evaluation of different steroid regimes in critically ill adult patients of COVID-19 admitted to intensive care units. ctri.nic.in/Clinicaltrials/showallp.php?mid1=50886&amp;EncHid=&amp;userName=30143 (first received 31 December 2020). ">CTRI/2020/12/030143</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maulana Azad Medical College and associated Lok Nayak Hospital<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted to ICU within 14 days of onset of symptoms; receiving invasive or non‐invasive positive pressure ventilation or respiratory support through HFNC <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0076" title="CTRI/2021/05/033873. Pre-emptive steroids to alter the disease course in COVID-19 patients. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2021/05/033873 (first received: 31 May 2021). ">CTRI/2021/05/033873</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JK Hospital and LN Medical College</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: moderate to severe type of disease; eligible for home isolation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0077" title="CTRI/2021/08/035822. Assessment of doubling dose of dexamethasone in progressively worsening severe COVID-19 pneumonia - a randomised controlled trial. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=57048 (first received 19 August 2021). ">CTRI/2021/08/035822</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Animesh Ray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe COVID‐19 pneumonia (SpO2 &lt; 94%; PaO2/FiO2 &lt; 300 mm Hg or respiratory rate (RR) &gt; 30 breaths/min) with lack of response to dexamethasone 6 mg after 48 hours (defined as similar or worsening oxygen requirement (margin of error is 5% Fio2 for high‐flow nasal cannula, 2 L/min for NRBM, and 1 L/min for low flow oxygen devices) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone high‐dose, dexamethasone low‐dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV or oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0078" title="EUCTR2020-001413-20-ES. Efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID-19 pneumonia. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001413-20 (first received 7 April 2020). ">EUCTR2020‐001413‐20‐ES</a> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundació Clínic per a la Recerca Biomèdica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐critical patient with pneumonia in radiological progression and/or patient with progressive respiratory failure in the last 24 to 48 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporarily halted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0079" title="EUCTR2020-001457-43-FR. Dexamethasone and oxygen support strategies in ICU patients with COVID-19 pneumonia. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001457-43 (first received 10 April 2020). ">EUCTR2020‐001457‐43‐FR</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>APHP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted to ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0080" title="EUCTR2020-001622-64-ES. Outpatient treatment of COVID-19 with early pulmonary corticosteroids as an opportunity to modify the course of the disease. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001622-64 (first received 19 April 2020). Saiz-RodríguezM , PeñaT , LázaroL , GonzálezA , MartínezA , CorderoJA , et al. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: a structured summary of a randomised controlled trial. Trials2020;21(632):1-3. [DOI: 10.1186/s13063-020-04575-w]">EUCTR2020‐001622‐64‐ES</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dra Ana Pueyo Bastida</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis of pulmonary involvement (respiratory symptoms ± pathological auscultation ± O<sub>2</sub> desaturation) + chest X‐ray with mild‐moderate or normal alterations </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0081" title="EUCTR2020-001707-16-ES. Phase III randomised, unicentric open, controlled clinical trial to demonstrate the effectiveness of tocilizumab against systemic corticotherapy in patients entered by COVID-19 with bilateral pneumonia and bad evolution. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001707-16/ES (first received 25 June 2020). ">EUCTR2020‐001707‐16‐ES</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iis Biodonostia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bilateral pneumonia caused by SARS‐CoV‐2 without response to the treatment: defined as persistence of fever (above 37.5 ºC without other focus) and respiratory worsening (more dyspnoea, more cough, oxygen therapy at increasing doses, worsening of the degree of respiratory distress according to the PaO<sub>2</sub>/FiO<sub>2</sub> ratio in categories 'mild, moderate or serious') or absence of improvement with respect to the previous state </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0082" title="BusaniS , TosiM , MighaliP , VandelliP , D'AmicoR , MariettaM , et al. Multi-centre, three arm, randomised controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):724. [DOI: 10.1186/s13063-020-04645-z]EUCTR2020-001921-30. Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomised, three arms study design. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001921-30 (first received 26 June 2020). ">EUCTR2020‐001921‐30</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azienda Ospedaliero‐Universitaria Policlinico di Modena</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive pressure ventilation (either non‐invasive or invasive) from &gt; 24 h, IMV from &lt; 96 h, PaO<sub>2</sub>/FiO<sub>2</sub> ratio &lt; 150 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0083" title="EUCTR2020-003363-25-DK. Higher vs. lower doses of dexamethasone in patients with COVID-19 and severe oxygen deficiency: the COVID STEROID 2 trial. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003363-25 (first received 18 August 2020). ">EUCTR2020‐003363‐25‐DK</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Department of Intensive Care, Rigshospitalet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Denmark)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe, IMV/NIV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone (high dose and low dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0084" title="EUCTR2020-006054-43-IT. Randomised controlled trial to evaluate the efficacy of per-protocol administration of methylprednisolone compared to dexamethasone in SARS-CoV-2 infections requiring respiratory support. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-006054-43-IT (first received 22 March 2021). ">EUCTR2020‐006054‐43‐IT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Università degli Studi di Trieste</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PaO2 ≤ 60 mmHg or SpO2 ≤ 90% or on HFNC, CPAP or NPPV at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0085" title="EUCTR2021-001416-29-ES. High-dose dexamethasone treatment for SARS-COV-2. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2021-001416-29-ES (first received 26 May 2021). ">EUCTR2021‐001416‐29‐ES</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Unive </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With need for oxygen therapy in NG = 1 lpm to maintain saturation = 94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone high‐dose, dexamethasone low‐dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0086" title="EUCTR2021-004021-71. Corticosteroids for loss of smell by COVID-19 infection – COCOS trial. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-004021-71 (first received 12 October 2021). ">EUCTR2021‐004021‐71</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University Medical Center Utrecht</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Netherlands)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recent COVID‐19 infection (&lt; 3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0087" title="IRCT20190606043826N2. Comparison of the effectiveness and complication of dexamethasone at doses of 8 and 24 mg in the treatment of in hospitalised patients with Covid-19. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190606043826N2 (first received 1 July 2021). ">IRCT20190606043826N2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Esfahan University of Medical Sciences</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised patients with COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone high‐dose, dexamethasone low‐dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruitment completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0088" title="NCT04329650. Efficacy and safety of siltuximab vs. corticosteroids in hospitalised patients with COVID19 pneumonia. clinicaltrials.gov/show/NCT04329650 (first received 1 April 2020). ">NCT04329650</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Judit Pich Martínez, Fundacion Clinic per a la Recerca Biomédica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐critical patient with pneumonia in radiological progression and/or patient with progressive respiratory failure in the last 24 to 48 h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0089" title="NCT04344730. Dexamethasone and oxygen support strategies in ICU patients with COVID-19 pneumonia. clinicaltrials.gov/show/NCT04344730 (first received 14 April 2020). ">NCT04344730</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assistance Publique ‐ Hôpitaux de Paris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted to ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Actual enrolment 550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0090" title="NCT04345445. Study to evaluate the efficacy and safety of tocilizumab versus corticosteroids in hospitalised COVID-19 patients with high risk of progression. clinicaltrials.gov/show/NCT04345445 (first received 14 April 2020). ">NCT04345445</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Malaya</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Malaysia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: receipt of mechanical ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0091" title="NCT04377503. Tocilizumab versus methylprednisolone in the cytokine release syndrome of patients with COVID-19. clinicaltrials.gov/show/NCT04377503 (first received 6 May 2020). ">NCT04377503</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital Sao Domingos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Brazil)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COVID diagnosis confirmed by real time PCR, PaO<sub>2</sub>/FIO<sub>2</sub> &lt; 200, laboratory: high sensitivity CRP &gt; 5 mg/L; LDH &gt; 245 U/L; ferritin &gt; 300; D‐dimer &gt; 1500; interleukin‐6 &gt; 7.0 pg/mL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0092" title="NCT04452565. NA-831, atazanavir and dexamethasone in the treatment of SARSCov-2 infection (NATADEX). clinicaltrials.gov/show/NCT04452565 (first received 30 June 2020). ">NCT04452565</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NeuroActiva, Inc.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(USA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: IMV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0093" title="NCT04499313. Dexamethasone versus methylprednisolone for the treatment of patients with ARDS caused by COVID-19. clinicaltrials.gov/show/NCT04499313 (first received 5 August 2020). ">NCT04499313</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chattogram General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Bangladesh)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe COVID‐19 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0094" title="MunchMW , GranholmA , MyatraSN , VijayaraghavanBK , CronhjortM , WahlinRR , et al. Higher vs. lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica2021;00:1-12. [DOI: 10.1111/aas.13795]NCT04509973. Higher vs. lower doses of dexamethasone for COVID-19 and severe hypoxia. clinicaltrials.gov/show/NCT04509973 (first received 12 August 2020). ">NCT04509973</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scandinavian Critical Care Trials Group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Denmark)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMV OR NIV or continuous use of CPAP for hypoxia OR oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active, not recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0095" title="NCT04513184. Randomised clinical trial of nasal dexamethasone as an adjuvant in patients with COVID-19. clinicaltrials.gov/show/NCT04513184 (first received 14 August 2020). ">NCT04513184</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Edda Sciutto Conde</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Mexico)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised patients with moderate to severe respiratory complications that have not received mechanical ventilation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV vs nasal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0096" title="NCT04528329. Anosmia and / or ageusia and early corticosteroid use. clinicaltrials.gov/show/NCT04528329 (first received 27 August 2020). ">NCT04528329</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ClinAmygate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Egypt)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0097" title="NCT04528888. Steroids and unfractionated heparin in critically ill patients with pneumonia from COVID-19 infection. clinicaltrials.gov/show/NCT04528888 (first received 27 August 2020). [EUDRA-CT: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001921-30/IT] [NCT: https://clinicaltrials.gov/ct2/show/study/NCT04528888]">NCT04528888</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Massimo Girardis, University of Modena and Reggio Emilia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included: positive pressure ventilation (IMV/NIV) for &gt; 24 h, IMV from &lt; 96 h, PaO2/FiO2 ratio &lt; 150 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0098" title="NCT04545242. Efficacy of dexamethasone in patients with acute hypoxemic respiratory failure caused by infections. clinicaltrials.gov/show/NCT04545242 (first received 10 September 2020). ">NCT04545242</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dr. Negrin University Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intubated and mechanically ventilated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0099" title="NCT04636671. Methylprednisolone vs. dexamethasone in COVID-19 pneumonia (MEDEAS RCT). clinicaltrials.gov/show/NCT04636671 (first received 19 November 2020). ">NCT04636671</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Trieste</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: on IMV</p> <p>Included: PaO<sub>2</sub> ≤ 60 mmHg or SpO<sub>2</sub> ≤ 90% or on HFNC, CPAP or NPPV at randomisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0100" title="NCT04663555. Effect of two different doses of dexamethasone in patients with ARDS and COVID-19. clinicaltrials.gov/show/NCT04663555 (first received 11 December 2020). ">NCT04663555</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brno University Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Czech Republic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intubation/mechanical ventilation or ongoing HFNC oxygen therapy; admission to ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0101" title="NCT04673162. Evaluation of the efficacy of high doses of methylprednisolone in SARS-CoV2 (COVID-19) pneumonia patients. clinicaltrials.gov/show/NCT04673162 (first received 17 December 2020). ">NCT04673162</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azienda Unità Sanitaria Locale Reggio Emilia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for supplemental oxygen in any delivery mode with the exception of IMV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0102" title="NCT04707534. Dexamethasone for COVID-19. clinicaltrials.gov/show/NCT04707534 (first received 13 January 2021). ">NCT04707534</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Oklahoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(USA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive pressure ventilation (non‐invasive or invasive) or HFNC or need supplemental oxygen with oxygen mask or nasal cannula </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0103" title="NCT04765371. Comparison between prednisolone and dexamethasone on mortality in patients on oxygen therapy, with COVID-19. clinicaltrials.gov/ct2/show/NCT04765371 (first received 21 February 2021). ">NCT04765371</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Centre Hospitalier René Dubos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient with SpaO<sub>2</sub> ≤ 94 % in room air (90% for patient with respiratory failure) and requiring an oxygen therapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0104" title="NCT04780581. Glucocorticoid therapy in coronavirus disease COVID-19 patients. clinicaltrials.gov/show/NCT04780581 (first received 3 March 2021). ">NCT04780581</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requires supplementary oxygen due to basal saturation ≤ 93% (with ambient O<sub>2</sub>, 21%), excluded if IMV, NIV, HFNC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone, methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0105" title="NCT04795583. Corticosteroids for COVID-19. clinicaltrials.gov/show/NCT04795583 (first received 12 March 2021). ">NCT04795583</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Alberta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Colombia, Mexico)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ambulatory, confirmed SARS‐CoV‐2. Clinical symptoms compatible with COVID‐19 for ≤ 14 days before randomisation. Oxygen saturation ≥ 95% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0106" title="NCT04834375. Randomised open investigation determining steroid dose. clinicaltrials.gov/show/NCT04834375 (first received 8 April 2021). ">NCT04834375</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Northwell Health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (USA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypoxaemia defined by an oxygen saturation &lt; 94% or the need for supplemental oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0107" title="NCT04836780. Dexamethasone early administration in hospitalised patients with COVID-19 pneumonia. clinicaltrials.gov/show/NCT04836780 (first received 8 April 2021). ">NCT04836780</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital Universitario Infanta Leonor<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peripheral capillary oxygen saturation (SpO<sub>2</sub>) ≥ 94% and &lt; 22 breaths per minute (bpm) breathing room air. High risk of developing ARDS<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0108" title="NCT04860518. Human intravenous interferon beta-Ia safety and preliminary efficacy in hospitalised subjects with coronavirus (HIBISCUS). https://clinicaltrials.gov/ct2/show/NCT04860518 (first received 22 April 2021). ">NCT04860518</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faron Pharmaceuticals Ltd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (USA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted to hospital with respiratory symptoms of COVID‐19 requiring hospital care and oxygen supplementation (≤ 8L/min) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone and human intravenous interferon beta‐Ia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0109" title="TCTR20211017001. A comparative study of the effectiveness between pulse regimen methylprednisolone versus high dose dexamethasone as the initial treatment of moderate Covid-19 pneumonia: an open-label randomised controlled trial. http://www.thaiclinicaltrials.org/show/TCTR20211017001 (first received 17 October 2021). ">TCTR20211017001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faculty of Medicine Ramathibodi Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Thailand)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resting oxygen saturation between 90% and 94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not yet recruiting</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>ARDS:</b> acute respiratory distress syndrome; <b>CPAP:</b> continuous positive airway pressure; <b>CRP:</b> c‐reactive protein; <b>FiO2:</b> fraction of inspired oxygen; <b>HFNC:</b> high‐flow nasal cannula; <b>ICU:</b> intensive care unit; <b>IMV:</b> invasive mechanical ventilation; <b>IV:</b> intravenous; <b>LDH:</b> lactic dehydrogenase; <b>NIV:</b> non‐invasive ventilation; <b>NPPV:</b> non‐invasive positive pressure ventilation; <b>PaO2:</b> partial pressure oxygen; <b>PCR:</b> polymerase chain reaction <b>RCT:</b> randomised; controlled trial; <b>RT‐PCR:</b> reverse transcription polymerase chain reaction; <b>SpO2:</b> blood oxygen saturation </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Characteristics of ongoing studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014963-tbl-0010"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Characteristics of studies awaiting classification</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sponsor/developer</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Place of residence (</b><a href="./references#CD014963-bbs2-0211" title="World Bank Country and Lending Groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed 15 April 2021). [WEBSITE: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups]"><b>World Bank 2021</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population/disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Route of administration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0046" title="EUCTR2020-001333-13-FR. Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19: a randomised controlled trial. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001333-13 (first received 9 April 2020). ">EUCTR2020‐001333‐13‐FR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Groupe Hospitalier Paris Saint‐Joseph</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included: patient diagnosed COVID positive by RT‐PCR and/or scanner (patients admitted with already mechanical ventilation and sedation, or with acute respiratory failure evolving very quickly) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prematurely ended<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0045" title="EUCTR2020-001307-16-ES. Efficacy and safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to coronavirus infection. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001307-16 (first received 1 April 2020). ">EUCTR2020‐001307‐16‐ES</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundación para la Investigación Biomédica Hospital Ramón y Cajal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prematurely ended</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0047" title="EUCTR2020-001553-48-FR. Corticoids in COVID-19 viral pneumonia in infection with SARS-CoV-2 (translation by the review authors) [Corticoides au cours de la pneumonie virale COVID-19 liee a linfection par le SARS-CoV-2]. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001553-48 (first received 13 April 2020). ">EUCTR2020‐001553‐48‐FR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospices Civils de Lyon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country</p> <p>(France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peripheral saturation by pulse oximeter SpO<sub>2</sub> ≤ 94% in ambient air measured twice at 5‐ to 15‐min intervals, or PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prematurely ended</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0052" title="IRCT20081027001411N3. Effect of prednisolone on treatment of COVID-19. irct.ir/trial/46975 (first received 6 January 2020). ">IRCT20081027001411N3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Teheran University of Medical Sciences<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood oxygen saturation &lt; 93%; with ARDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0053" title="IRCT20120215009014N354. Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19. irct.ir/trial/48043 (first received 12 May 2020). ">IRCT20120215009014N354</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hamedan University of Medical Sciences<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised in ICU, bilateral pulmonary infiltration in chest X‐ray or CT‐scan; respiratory distress with &gt; 24 breaths per minute<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydrocortisone, methylprednisolone, dexamethasone<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0054" title="IRCT20160118026097N4. The effect of dexamethasone in the treatment of high-risk COVID-19 patients. irct.ir/trial/48310 (first received 13 September 2020). ">IRCT20160118026097N4</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ghoum University of Medical Sciences<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypoxia requires supplemental oxygen to maintain oxygen saturation &gt; 90%<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0055" title="IRCT20200611047727N3. Evaluation of efficacy and safety of low dose corticosteroid with severe pneumonia COVID-19. irct.ir/trial/49116 (first received 3 January 2021). ">IRCT20200611047727N3</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Shahid Beheshti University of Medical Sciences<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen saturation level &lt; 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0056" title="IRCT20201015049030N1. Effect of dexamethasone on treatment of COVID-19. www.irct.ir/trial/51736 (first received 7 November 2020). ">IRCT20201015049030N1</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Teheran University of Medical Sciences<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood oxygen saturation between 90% and 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0057" title="ISRCTN33037282. Comparing two medications (dexamethasone and methylprednisolone high dose) for the treatment of pneumonia in patients with COVID-19. www.isrctn.com/ISRCTN33037282 (first received 26 November 2020). ">ISRCTN33037282</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clínica Medellín ‐ Grupo Quirónsalud</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Colombia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PaO<sub>2</sub> ≤ 60 mmHg or SpO<sub>2</sub> ≤ 90% or on HFNC, CPAP or NPPV at randomisation </p> <p>Excluded: on IMV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0059" title="NCT04244591. Glucocorticoid therapy for novel coronavirus critically ill patients with severe acute respiratory failure. www.clinicaltrials.gov/ct2/show/NCT04244591 (first received 28 January 2020). ">NCT04244591</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peking Union Medical College Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (China)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 200 mmHg; positive pressure ventilation (non‐invasive or invasive) or HFNC &gt; 45 L/min for &lt; 48 h; requiring ICU admission </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0060" title="NCT04325061. Efficacy of dexamethasone treatment for patients with ARDS caused by COVID-19. clinicaltrials.gov/ct2/show/NCT04325061 (first received 27 March 2020). ">NCT04325061</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dr. Negrin University Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intubated and mechanically ventilated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (lack of enrolment)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0064" title="NCT04530409. Timing of corticosteroids in COVID-19. clinicaltrials.gov/show/NCT04530409 (first received 28 August 2020). ">NCT04530409</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ClinAmygate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Egypt)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild and moderate severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0065" title="NCT04746430. COVID-19 primary care platform for early treatment and recovery (COPPER) study. clinicaltrials.gov/show/NCT04746430 (first received 9 February 2021). ">NCT04746430</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General Practitioners Research Institute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Netherlands)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exercise‐induced desaturation, defined as SpO<sub>2</sub> &lt; 92% (&lt; 90% for COPD patients) and/or an absolute drop of ≥ 4% in SpO<sub>2</sub> after a 1‐min sit‐to‐stand test or SpO<sub>2</sub> &lt; 92% (&lt; 90% for COPD patients) at rest with GP's and patient's shared decision to keep patient at home despite this in itself being an indication for referral to hospital </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear, most likely systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (too few patients)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0048" title="EUCTR2020-002186-34-ES. Efficacy of the early use of corticotherapy in CoV-2 infection to prevent the progression of acute respiratory distress syndrome (ARDS). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002186-34 (first received 22 July 2020). ">EUCTR2020‐002186‐34‐ES</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundació Hospital Universitari Vall d'Hebron ‐ Institut de Recerca (VHIR)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Air oxygen saturation &gt; 90 and &lt; 94%; PaO<sub>2</sub>/FiO<sub>2</sub> &gt; 200 and ≤ 300 mmHg; Sa:FiO<sub>2</sub> (O<sub>2</sub> saturation measured with pulse oximeter/inspired O<sub>2</sub> fraction) ≤ 350<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prematurely ended</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p><a href="./references#CD014963-bbs2-0049" title="EUCTR2020-004323-16. Evaluation of the efficacy of high doses of methylprednisolone in SARS-CoV2 pneumonia patients. www.clinicaltrialsregister.eu/ctr-search/trial/2020-004323-16/IT (first received 23 November 2020). ">EUCTR2020‐004323‐16</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azienda Ospedaliera Arcispedale Santa Maria Nuova/IRCCS di Reggio Emilia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Italy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for supplemental oxygen in any delivery mode with the exception of IMV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0061" title="NCT04347980. Dexamethasone treatment for severe acute respiratory distress syndrome. clinicaltrials.gov/show/NCT04347980 (first received 15 April 2020). ">NCT04347980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Centre Chirurgical Marie Lannelongue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (France)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admitted to ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (ANSM (Agence nationale de sécurité du médicament et des produits de santé) Recommendation) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0062" title="Les BujandaI , Loureiro-AmigoJ , Capdevila BastonsF , Elejalde GuerraI , Anniccherico SánchezJ , Murgadella-SanchoA , et al. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial. Trials2021;22(1):43. [DOI: 10.1186/s13063-020-04999-4]NCT04438980. Glucocorticoids in COVID-19 (CORTIVID). clinicaltrials.gov/show/NCT04438980 (first received 19 June 2020). ">NCT04438980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fundacion Miguel Servet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Spain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised</p> <p>Excluded: SpO<sub>2</sub> &lt; 90% (in air ambient) or PaO<sub>2</sub> &lt; 60 mmHg (in ambient air) or PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 mmHg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0063" title="NCT04451174. Early use of corticosteroids in hospitalised patients with moderate COVID19 pneumonia. clinicaltrials.gov/show/NCT04451174 (first received 30 June 2020). SalinasM , AndinoP , PalmaL , ValenciaJ , FigueroaE , OrtegaJ . Early use of corticosteroids in non-critical patients with COVID-19 pneumonia (PREDCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2021;22(1):92. [DOI: 10.1186/s13063-021-05046-6.]">NCT04451174</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Chile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐income country (Chile)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded: requirements of mechanical ventilation (IMV/NIV)</p> <p>Included: oxygen requirements until 35 % by Venturi mask or 5 L/min by nasal cannula</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminated (corticosteroid use approval)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0067" title="SalukhovVV , KryukovEV , ChugunovAA , KharitonovMA , RudakovYV , LakhinRE , et al. The role and place of glucocorticosteroids in treatment of COVID-19 pneumonia without hypoxemia [Роль и место глюкокортикостероидов в терапии пневмоний, вызванных COVID-19, без гипоксемии]. Meditsinskiy Sovet = Medical Council2021;16(60):162-72. [DOI: 10.21518/2079- 701X-2021-12-162-172]">Salukhov 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT (unclear randomisation process)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Russia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe course with process prevalence according to computed tomography without hypoxaemia (saturation SpO2 &gt; 93%) with a duration of hyperthermia &gt; 38 °C for 3 days or more and C‐reactive protein levels of 15 to 50 mg/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed and published (but unclear randomisation process)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0051" title="GhaneiM , Solaymani‑DodaranM , QazviniA , Ghazale AH, SetarehdanSA , SaadatSH , et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respiratory Research2021;22(245):1-14. [DOI: 10.1186/s12931-021-01833-6]">Ghanei 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Iran)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen saturation (Spo2) less than 94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed and published (not pre‐registered, no ethics vote named, no patient informed consent) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0050" title="GautamPB , KumarA , KannojiaBL , ChaudharyR . A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease. Asian Journal of Medical Sciences2021;12(12):17-22. [DOI: 10.3126/ajms.v12i12.39294]">Gautam 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (India)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe COVID‐19, oxygen saturation &lt; 93% on room air</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone, dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed and published (not pre‐registered, no ethics vote named, no patient informed consent, no information about randomisation) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0058" title="MontalvanE , CarcamoB , PalacionD , RiveraS , EstevezR , NorwoodD , et al. High-dose vs low-dose dexamethasone in patients with COVID-19 in a tertiary hospital in Western Honduras. Chest2021;160(4):A1117-8. [DOI: 10.1016/j.chest.2021.07.1027]">Montalvan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT (unclear randomisation process)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country</p> <p>(Honduras)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed and abstract published (no registration number, no information about randomisation process), only abstract available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD014963-bbs2-0066" title="NCT04519385. Tocilizumab versus dexamethasone in severe COVID19 cases. clinicaltrials.gov/show/NCT04519385 (first received 19 August 2020). RashadA , MousaS , Nafady‑HegoH , NafadyA , ElgendyH . Short term survival of critically ill COVID‑19 Egyptian patients on assisted ventilation treated by either dexamethasone or tocilizumab. Scientific Reports2021;11(8816):1-7. [DOI: 10.1038/s41598-021-88086-x]">Rashad 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Valley University</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT (unclear randomisation process)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle‐income country (Egypt)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe ≥ 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed and published (no pre‐registration, unclear randomisation process)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>ARDS:</b> acute respiratory distress syndrome; <b>COPD:</b> chronic obstructive pulmonary disease; <b>CT:</b> computed tomography; <b>HFNC:</b> high‐flow nasal cannula;<b>ICU:</b> intensive care unit; <b>RCT:</b> randomised controlled trial; <b>RT‐PCR:</b> reverse transcription polymerase chain reaction. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Characteristics of studies awaiting classification</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014963-tbl-0011"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Sensitivity analyses for the comparison: systemic corticosteroids plus standard care versus standard care (plus/minus placebo)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analyses</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of bias (excluding studies at high risk of bias)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fixed‐effect model or random‐effects model</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Preprint (excluding preprints)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platform trial (excluding platform trials<sup>a</sup>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90, 95% CI 0.84 to 0.97; 9 studies, 7898 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs with high risk of bias concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90, 95% CI 0.83 to 0.97; 9 studies, 7898 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs as a preprint concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94, 95% CI 0.82 to 1.08; 7 studies, 1094 participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 120 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.74, 95% CI 0.23 to 2.34; 3 studies, 485 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs with high risk of bias concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92, 95% CI 0.73 to 1.15; 3 studies, 485 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs as a preprint concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no platform trials concerning this outcome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: discharged alive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07, 95% CI 1.03 to 1.11; 3 studies, 6786 participants<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs with high risk of bias concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.36, 95% CI 0.95 to 1.96; 3 studies, 6786 participants<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs as a preprint concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.65, 95% CI 1.23 to 2.21; 2 studies, 361 participants</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Excluding platform trials: <a href="./references#CD014963-bbs2-0001" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomised embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]AngusDC , DerdeL , Al-BeidhF , AnnaneD , ArabiY , BeaneA , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial. JAMA2020;324(13):1317-29. [DOI: 10.1001/jama.2020.17022] [NCT02735707]">Angus 2020</a>; <a href="./references#CD014963-bbs2-0006" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalised patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.06.22.20137273]HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalised patients with COVID-19. New England Journal of Medicine2021;384(8):693-704. [DOI: 10.1056/NEJMoa2021436] [NCT04381936]Oxford University. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford2020. ">Horby 2021</a>. </p> <p><sup>b</sup>Using the fixed‐effect model. </p> <p><sup>c</sup> Using the random‐effects model. </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Sensitivity analyses for the comparison: systemic corticosteroids plus standard care versus standard care (plus/minus placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014963-tbl-0012"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Sensitivity analyses for the comparison: high‐dose dexamethasone versus low‐dose dexamethasone</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analyses</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of bias (excluding studies at high risk of bias)<sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fixed‐effect model or random‐effects model</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Preprint (excluding preprints)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platform trials (excluding platform trials)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87, 95% CI 0.73 to 1.04; 3 studies, 1269 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs with high risk of bias concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87, 95% CI 0.73 to 1.04; 3 studies, 1269 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs as a preprint concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no platform trials concerning this outcome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality up to 120 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05, 95% CI 0.74 to 1.48; 4 studies, 1399 participants<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.87, 95% CI 0.74 to 1.02; 3 studies, 1266 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.93, 95% CI 0.79 to 1.08; 4 studies, 1399 participants<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no RCTs as a preprint concerning this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no platform trials concerning this outcome</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Using the fixed‐effect model. </p> <p><sup>b</sup>Excluded studies with high risk of bias: <a href="./references#CD014963-bbs2-0016" title="IRCT20100228003449N31. Corticosteroids in COVID-19. irct.ir/trial/51163 (first received 8 October 2020). ToroghiN , AbbasianL , Anahid NourianA , Davoudi-MonfaredE , KhaliliH , HasannezhadM , et al. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial. Pharmacological Reports2021;Version 1:1-12. [DOI: 10.1007/s43440-021-00341-0]">Toroghi 2021</a>. </p> <p><sup>c</sup>Using the random‐effects model. </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Sensitivity analyses for the comparison: high‐dose dexamethasone versus low‐dose dexamethasone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/full#CD014963-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause mortality up to 120 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.23, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Clinical improvement: discharged alive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [1.03, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Clinical worsening: new need for IMV or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.84, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Hospital‐acquired infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Invasive fungal infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Quality of life up to 120 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 New need for dialysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Viral clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Systemic corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: respiratory support for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.81, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 No oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.00, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Low‐flow oxygen only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.50, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 NIV, high‐flow, and low‐flow oxygen combined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3883</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.79, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 NIV or high‐flow oxygen only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.53, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 Invasive ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: respiratory support for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis: dexamethasone versus methylprednisolone versus hydrocortisone for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.83, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.77, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.56, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 All‐cause mortality up to 120 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.23, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.65, 6.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.06, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Clinical improvement: discharged alive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [1.03, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [1.03, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Methylprednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.18, 2.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis: dexamethasone versus methylprednisolone versus hydrocortisone for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analysis: female versus male for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.83, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.80, 0.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analysis: female versus male for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis: &lt; 70 years versus ≥ 70 years for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.71, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 &lt; 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.60, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 ≥ 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.92, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis: &lt; 70 years versus ≥ 70 years for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subgroup analysis: White versus Black, Asian or minority ethnic group versus unknown for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.60, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.87, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 Black, Asian or minority ethnic group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.41, 0.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subgroup analysis: White versus Black, Asian or minority ethnic group versus unknown for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Low‐ and middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 All‐cause mortality up to 120 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.20, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.62 [0.63, 10.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Low‐ and middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.06, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Clinical improvement: discharged alive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [1.03, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.02, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 Low‐ and middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.23, 2.21]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of corticosteroids plus standard care versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Methylprednisolone versus dexamethasone for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Methylprednisolone versus dexamethasone for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 All‐cause mortality up to 120 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Clinical improvement: discharged alive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Hospital‐acquired infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.7 Invasive fungal infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">High‐dose dexamethasone (12 mg/d or higher) versus low‐dose dexamethasone (6 to 8 mg/d) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis: female versus male for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.72, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.65, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.62, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 All‐cause mortality up to 120 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.70, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis: female versus male for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Subgroup analysis: &lt; 70 years versus ≥ 70 years for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 &lt;70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.63, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 ≥ 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.73, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 All‐cause mortality up to 120 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.76, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 &lt;70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.63, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.2 ≥ 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.78, 1.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Subgroup analysis: &lt; 70 years versus ≥ 70 years for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014963-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 All‐cause mortality up to 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 Low‐ and middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.65, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 All‐cause mortality up to 120 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 Low‐ and middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.93, 1.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Subgroup analysis: high‐income countries versus low‐ and middle‐income countries for the comparison of high‐dose dexamethasone (12 mg or higher) versus low‐dose dexamethasone (6 mg to 8mg) for hospitalised individuals with a confirmed diagnosis of symptomatic COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#CD014963-tbl-0024">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Angus 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised to each locally available group using balanced assignment. Participants were randomly assigned via a computer software program to each locally available group using proportional assignment (e.g., 1:1 if 2 groups available and 1:1:1 if 3 groups available) </p> <p>Protocol: The RAR will occur centrally as part of the computerised randomisation process. Sites will receive the allocation status and will not be informed of the randomisation proportions. Each region will maintain its own computer‐based randomisation program that is accessed by sites in that region but the RAR proportions will be determined by a SAC and provided monthly to the administrator of each region's randomisation program who will update the RAR proportions </p> <p>Baseline characteristics were similar across groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>15% of the participants in the no hydrocortisone group received hydrocortisone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for this outcome. 238 participants were randomised and 238 were analysed. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an observer‐reported outcome not involving judgement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and SAP are available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention</p> </td> </tr> <tr class="study-data"> <td> <p>Angus 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised to each locally available group using balanced assignment. Participants were randomly assigned via a computer software program to each locally available group using proportional assignment (e.g., 1:1 if 2 groups available and 1:1:1 if 3 groups available) </p> <p>Protocol: The RAR will occur centrally as part of the computerised randomisation process. Sites will receive the allocation status and will not be informed of the randomisation proportions. Each region will maintain its own computer‐based randomisation program that is accessed by sites in that region but the RAR proportions will be determined by a SAC and provided monthly to the administrator of each region's randomisation program who will update the RAR proportions </p> <p>Baseline characteristics were similar across groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>15% of the participants in the no hydrocortisone group received hydrocortisone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for this outcome. 238 participants were randomised and 238 were analysed. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an observer‐reported outcome not involving judgement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and SAP are available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention</p> </td> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label design (participants and clinicians were aware of the assigned treatment). ITT data presented. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No substantial data missing.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time and the measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was registered in Eudra‐CT as in‐hospital mortality but reported as 28‐day‐mortality in the supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results and missing information about the allocation concealment. </p> </td> </tr> <tr class="study-data"> <td> <p>Dequin 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was centralised and performed electronically. Allocation sequences were generated in a 1:1 ratio by a computer‐generated random number using a blocking schema. There were no baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol: Patients, investigators and care providers will be blinded for the patient‐arm. ITT was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for this outcome.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. 21‐day mortality was a post hoc outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results.</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 participants were randomised and 6425 were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr class="study-data"> <td> <p>Jamaati 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The selected patients were allocated to either the dexamethasone group or the control group by block randomisation. Ten blocks were generated by the Online Randomiser website. </p> <p>Pulmonary disease was highly significantly more prevalent in the control group. Additionally, baseline level of respiratory support was not reported so that we can only assume the most likely circumstance, i.e. that no support beyond oxygen insufflation had been given until randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No deviations mentioned. ITT data reported.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial registered after recruitment stop. No analysis plan published beyond registry entry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Potential bias through probably problematic block randomisation with significant baseline imbalance for pulmonary disease, very delayed registration, and potentially not pre‐specified stop for futility raise some concerns. The issues were not discussed. Potential mild bias towards experimental. </p> </td> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment </p> <p>Control group: 5 excluded before starting treatment, 3 excluded after starting treatment</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>416 participants randomised and 416 participants analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available. Data analysed and presented according to a pre‐specified plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations.</p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals with consecutive open‐label steroids may have affected the outcome, but withdrawals and non‐compliance was rather balanced after all. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with the reported result.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals because of the experimental context lead to some concerns (but it is less than 10% of all patients). </p> </td> </tr> <tr class="study-data"> <td> <p>Tang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was stratified by the statistician of the leading site, who produced computer‐generated block randomisation lists with a block size of 4 patients. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single‐blind design (participants), ITT data presented. No deviations reported.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data collection and end point judgement were blinded, and the statisticians were also blinded during the statistical analysis. The measurements were similar between groups </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>30‐day mortality as pre‐specified in the trial registration was not explicitly reported, but could reliably derive from a synopsis of full text, figures, and supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All domains were rated low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Individuals who assessed the outcomes were not blinded for the assigned treatment. Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns because of protocol deviations</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 All‐cause mortality up to 120 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Edalatifard 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information about the allocation concealment.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6 patients in the control group received the intervention drug and were excluded from the analyses (17%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data were requested from the authors because the follow‐up time was not clearly visible from the publication. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Neither the protocol nor the SAP were available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to the randomisation process, protocol deviations and the selection of the reported results. </p> </td> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment </p> <p>Control group: 5 excluded before starting treatment, 3 excluded after starting treatment</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>416 participants randomised and 416 participants analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available. Outcome was not pre‐specified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations and selective reporting.</p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals with consecutive open‐label steroids may have affected the outcome, but withdrawals and non‐compliance was rather balanced after all. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with the reported result.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals because of the experimental context lead to some concerns (below 10% of all patients). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 All‐cause mortality up to 120 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Clinical improvement: discharged alive</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Edalatifard 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information about the allocation concealment.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>In this study, patients did not know which group of them used medicine</p> <p>Physicians and clinicians team know about the medicine and intervention groups.</p> <p>6 patients in the control group received the intervention drug and were excluded from the analyses </p> <p>Intention‐to‐treat</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomised</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the treatment assignments. Knowledge of intervention received could have affected ascertainment only in patients who had not died. So the influence of the unblinded assessor is limited but existing ‐ therefore deviation between algorithm and judgement.No protocol or SAP available. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Neither the protocol nor the SAP were available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to missing information about the allocation concealment, deviations from the intended interventions, measurement of the outcome and selection of the reported result </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomised</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the treatment assignments. Knowledge of intervention received could have affected ascertainment only in patients who had not died. So the influence of the unblinded assessor is limited but existing ‐ therefore deviation between algorithm and judgement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issue with selective reporting</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to the randomisation process, protocol deviations and limited bias in measurement. </p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomised</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the treatment assignments. Knowledge of intervention received could have affected ascertainment only in patients who had not died. So the influence of the unblinded assessor is limited but existing ‐ therefore deviation between algorithm and judgement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall rated some concerns due to protocol deviations and measurement of the outcome.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Clinical improvement: discharged alive</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Clinical worsening: new need for IMV or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Angus 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised to each locally available group using balanced assignment. Participants were randomly assigned via a computer software program to each locally available group using proportional assignment (e.g., 1:1 if 2 groups available and 1:1:1 if 3 groups available) </p> <p>Protocol: The RAR will occur centrally as part of the computerised randomisation process. Sites will receive the allocation status and will not be informed of the randomisation proportions. Each region will maintain its own computer‐based randomisation program that is accessed by sites in that region but the RAR proportions will be determined by a SAC and provided monthly to the administrator of each region's randomisation program who will update the RAR proportions </p> <p>Baseline characteristics were similar across groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and clinicians were aware of the assigned treatment. Furthermore, 15% of the participants in the no hydrocortisone group received hydrocortisone, and although we deem it rather unlikely that a larger part of these deviations arose from the experimental context, we see some concerns. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the data were available for all participants, we arrive at the following assessment of domain 3: Low </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Assessment of new need for IMV is partly subjective, but we deem it unlikely that large efforts were made or feasible to treat one arm different from another. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Because the data were analysed in accordance with a pre‐specified analysis plan we judged this domain low. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns because of some degree of deviations and some concerns arising from assessment of the outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Angus 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised to each locally available group using balanced assignment. Participants were randomly assigned via a computer software program to each locally available group using proportional assignment (e.g., 1:1 if 2 groups available and 1:1:1 if 3 groups available) </p> <p>Protocol: The RAR will occur centrally as part of the computerised randomisation process. Sites will receive the allocation status and will not be informed of the randomisation proportions. Each region will maintain its own computer‐based randomisation program that is accessed by sites in that region but the RAR proportions will be determined by a SAC and provided monthly to the administrator of each region's randomisation program who will update the RAR proportions </p> <p>Baseline characteristics were similar across groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and clinicians were aware of the assigned treatment. Furthermore, 15% of the participants in the no hydrocortisone group received hydrocortisone, and although we deem it rather unlikely that a larger part of these deviations arose from the experimental context, we see some concerns. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since the data were available for all participants, we arrive at the following assessment of domain 3: Low </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Assessment of new need for IMV is partly subjective, but we deem it unlikely that large efforts were made or feasible to treat one arm different from another. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Because the data were analysed in accordance with a pre‐specified analysis plan we judged this domain low. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns because of some degree of deviations and some concerns arising from assessment of the outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Because data is available for all participants we judged this domain low.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the treatment assignments. Knowledge of intervention received could have affected ascertainment only in patients who had not died. So the influence of the unblinded assessor is limited but existing ‐ therefore deviation between algorithm and judgement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The analysis for this result was prespecified in the protocol</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group and limited bias in measurement. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Clinical worsening: new need for IMV or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Angus 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised to each locally available group using balanced assignment. Participants were randomly assigned via a computer software program to each locally available group using proportional assignment (e.g., 1:1 if 2 groups available and 1:1:1 if 3 groups available) </p> <p>Protocol: The RAR will occur centrally as part of the computerised randomisation process. Sites will receive the allocation status and will not be informed of the randomisation proportions. Each region will maintain its own computer‐based randomisation program that is accessed by sites in that region but the RAR proportions will be determined by a SAC and provided monthly to the administrator of each region's randomisation program who will update the RAR proportions </p> <p>Baseline characteristics were similar across groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and clinicians were aware of the assigned treatment. Further 15% of the participants in the no hydrocortisone group received hydrocortisone, and although we deem it rather unlikely that a larger part of these deviations arose from the experimental context, we see some concerns. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since data were not adjusted for competing risk of death in the presence of a relevant death rate, risk of bias is high. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement method was appropriate.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and SAP available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Because of the issue of competing risk of death all data for this outcome might not be available. There was no adjustment in the analysis for competing risk of death. </p> </td> </tr> <tr class="study-data"> <td> <p>Angus 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised to each locally available group using balanced assignment. Participants were randomly assigned via a computer software program to each locally available group using proportional assignment (e.g., 1:1 if 2 groups available and 1:1:1 if 3 groups available) </p> <p>Protocol: The RAR will occur centrally as part of the computerised randomisation process. Sites will receive the allocation status and will not be informed of the randomisation proportions. Each region will maintain its own computer‐based randomisation program that is accessed by sites in that region but the RAR proportions will be determined by a SAC and provided monthly to the administrator of each region's randomisation program who will update the RAR proportions </p> <p>Baseline characteristics were similar across groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and clinicians were aware of the assigned treatment. Further 15% of the participants in the no hydrocortisone group received hydrocortisone, and although we deem it rather unlikely that a larger part of these deviations arose from the experimental context, we see some concerns. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Since data were not adjusted for competing risk of death in the presence of a relevant death rate, risk of bias is high. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement method was appropriate.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and SAP available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Because of the issue of competing risk of death all data for this outcome might not be available. There was no adjustment in the analysis for competing risk of death. </p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Occurrence of non‐terminal events can be precluded by death as a competing risk. Without adjustment this leads to high risk of bias, so overall we judged high risk of bias. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Edalatifard 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information about the allocation concealment.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6 patients in the control group received the intervention drug and were excluded from the analyses (17%) </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6 patients in the control group were not included in the analysis because of deviations from the protocol (17%) </p> <p>Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Neither the protocol nor statistical analysis plan were available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged high because 6 patients in the control group received the intervention drug and were excluded from the analyses. Moreover, occurrence of non‐terminal events can be precluded by death as a competing risk. Without adjustment this leads to high risk of bias. </p> </td> </tr> <tr class="study-data"> <td> <p>Tang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was stratified by the statistician of the leading site, who produced computer‐generated block randomisation lists with a block size of 4 patients. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>ITT presented. The participants were blinded, and the physicians were aware of the treatment assignment. No protocol deviations. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Endpoint including its subitems were not named in NCT registration.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Occurrence of non‐terminal events can be precluded by death as a competing risk. Without adjustment this leads to high risk of bias, so overall we judged high risk of bias. </p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Occurrence of non‐terminal events can be precluded by death as a competing risk. Without adjustment this leads to high risk of bias, so overall we judged high risk of bias. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Hospital‐acquired infections</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No deviations from the protocol.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We request data from the authors. Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Endpoint and definition is not pre‐specified in Eudra‐CT registration.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Occurrence of non‐terminal events can be precluded by death as a competing risk. Without adjustment this leads to high risk of bias, so overall we judged high risk of bias. </p> </td> </tr> <tr class="study-data"> <td> <p>Dequin 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was centralised and performed electronically. Allocation sequences were generated in a 1:1 ratio by a computer‐generated random number using a blocking schema. There were no baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol: Patients, investigators and care providers will be blinded for the patient‐arm</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Occurrence of non‐terminal events can be precluded by death as a competing risk. Without adjustment this leads to high risk of bias, so overall we judged high risk of bias. </p> </td> </tr> <tr class="study-data"> <td> <p>Tang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was stratified by the statistician of the leading site, who produced computer‐generated block randomisation lists with a block size of 4 patients. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single‐blind design, ITT data presented. No deviations reported.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Endpoint was not named in NCT registration.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Occurrence of non‐terminal events can be precluded by death as a competing risk. Without adjustment this leads to high risk of bias, so overall we judged high risk of bias. </p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Occurrence of non‐terminal events can be precluded by death as a competing risk. Without adjustment this leads to high risk of bias, so overall we judged high risk of bias. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Hospital‐acquired infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Invasive fungal infections</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and clinicians were aware of the assigned treatment. The intention‐to‐treat‐analysis was used to estimate the effect of the assignment to intervention. All this leads us to the following judgement for domain 2: Low. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Because of the issue of competing risk of death all data for this outcome might not be available. There was no adjustment in the analysis for competing risk of death. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged some concerns as the outcome was not pre‐specified but requested from the authors. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall we judged risk of bias to be high mainly because of missing adjustment for competing risk of death in domain 3. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Invasive fungal infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 Quality of life up to 120 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment; Control group: 5 excluded before starting treatment, 3 excluded after starting treatment </p> <p>As the study is meant to detect a positive effect of corticosteroids, participants in the control group receiving the experimental medication lead to expected bias towards null. Hence, we only see a slight tendency of under‐estimating the effect, but there is no increase in the risk to mistakenly introduce a medication for its beneficial effect. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Because of the issue of competing risk of death all data for this outcome might not be available. There was no adjustment in the analysis for competing risk of death. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged this domain low because the measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was presented on a single scale and with one analysis only, but was not prespecified which leads to some concerns. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall we see high risk bias due to missing adjustment for competing risks</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 Quality of life up to 120 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 New need for dialysis</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Occurrence of non‐terminal events can be precluded by death as a competing risk. Without adjustment this leads to high risk of bias, so overall we judged high risk of bias. </p> </td> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment; Control group: 5 excluded before starting treatment, 3 excluded after starting treatment </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available. Data analysed and presented according to a pre‐specified plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged high due to missing outcome data.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 New need for dialysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Viral clearance</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment; Control group: 5 excluded before starting treatment, 3 excluded after starting treatment </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unknown amount of missing data because of competing risk, and no analysis to adjust for this was made. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available. Data analysed and presented according to a pre‐specified plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged high due to missing outcome data.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Viral clearance</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-12"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.1 No oxygen</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 randomised, 6425 analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.2 Low‐flow oxygen only</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol deviations. ITT data presented.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested the data from the authors, as the data was not broken down by our subgroups of interest in the publication </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was registered in Eudra‐CT as in‐hospital mortality but reported as 28‐day‐mortality in the supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results.</p> </td> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment </p> <p>Control group: 5 excluded before starting treatment, 3 excluded after starting treatment</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>416 participants randomised and 416 participants analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available. Data analysed and presented according to a pre‐specified plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.3 NIV, high‐flow, and low‐flow oxygen combined</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 randomised, 6425 analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.4 NIV or high‐flow oxygen only</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol deviations. ITT data presented.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested the data from the authors, as the data was not broken down by our subgroups of interest in the publication </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was registered in Eudra‐CT as in‐hospital mortality but reported as 28‐day‐mortality in the supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results.</p> </td> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment </p> <p>Control group: 5 excluded before starting treatment, 3 excluded after starting treatment</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>416 participants randomised and 416 participants analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available. Data analysed and presented according to a pre‐specified plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.5 Invasive ventilation</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 randomised, 6425 analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment </p> <p>Control group: 5 excluded before starting treatment, 3 excluded after starting treatment</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>416 participants randomised and 416 participants analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available. Data analysed and presented according to a pre‐specified plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations.</p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns because of protocol deviations.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-12">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-13"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.1 Dexamethasone</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 randomised, 6425 analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations.</p> </td> </tr> <tr class="study-data"> <td> <p>Jamaati 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The selected patients were allocated to either the dexamethasone group or the control group by block randomisation. Ten blocks were generated by the Online Randomiser website. </p> <p>Pulmonary disease was highly significantly more prevalent in the control group. Additionally, baseline level of respiratory support was not reported so that we can only assume the most likely circumstance, i.e. that no support beyond oxygen insufflation had been given until randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No deviations mentioned. ITT data reported.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial registered after recruitment stop. No analysis plan published beyond registry entry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selective reporting and baseline differences.</p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.2 Methylprednisolone</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label study. ITT data presented.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No substantial data missing.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Endpoint was registered in Eudra‐CT as in‐hospital mortality but reported as 28d‐mortality in the supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selective reporting.</p> </td> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment </p> <p>Control group: 5 excluded before starting treatment, 3 excluded after starting treatment</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>416 participants randomised and 416 participants analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available. Data analysed and presented according to a pre‐specified plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations.</p> </td> </tr> <tr class="study-data"> <td> <p>Tang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was stratified by the statistician of the leading site, who produced computer‐generated block randomisation lists with a block size of 4 patients. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>ITT data presented. No deviations reported.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>30‐day mortality as pre‐specified in the trial registration could was not explicitly reported, but could reliably derive from a synopsis of full text, figures, and supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All domains were rated low.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.3 Hydrocortisone</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Angus 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised to each locally available group using balanced assignment. Participants were randomly assigned via a computer software program to each locally available group using proportional assignment (e.g., 1:1 if 2 groups available and 1:1:1 if 3 groups available) </p> <p>Protocol: The RAR will occur centrally as part of the computerised randomisation process. Sites will receive the allocation status and will not be informed of the randomisation proportions. Each region will maintain its own computer‐based randomisation program that is accessed by sites in that region but the RAR proportions will be determined by a SAC and provided monthly to the administrator of each region's randomisation program who will update the RAR proportions </p> <p>Baseline characteristics were similar across groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>15% of the participants in the no hydrocortisone group received corticosteroids</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an observer‐reported outcome not involving judgement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and SAP available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations</p> </td> </tr> <tr class="study-data"> <td> <p>Angus 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised to each locally available group using balanced assignment. Participants were randomly assigned via a computer software program to each locally available group using proportional assignment (e.g., 1:1 if 2 groups available and 1:1:1 if 3 groups available) </p> <p>Protocol: The RAR will occur centrally as part of the computerised randomisation process. Sites will receive the allocation status and will not be informed of the randomisation proportions. Each region will maintain its own computer‐based randomisation program that is accessed by sites in that region but the RAR proportions will be determined by a SAC and provided monthly to the administrator of each region's randomisation program who will update the RAR proportions </p> <p>Baseline characteristics were similar across groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>15% of the participants in the no hydrocortisone group received corticosteroids</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an observer‐reported outcome not involving judgement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and SAP available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations</p> </td> </tr> <tr class="study-data"> <td> <p>Dequin 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was centralised and performed electronically. Allocation sequences were generated in a 1:1 ratio by a computer‐generated random number using a blocking schema. There were no baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol: Patients, investigators and care providers will be blinded for the patient‐arm</p> <p>ITT was used</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. 21‐day mortality was a post hoc outcome </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selective reporting.</p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals with consecutive open‐label steroids may have affected the outcome, but withdrawals and non‐compliance was rather balanced after all. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with the reported result.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals because of the experimental context lead to some concerns (below 10% of all patients). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-13">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-14"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 All‐cause mortality up to 120 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.2.1 Hydrocortisone</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals with consecutive open‐label steroids may have affected the outcome, but withdrawals and non‐compliance was rather balanced after all. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with the reported result.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals because of the experimental context lead to some concerns (below 10% of all patients). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.2.2 Methylprednisolone</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Edalatifard 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information about the allocation concealment.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6 patients in the control group received the intervention drug and were excluded from the analyses (17%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data were requested from the authors because the follow‐up time was not clearly visible from the publication. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Neither the protocol nor the SAP were available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to the randomisation process, protocol deviations and the selection of the reported results. </p> </td> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment ; Control group: 5 excluded before starting treatment, 3 excluded after starting treatment </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data is available for all participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups,</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specification of the outcome in the protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall we judged some concern due to protocol deviations and selective reporting</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 All‐cause mortality up to 120 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-14">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-15"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Clinical improvement: discharged alive</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.3.1 Dexamethasone</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the treatment assignments. Knowledge of intervention received could have affected ascertainment only in patients who had not died. So the influence of the unblinded assessor is limited but existing ‐ therefore deviation between algorithm and judgement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issue with selective reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to the randomisation process, protocol deviations and limited bias in measurement. </p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomised</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the treatment assignments. Knowledge of intervention received could have affected ascertainment only in patients who had not died. So the influence of the unblinded assessor is limited but existing ‐ therefore deviation between algorithm and judgement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall rated some concerns due to protocol deviations and measurement of the outcome.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.3.2 Methylprednisolone</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Edalatifard 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information about the allocation concealment.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>In this study, patients did not know which group of them used medicine</p> <p>Physicians and clinicians team know about the medicine and intervention groups.</p> <p>6 patients in the control group received the intervention drug and were excluded from the analyses </p> <p>Intention‐to‐treat</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomised</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the treatment assignments. Knowledge of intervention received could have affected ascertainment only in patients who had not died. So the influence of the unblinded assessor is limited but existing ‐ therefore deviation between algorithm and judgement.No protocol or SAP available. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Neither the protocol nor the SAP were available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to missing information about the allocation concealment, deviations from the intended interventions, measurement of the outcome and selection of the reported result </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Clinical improvement: discharged alive</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-15">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-16"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 4.1.1 Female</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label design (participants and clinicians were aware of the assigned treatment). ITT data presented. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No substantial data missing.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time and the measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was registered in Eudra‐CT as in‐hospital mortality but reported as 28‐day‐mortality in the supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results and missing information about the allocation concealment. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 participants were randomised and 6425 were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data. We requested the data from the authors.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Individuals who assessed the outcomes were not blinded for the assigned treatment. Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns because of protocol deviations</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 4.1.2 Male</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label design (participants and clinicians were aware of the assigned treatment). ITT data presented. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No substantial data missing.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time and the measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was registered in Eudra‐CT as in‐hospital mortality but reported as 28‐day‐mortality in the supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results and missing information about the allocation concealment. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 participants were randomised and 6425 were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data. We requested the data from the authors.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Individuals who assessed the outcomes were not blinded for the assigned treatment. Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns because of protocol deviations</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-16">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-17"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 5.1.1 &lt; 70 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label design (participants and clinicians were aware of the assigned treatment). ITT data presented. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. No substantial data missing.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time and the measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was registered in Eudra‐CT as in‐hospital mortality but reported as 28‐day‐mortality in the supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results and missing information about the allocation concealment. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 participants were randomised and 6425 were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data. We requested the data from the authors.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Individuals who assessed the outcomes were not blinded for the assigned treatment. Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns because of protocol deviations</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 5.1.2 ≥ 70 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label design (participants and clinicians were aware of the assigned treatment). ITT data presented. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. No substantial data missing.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time and the measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was registered in Eudra‐CT as in‐hospital mortality but reported as 28‐day‐mortality in the supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results and missing information about the allocation concealment. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 participants were randomised and 6425 were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data. We requested the data from the authors.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Individuals who assessed the outcomes were not blinded for the assigned treatment. Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns because of protocol deviations</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-17">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-18"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 6.1.1 White</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label design (participants and clinicians were aware of the assigned treatment). ITT data presented. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No substantial data missing.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time and the measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was registered in Eudra‐CT as in‐hospital mortality but reported as 28‐day‐mortality in the supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results and missing information about the allocation concealment. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 participants were randomised and 6425 were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 6.1.2 Black, Asian or minority ethnic group</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 participants were randomised and 6425 were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 6.1.3 Unknown</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 participants were randomised and 6425 were analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both groups were measured at the same time. The measurements were similar between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-18">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-19"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.1.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Angus 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised to each locally available group using balanced assignment. Participants were randomly assigned via a computer software program to each locally available group using proportional assignment (e.g., 1:1 if 2 groups available and 1:1:1 if 3 groups available) </p> <p>Protocol: The RAR will occur centrally as part of the computerised randomisation process. Sites will receive the allocation status and will not be informed of the randomisation proportions. Each region will maintain its own computer‐based randomisation program that is accessed by sites in that region but the RAR proportions will be determined by a SAC and provided monthly to the administrator of each region's randomisation program who will update the RAR proportions </p> <p>Baseline characteristics were similar across groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>15% of the participants in the no hydrocortisone group received hydrocortisone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for this outcome. 238 participants were randomised and 238 were analysed. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an observer‐reported outcome not involving judgement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and SAP are available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention</p> </td> </tr> <tr class="study-data"> <td> <p>Angus 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised to each locally available group using balanced assignment. Participants were randomly assigned via a computer software program to each locally available group using proportional assignment (e.g., 1:1 if 2 groups available and 1:1:1 if 3 groups available) </p> <p>Protocol: The RAR will occur centrally as part of the computerised randomisation process. Sites will receive the allocation status and will not be informed of the randomisation proportions. Each region will maintain its own computer‐based randomisation program that is accessed by sites in that region but the RAR proportions will be determined by a SAC and provided monthly to the administrator of each region's randomisation program who will update the RAR proportions </p> <p>Baseline characteristics were similar across groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>15% of the participants in the no hydrocortisone group received hydrocortisone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for this outcome. 238 participants were randomised and 238 were analysed. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an observer‐reported outcome not involving judgement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and SAP are available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention</p> </td> </tr> <tr class="study-data"> <td> <p>Corral‐Gudino 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the domain some concerns due to missing information about the allocation concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol deviations. ITT data presented.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested the data from the authors, as the data was not broken down by our subgroups of interest in the publication </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was registered in Eudra‐CT as in‐hospital mortality but reported as 28‐day‐mortality in the supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results.</p> </td> </tr> <tr class="study-data"> <td> <p>Dequin 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was centralised and performed electronically. Allocation sequences were generated in a 1:1 ratio by a computer‐generated random number using a blocking schema. There were no baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol: Patients, investigators and care providers will be blinded for the patient‐arm. ITT was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for this outcome.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. 21‐day mortality was a post hoc outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selection of reported results.</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6425 randomised, 6425 analysed</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to deviations from the intended intervention in the control group. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals with consecutive open‐label steroids may have affected the outcome, but withdrawals and non‐compliance was rather balanced after all. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with the reported result.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals because of the experimental context lead to some concerns (but it is less than 10% of all patients). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.1.2 Low‐ and middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Jamaati 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The selected patients were allocated to either the dexamethasone group or the control group by block randomisation. Ten blocks were generated by the Online Randomiser website. </p> <p>Pulmonary disease was highly significantly more prevalent in the control group. Additionally, baseline level of respiratory support was not reported so that we can only assume the most likely circumstance, i.e. that no support beyond oxygen insufflation had been given until randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No deviations mentioned. ITT data reported.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial registered after recruitment stop. No analysis plan published beyond registry entry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Potential bias through probably problematic block randomisation with significant baseline imbalance for pulmonary disease, very delayed registration, and potentially not pre‐specified stop for futility raise some concerns. The issues were not discussed. Potential mild bias towards experimental. </p> </td> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment </p> <p>Control group: 5 excluded before starting treatment, 3 excluded after starting treatment</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>416 participants randomised and 416 participants analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available. Data analysed and presented according to a pre‐specified plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations.</p> </td> </tr> <tr class="study-data"> <td> <p>Tang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was stratified by the statistician of the leading site, who produced computer‐generated block randomisation lists with a block size of 4 patients. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Single‐blind design (participants), ITT data presented. No deviations reported.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data collection and end point judgement were blinded, and the statisticians were also blinded during the statistical analysis. The measurements were similar between groups </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>30‐day mortality as pre‐specified in the trial registration was not explicitly reported, but could reliably derive from a synopsis of full text, figures, and supplemental material. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All domains were rated low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns because of protocol deviations.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-19">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-20"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.2 All‐cause mortality up to 120 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.2.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals with consecutive open‐label steroids may have affected the outcome, but withdrawals and non‐compliance was rather balanced after all. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with the reported result.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Withdrawals because of the experimental context lead to some concerns (but it is less than 10% of all patients). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.2.2 Low‐ and middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Edalatifard 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information about the allocation concealment.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6 patients in the control group received the intervention drug and were excluded from the analyses (17%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data were requested from the authors because the follow‐up time was not clearly visible from the publication. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Neither the protocol nor the SAP were available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to the randomisation process, protocol deviations and the selection of the reported results. </p> </td> </tr> <tr class="study-data"> <td> <p>Jeronimo 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>An independent statistician prepared an electronically generated randomisation list with 14 blocks of 30 participants per block, generated via R software version 3.6.1 (blockrand package). The list was accessible only to non‐blinded pharmacists in the study. Participants were randomised by the study pharmacist to their designated treatment regimen at the time of inclusion and were subsequently identified throughout the study only by their allocated study number. </p> <p>There were no major differences in baseline characteristics between the intervention and placebo groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intervention group: 14 excluded before starting treatment, 1 excluded after starting treatment </p> <p>Control group: 5 excluded before starting treatment, 3 excluded after starting treatment</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>416 participants randomised and 416 participants analysed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and statistical plan available. Data analysed and presented according to a pre‐specified plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to protocol deviations.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.2 All‐cause mortality up to 120 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-20">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-21"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.3 Clinical improvement: discharged alive</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.3.1 High‐income country</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed with the use of a web‐based system with concealment of the trial‐group assignment. No baseline differences between the groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8% of the participants in the control group received dexamethasone</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the treatment assignments. Knowledge of intervention received could have affected ascertainment only in patients who had not died. So the influence of the unblinded assessor is limited but existing ‐ therefore deviation between algorithm and judgement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issue with selective reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to the randomisation process, protocol deviations and limited bias in measurement. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.3.2 Low‐ and middle‐income country</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Edalatifard 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information about the allocation concealment.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>In this study, patients did not know which group of them used medicine</p> <p>Physicians and clinicians team know about the medicine and intervention groups.</p> <p>6 patients in the control group received the intervention drug and were excluded from the analyses </p> <p>Intention‐to‐treat</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomised</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the treatment assignments. Knowledge of intervention received could have affected ascertainment only in patients who had not died. So the influence of the unblinded assessor is limited but existing ‐ therefore deviation between algorithm and judgement.No protocol or SAP available. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Neither the protocol nor the SAP were available</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to missing information about the allocation concealment, deviations from the intended interventions, measurement of the outcome and selection of the reported result </p> </td> </tr> <tr class="study-data"> <td> <p>Tomazini 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed through an online web‐based system using computer‐generated random numbers and blocks of 2 and 4, unknown to the investigators, and was stratified by centre. The group treatment was disclosed to the investigator only after all information regarding patient enrolment was recorded in the online system. </p> <p>Baseline characteristics were well‐balanced between groups.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>25 deviations from protocol in the intervention arm (16.55%); 1 patient received a corticosteroid other than dexamethasone. In the control arm, 52 patients received corticosteroids, of which 14 were protocol deviations (9.4%). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomised</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the treatment assignments. Knowledge of intervention received could have affected ascertainment only in patients who had not died. So the influence of the unblinded assessor is limited but existing ‐ therefore deviation between algorithm and judgement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol and statistical analysis plan were available. Outcomes reported as prespecified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall rated some concerns due to protocol deviations and measurement of the outcome.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.3 Clinical improvement: discharged alive</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-21">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-22"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Ranjbar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random allocation using the block randomisation method was performed in all four branches of the strata, based on two prognostic factors such as age (&lt; 55 and ≥55) and disease severity based on O2 saturation (&lt;85 and ≥85). The patient, assessor, and analyser in the two groups did not have access to the randomisation list and type of administered drug (Triple blind). No major differences in the baseline characteristics. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The patient, assessor, and analyser in the two groups did not have access to the randomisation list and type of administered drug (Triple blind). ITT analysis was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurements were similar between groups</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol and SAP are not available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to selective reporting.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-22">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-23"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Few, balanced, and blinded exclcusions for similar reasons in both arms.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Taboada 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are no further information regarding the concealment of the allocation sequence</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 200 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome is pre‐specified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>However, there are some concerns for bias in the randomisation process.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-23">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-24"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.2 All‐cause mortality up to 120 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Few, balanced, and blinded exclcusions for similar reasons in both arms.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Taboada 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are no further information regarding the concealment of the allocation sequence</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 200 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol available. Outcome pre‐specified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is low risk of bias due to deviations from intended interventions, due to missing outcome data and in measurement of the outcome. However, there are some concerns for bias in the randomisation process. </p> </td> </tr> <tr class="study-data"> <td> <p>Toroghi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomised, and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study design was blind on patient level, but there were no arrangements that ensured blinding. Therefore, we do not know whether the higher dropout rate in the intermediate/high‐dose groups occurred due to the assigned intervention. No information on treatment adherence was reported. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for nearly all participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was a trial register entry, which provided details of the pre‐specified outcomes, but "mortality" was not pre‐specified at trial registration and in the protocol </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study design was blind on patient level, but there were no arrangements that ensured blinding. Therefore, we do not know whether the higher dropout rate in the intermediate/high‐dose groups occurred due to the assigned intervention. No information on treatment adherence was reported. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.2 All‐cause mortality up to 120 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-24">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-25"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.3 Clinical improvement: discharged alive</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Taboada 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are no further information regarding the concealment of the allocation sequence</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 200 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol available. Outcome pre‐specified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is low risk of bias due to deviations from intended interventions, due to missing outcome data and in measurement of the outcome. However, there are some concerns for bias in selection of the reported result and the randomisation process. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.3 Clinical improvement: discharged alive</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-25">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-26"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.4 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with appropriate analysis but no relevant number of deviations or exclusions from analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing adjustment for competing risk of death in a trial with relevant death rate.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias due to missing adjustment for competing risk of death in domain 3. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Few, balanced, and blinded exclusions for similar reasons in both arms. Missing adjustment for competing risk of death. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No extraordinary issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias due to missing adjustment for competing risk of death.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.4 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-26">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-27"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.5 Adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with appropriate analysis but no relevant number of deviations or exclusions from analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing adjustment for competing risk of death in a trial with relevant death rate.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias due to missing adjustment for competing risk of death in domain 3. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.5 Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-27">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-28"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.6 Hospital‐acquired infections</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with appropriate analysis but no relevant number of deviations or exclusions from analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing adjustment for competing risk of death in a trial with relevant death rate.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns because also subjective clinical assessment was allowed but not deemed of major concern. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias due to missing adjustment for competing risk of death in domain 3. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. No adjustment for competing risk of death done or supported. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No extraordinary issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias due to missing adjustment for competing risk of death.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.6 Hospital‐acquired infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-28">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-29"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.7 Invasive fungal infections</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with appropriate analysis but no relevant number of deviations or exclusions from analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Missing adjustment for competing risk of death in a trial with relevant death rate.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias due to missing adjustment for competing risk of death in domain 3. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Adjustment for competing risk of death missing or not possible on time‐to‐event scale.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection, extraction initiated by review authors.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias due to missing data or adjustment regarding competing risk of death in circumstances of relevant mortality. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.7 Invasive fungal infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-29">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-30"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 10.1.1 Female</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested the data from the authors. No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. Few, balanced, and blinded exclusions for similar reasons in both arms. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 10.1.2 Male</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested the data from the authors. No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. Few, balanced, and blinded exclusions for similar reasons in both arms. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-30">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-31"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.2 All‐cause mortality up to 120 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 10.2.1 Female</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. Few, balanced, and blinded exclcusions for similar reasons in both arms. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 10.2.2 Male</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. Few, balanced, and blinded exclcusions for similar reasons in both arms. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.2 All‐cause mortality up to 120 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-31">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-32"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 11.1.1 &lt;70 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. Few, balanced, and blinded exclusions for similar reasons in both arms. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 11.1.2 ≥ 70 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. Few, balanced, and blinded exclusions for similar reasons in both arms. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-32">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-33"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.2 All‐cause mortality up to 120 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 11.2.1 &lt;70 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. Few, balanced, and blinded exclusions for similar reasons in both arms. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 11.2.2 ≥ 70 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We requested data from the authors. Few, balanced, and blinded exclusions for similar reasons in both arms. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.2 All‐cause mortality up to 120 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-33">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-34"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.1 All‐cause mortality up to 30 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 12.1.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Few, balanced, and blinded exclusions for similar reasons in both arms.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Taboada 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are no further information regarding the concealment of the allocation sequence</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 200 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome is pre‐specified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>However, there are some concerns for bias in the randomisation process.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 12.1.2 Low‐ and middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.1 All‐cause mortality up to 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-34">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-35"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.2 All‐cause mortality up to 120 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 12.2.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Munch 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation process.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with deviations from intended interventions</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Few, balanced, and blinded exclusions for similar reasons in both arms.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with measurement</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with potential selection.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Taboada 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are no further information regarding the concealment of the allocation sequence</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 200 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol available. Outcome pre‐specified.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is low risk of bias due to deviations from intended interventions, due to missing outcome data and in measurement of the outcome. However, there are some concerns for bias in the randomisation process. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 12.2.2 Low‐ and middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Maskin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with randomisation.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Minor issues with deviations (2/51 patients from the control received not intended intervention) and appropriate analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant amount of missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with measurement.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No relevant issues with reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some minor concerns regarding deviations in about 5% of patients and their exclusion from analysis. </p> </td> </tr> <tr class="study-data"> <td> <p>Toroghi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomised, and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study design was blind on patient level, but there were no arrangements that ensured blinding. Therefore, we do not know whether the higher dropout rate in the intermediate/high‐dose groups occurred due to the assigned intervention. No information on treatment adherence was reported. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for nearly all participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was a trial register entry, which provided details of the pre‐specified outcomes, but "mortality" was not pre‐specified at trial registration and in the protocol </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study design was blind on patient level, but there were no arrangements that ensured blinding. Therefore, we do not know whether the higher dropout rate in the intermediate/high‐dose groups occurred due to the assigned intervention. No information on treatment adherence was reported. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.2 All‐cause mortality up to 120 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014963.pub2/references#riskOfBias2Table-35">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014963.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD014963-note-0015">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD014963-note-0033">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014963-note-0027">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014963-note-0030">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD014963-note-0024">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD014963-note-0021">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014963-note-0018">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014963\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014963\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014963\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014963\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014963\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014963.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014963.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014963.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014963.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014963.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717862889"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014963.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717862893"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014963.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc24259d99377',t:'MTc0MDcxNzg2My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 